# data[].attributes.title
Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.

This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms of glaucoma and screen for therapeutic agents. Glaucoma, a leading cause of blindness, is often associated with mutations in the myocilin gene, but the exact mechanisms by which these mutations lead to cell death are not fully understood. By utilizing these cell lines, researchers can investigate how mutant myocilin induces endoplasmic reticulum stress and apoptosis, particularly under oxidative stress conditions. This understanding could pave the way for the development of targeted therapies that mitigate the effects of these mutations and improve patient outcomes.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.

This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms of glaucoma and screen for therapeutic agents. Glaucoma, a leading cause of blindness, is often associated with mutations in the myocilin gene, but the exact mechanisms by which these mutations lead to cell death are not fully understood. By utilizing these cell lines, researchers can investigate how mutant myocilin induces endoplasmic reticulum stress and apoptosis, particularly under oxidative stress conditions. This understanding could pave the way for the development of targeted therapies that mitigate the effects of these mutations and improve patient outcomes.

# data[].attributes.field_commercial_applications.value
•	Drug discovery and development for glaucoma treatments.
•	Research into the molecular mechanisms of glaucoma pathogenesis.
•	Screening for compounds that can reduce oxidative stress in retinal cells.
•	Development of personalized medicine approaches for patients with myocilin mutations.

# data[].attributes.field_commercial_applications.processed
•	Drug discovery and development for glaucoma treatments.
•	Research into the molecular mechanisms of glaucoma pathogenesis.
•	Screening for compounds that can reduce oxidative stress in retinal cells.
•	Development of personalized medicine approaches for patients with myocilin mutations.

# data[].attributes.field_competitive_advantages.value
•	Enables high-throughput screening of potential therapeutic agents targeting myocilin mutations.
•	Provides a controlled environment to study the effects of oxidative stress on cell viability.
•	Facilitates the understanding of the molecular mechanisms underlying myocilin-induced glaucoma.
•	Offers a unique model for testing drug efficacy and safety in a relevant biological context.

# data[].attributes.field_competitive_advantages.processed
•	Enables high-throughput screening of potential therapeutic agents targeting myocilin mutations.
•	Provides a controlled environment to study the effects of oxidative stress on cell viability.
•	Facilitates the understanding of the molecular mechanisms underlying myocilin-induced glaucoma.
•	Offers a unique model for testing drug efficacy and safety in a relevant biological context.

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening&body=Please send me information about technology [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening&body=Please send me information about technology [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_publications[].value
Joe MK, et al., 2010 (PMID: 20382707)

# data[].attributes.field_publications[].processed
Joe MK, et al., 2010 (PMID: 20382707)

# data[].attributes.field_technology_names[]
ManufacturersExpression Of Myocilin Mutants Sensitizes Cells To Oxidative Stress-Induced Apoptosis

# data[].attributes.field_technology_owners[]
National Eye Institute (NEI), PTC Therapeutics, Inc.

# data[].attributes.title
iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel iPSC differentiation protocol for generating fibroblasts and endothelial cells.

This technology includes a novel protocol for differentiating induced pluripotent stem cells (iPSCs) into fibroblasts and endothelial cells, which are crucial for tissue engineering and regenerative medicine applications. Current methods for generating these cell types can be inefficient and inconsistent, leading to challenges in research and therapeutic applications. This protocol aims to streamline the differentiation process, enhancing the yield and quality of the derived cells.

The technical solution leverages optimized culture conditions and growth factors to promote the efficient differentiation of iPSCs into fibroblasts and endothelial cells. This is significant because it addresses the growing demand for reliable and reproducible cell sources in research and clinical settings. By providing a standardized method, this technology can facilitate advancements in tissue engineering, drug testing, and regenerative therapies.

The licensing opportunity for this technology is open to partnerships with companies and research institutions interested in cell therapy, regenerative medicine, and related fields. Collaborators can expect to engage in co-development efforts to further refine and commercialize the protocol, ensuring its applicability in various biomedical applications.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel iPSC differentiation protocol for generating fibroblasts and endothelial cells.

This technology includes a novel protocol for differentiating induced pluripotent stem cells (iPSCs) into fibroblasts and endothelial cells, which are crucial for tissue engineering and regenerative medicine applications. Current methods for generating these cell types can be inefficient and inconsistent, leading to challenges in research and therapeutic applications. This protocol aims to streamline the differentiation process, enhancing the yield and quality of the derived cells.

The technical solution leverages optimized culture conditions and growth factors to promote the efficient differentiation of iPSCs into fibroblasts and endothelial cells. This is significant because it addresses the growing demand for reliable and reproducible cell sources in research and clinical settings. By providing a standardized method, this technology can facilitate advancements in tissue engineering, drug testing, and regenerative therapies.

The licensing opportunity for this technology is open to partnerships with companies and research institutions interested in cell therapy, regenerative medicine, and related fields. Collaborators can expect to engage in co-development efforts to further refine and commercialize the protocol, ensuring its applicability in various biomedical applications.

# data[].attributes.field_commercial_applications.value
•	Regenerative medicine
•	Tissue engineering
•	Drug testing and development
•	Cell therapy
•	Research in developmental biology

# data[].attributes.field_commercial_applications.processed
•	Regenerative medicine
•	Tissue engineering
•	Drug testing and development
•	Cell therapy
•	Research in developmental biology

# data[].attributes.field_competitive_advantages.value
•	Streamlined differentiation process for iPSCs into fibroblasts and endothelial cells
•	High yield and quality of differentiated cells
•	Standardized protocol enhances reproducibility
•	Potential for broad applications in regenerative medicine and tissue engineering
•	Addresses current inefficiencies in existing methods

# data[].attributes.field_competitive_advantages.processed
•	Streamlined differentiation process for iPSCs into fibroblasts and endothelial cells
•	High yield and quality of differentiated cells
•	Standardized protocol enhances reproducibility
•	Potential for broad applications in regenerative medicine and tissue engineering
•	Addresses current inefficiencies in existing methods

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation&body=Please send me information about technology [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation&body=Please send me information about technology [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_technology_names[]
Fibroblasts, Pericytes, And Endothelial Cells As Generated By An IPSC Differentiation Protocol

# data[].attributes.title
Thermosensitive Hydrogel Bioink for Vascular Tissue Engineering

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for a thermosensitive, pro-angiogenic material designed for 3D bioprinting.

This technology includes a thermosensitive hydrogel bioink designed for vascular tissue engineering. The hydrogel is unique in that it transitions from a gel state at room temperature to a liquid state at physiological temperatures, allowing for easy handling and application in bioprinting. The primary challenge in tissue engineering is the formation of functional blood vessels, which is critical for tissue viability. Current methods often involve harmful chemical crosslinkers or UV light, which can compromise cell viability. This hydrogel, made from fibrinogen and gelatin, promotes blood vessel formation by providing a supportive extracellular matrix without the use of harmful agents.

The technical solution involves a combination of fibrinogen, which serves as a provisional extracellular matrix, and gelatin, which adjusts viscosity with temperature changes. This innovative approach not only enhances cell viability but also reduces material costs, making it a compelling option for researchers and companies in the field of tissue engineering. You should care about this technology because it represents a significant advancement in bioprinting techniques, enabling the creation of vascularized tissues that closely mimic natural environments.

The licensing opportunity for this technology is open to interested parties looking to collaborate in further development or commercialization. The inventors are seeking partners who can help bring this innovative bioink to market, potentially leading to groundbreaking applications in regenerative medicine and tissue engineering.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for a thermosensitive, pro-angiogenic material designed for 3D bioprinting.

This technology includes a thermosensitive hydrogel bioink designed for vascular tissue engineering. The hydrogel is unique in that it transitions from a gel state at room temperature to a liquid state at physiological temperatures, allowing for easy handling and application in bioprinting. The primary challenge in tissue engineering is the formation of functional blood vessels, which is critical for tissue viability. Current methods often involve harmful chemical crosslinkers or UV light, which can compromise cell viability. This hydrogel, made from fibrinogen and gelatin, promotes blood vessel formation by providing a supportive extracellular matrix without the use of harmful agents.

The technical solution involves a combination of fibrinogen, which serves as a provisional extracellular matrix, and gelatin, which adjusts viscosity with temperature changes. This innovative approach not only enhances cell viability but also reduces material costs, making it a compelling option for researchers and companies in the field of tissue engineering. You should care about this technology because it represents a significant advancement in bioprinting techniques, enabling the creation of vascularized tissues that closely mimic natural environments.

The licensing opportunity for this technology is open to interested parties looking to collaborate in further development or commercialization. The inventors are seeking partners who can help bring this innovative bioink to market, potentially leading to groundbreaking applications in regenerative medicine and tissue engineering.

# data[].attributes.field_commercial_applications.value
•	Vascular tissue engineering
•	Bioprinting of complex tissue structures
•	Angiogenesis assays for research and drug testing
•	Regenerative medicine applications

# data[].attributes.field_commercial_applications.processed
•	Vascular tissue engineering
•	Bioprinting of complex tissue structures
•	Angiogenesis assays for research and drug testing
•	Regenerative medicine applications

# data[].attributes.field_competitive_advantages.value
•	Thermosensitive properties allow for easy handling and application in bioprinting
•	Promotes cell viability by avoiding harmful crosslinking methods
•	Biodegradable materials that can be converted to native extracellular matrix by embedded cells
•	Cost-effective compared to traditional bioinks

# data[].attributes.field_competitive_advantages.processed
•	Thermosensitive properties allow for easy handling and application in bioprinting
•	Promotes cell viability by avoiding harmful crosslinking methods
•	Biodegradable materials that can be converted to native extracellular matrix by embedded cells
•	Cost-effective compared to traditional bioinks

# data[].attributes.field_inventor_companies[]
National Center for Advancing Translational Sciences

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_publications[].value
Min Jae Song et al., 2022 (PMID: 36550275)

# data[].attributes.field_publications[].processed
Min Jae Song et al., 2022 (PMID: 36550275)

# data[].attributes.field_technology_names[]
Fibrin And Gelatin-based Bioink And Associated Supporting Fibrin Hydrogel

# data[].attributes.field_technology_owners[]
National Center for Advancing Translational Sciences, National Eye Institute (NEI), NCATS - NCGC

# data[].attributes.title
Interferon Gamma for Retinal Fluid Absorption Restoration

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.

This technology includes the use of Interferon gamma to restore fluid absorption in retinal pigment epithelial (RPE) cells, specifically targeting the adverse effects of fluid accumulation under the retina caused by small molecule cancer therapeutic drugs like Meki. The problem arises when cancer treatments, particularly MAP Kinase/ERK Kinase Inhibitors, lead to unwanted fluid build-up, which can impair vision and overall retinal health. This technology addresses a significant challenge in ocular health by providing a potential therapeutic solution to mitigate these side effects of cancer treatment.

The technical solution involves leveraging the previously established method of fluid transport across RPE cells, enhanced by the application of Interferon gamma. This approach not only aims to alleviate fluid accumulation but also seeks to improve the overall efficacy of cancer therapies by minimizing their ocular side effects. You should care about this technology because it represents a novel intersection of oncology and ophthalmology, potentially improving patient outcomes for those undergoing cancer treatment.

Currently, the National Eye Institute (NEI) is seeking collaborative support to fund or provide a source of Interferon gamma for larger clinical trials. There is an opportunity for licensing this technology, especially as NEI is in discussions with potential partners, including a start-up and Merck, to further clinical trials related to this innovative approach. This presents a unique chance for collaboration and investment in a promising therapeutic avenue.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.

This technology includes the use of Interferon gamma to restore fluid absorption in retinal pigment epithelial (RPE) cells, specifically targeting the adverse effects of fluid accumulation under the retina caused by small molecule cancer therapeutic drugs like Meki. The problem arises when cancer treatments, particularly MAP Kinase/ERK Kinase Inhibitors, lead to unwanted fluid build-up, which can impair vision and overall retinal health. This technology addresses a significant challenge in ocular health by providing a potential therapeutic solution to mitigate these side effects of cancer treatment.

The technical solution involves leveraging the previously established method of fluid transport across RPE cells, enhanced by the application of Interferon gamma. This approach not only aims to alleviate fluid accumulation but also seeks to improve the overall efficacy of cancer therapies by minimizing their ocular side effects. You should care about this technology because it represents a novel intersection of oncology and ophthalmology, potentially improving patient outcomes for those undergoing cancer treatment.

Currently, the National Eye Institute (NEI) is seeking collaborative support to fund or provide a source of Interferon gamma for larger clinical trials. There is an opportunity for licensing this technology, especially as NEI is in discussions with potential partners, including a start-up and Merck, to further clinical trials related to this innovative approach. This presents a unique chance for collaboration and investment in a promising therapeutic avenue.

# data[].attributes.field_commercial_applications.value
•	Treatment of fluid accumulation under the retina in cancer patients
•	Enhancement of cancer therapy efficacy by reducing ocular side effects
•	Potential use in other retinal diseases associated with fluid dysregulation
•	Research applications in the field of ocular pharmacology
•	Development of combination therapies for cancer and retinal health

# data[].attributes.field_commercial_applications.processed
•	Treatment of fluid accumulation under the retina in cancer patients
•	Enhancement of cancer therapy efficacy by reducing ocular side effects
•	Potential use in other retinal diseases associated with fluid dysregulation
•	Research applications in the field of ocular pharmacology
•	Development of combination therapies for cancer and retinal health

# data[].attributes.field_competitive_advantages.value
•	Utilizes a well-studied cytokine (Interferon gamma) for a novel application in retinal health
•	Addresses a significant unmet need in patients undergoing cancer treatment
•	Potential for improved patient outcomes by mitigating side effects of cancer therapies
•	Established preliminary clinical trial data supporting efficacy
•	Collaboration opportunities with established pharmaceutical companies like Merck

# data[].attributes.field_competitive_advantages.processed
•	Utilizes a well-studied cytokine (Interferon gamma) for a novel application in retinal health
•	Addresses a significant unmet need in patients undergoing cancer treatment
•	Potential for improved patient outcomes by mitigating side effects of cancer therapies
•	Established preliminary clinical trial data supporting efficacy
•	Collaboration opportunities with established pharmaceutical companies like Merck

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration&body=Please send me information about technology [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration&body=Please send me information about technology [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/721,810
Filed on 2012-11-02
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/721,810
Filed on 2012-11-02
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2013/068056
Filed on 2013-11-01
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2013/068056
Filed on 2013-11-01
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 2013337702
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patents[].processed
Australia
National Stage 2013337702
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patents[].value
Canada
National Stage 2890238
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patents[].processed
Canada
National Stage 2890238
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patents[].value
European Patent
National Stage 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].value
US
National Stage 14/440,218
Filed on 2015-05-01
Status: Abandoned

# data[].attributes.field_patents[].processed
US
National Stage 14/440,218
Filed on 2015-05-01
Status: Abandoned

# data[].attributes.field_patents[].value
Germany
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].value
Ireland
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patents[].processed
Ireland
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/721,810
Filed on 2012-11-02
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2013/068056
Filed on 2013-11-01
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2013337702
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2890238
Filed on 2013-11-01
Status: Abandoned

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
US
National Stage 14/440,218
Filed on 2015-05-01
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_htmls[]
Ireland
European patent (EP) 13792162.3
Filed on 2015-06-02
Status: Issued

# data[].attributes.field_patent_titles[]
METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT DURING TREATMENT WITH A MEK INHIBITOR

# data[].attributes.field_patent_titles[]
Methods of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_patent_titles[]
Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor

# data[].attributes.field_technology_names[]
Interferon Gamma Restores Retinal Pigment Epithelial (RPE) Fluid Absorption Suppressed By Small Molecule Cancer Therapeutic Drug Meki (Merck)

# data[].attributes.field_technology_owners[]
Dupont Merck Pharmaceutical Company, National Eye Institute (NEI)

# data[].attributes.title
Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.

This technology includes the use of Interferon-gamma (IFN-y) as a therapeutic agent to inhibit the proliferation and migration of human retinal pigment epithelial (RPE) cells, which is crucial in treating proliferative eye diseases such as age-related macular degeneration and proliferative vitreoretinopathy. The problem at hand is that abnormal RPE cell behavior is linked to severe ocular diseases that can lead to vision loss, affecting millions of individuals, particularly the elderly. The inventors have discovered that IFN-y can significantly reduce this abnormal cell activity, providing a potential treatment pathway for these debilitating conditions.

The technical solution involves intraocular injections of IFN-y, which have shown promise in halting excessive RPE proliferation and migration, thereby preventing the formation of abnormal tissues in the eye. This technology is important because it addresses a significant unmet medical need in ophthalmology, offering a novel approach to managing diseases that currently have limited treatment options. By targeting the underlying cellular mechanisms, this therapy could improve patient outcomes and reduce the burden of vision loss associated with these conditions.

The licensing opportunity for this technology is aimed at pharmaceutical companies and research institutions interested in developing new treatments for ocular diseases. The inventors are seeking partners for co-development and commercialization, emphasizing the potential for collaborative efforts to bring this innovative therapy to market. This collaboration could involve further clinical trials and research to validate the efficacy and safety of IFN-y in treating proliferative eye diseases.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.

This technology includes the use of Interferon-gamma (IFN-y) as a therapeutic agent to inhibit the proliferation and migration of human retinal pigment epithelial (RPE) cells, which is crucial in treating proliferative eye diseases such as age-related macular degeneration and proliferative vitreoretinopathy. The problem at hand is that abnormal RPE cell behavior is linked to severe ocular diseases that can lead to vision loss, affecting millions of individuals, particularly the elderly. The inventors have discovered that IFN-y can significantly reduce this abnormal cell activity, providing a potential treatment pathway for these debilitating conditions.

The technical solution involves intraocular injections of IFN-y, which have shown promise in halting excessive RPE proliferation and migration, thereby preventing the formation of abnormal tissues in the eye. This technology is important because it addresses a significant unmet medical need in ophthalmology, offering a novel approach to managing diseases that currently have limited treatment options. By targeting the underlying cellular mechanisms, this therapy could improve patient outcomes and reduce the burden of vision loss associated with these conditions.

The licensing opportunity for this technology is aimed at pharmaceutical companies and research institutions interested in developing new treatments for ocular diseases. The inventors are seeking partners for co-development and commercialization, emphasizing the potential for collaborative efforts to bring this innovative therapy to market. This collaboration could involve further clinical trials and research to validate the efficacy and safety of IFN-y in treating proliferative eye diseases.

# data[].attributes.field_commercial_applications.value
•	Treatment of age-related macular degeneration
•	Management of proliferative vitreoretinopathy
•	Therapeutic intervention for proliferative diabetic retinopathy
•	Potential use in retinal detachment cases

# data[].attributes.field_commercial_applications.processed
•	Treatment of age-related macular degeneration
•	Management of proliferative vitreoretinopathy
•	Therapeutic intervention for proliferative diabetic retinopathy
•	Potential use in retinal detachment cases

# data[].attributes.field_competitive_advantages.value
•	Significant inhibition of RPE cell proliferation and migration
•	Potential to treat multiple proliferative eye diseases
•	Novel therapeutic approach with limited current competition
•	Intraocular delivery method for targeted treatment

# data[].attributes.field_competitive_advantages.processed
•	Significant inhibition of RPE cell proliferation and migration
•	Potential to treat multiple proliferative eye diseases
•	Novel therapeutic approach with limited current competition
•	Intraocular delivery method for targeted treatment

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases&body=Please send me information about technology [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases&body=Please send me information about technology [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/089,157
Filed on 2008-08-15
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/089,157
Filed on 2008-08-15
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2009/053808
Filed on 2009-08-14
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2009/053808
Filed on 2009-08-14
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 2009281849
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
Australia
National Stage 2009281849
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
Canada
National Stage 2734185
Filed on 2011-02-14
Status: Issued

# data[].attributes.field_patents[].processed
Canada
National Stage 2734185
Filed on 2011-02-14
Status: Issued

# data[].attributes.field_patents[].value
European Patent
National Stage 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
US Patent 8,697,046
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 8,697,046
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
US Patent 9,486,502
Filed on 2014-04-14
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 9,486,502
Filed on 2014-04-14
Status: Issued

# data[].attributes.field_patents[].value
Germany
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/089,157
Filed on 2008-08-15
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2009/053808
Filed on 2009-08-14
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2009281849
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2734185
Filed on 2011-02-14
Status: Issued

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 8,697,046
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 9,486,502
Filed on 2014-04-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 09791514.4
Filed on 2009-08-14
Status: Issued

# data[].attributes.field_patent_titles[]
METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE

# data[].attributes.field_patent_titles[]
METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE

# data[].attributes.field_patent_titles[]
Methods For Using Interferon Gamma To Absorb Fluid Form The Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for Using Interferon Gamma to Absorb Fluid From the Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_patent_titles[]
METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE

# data[].attributes.field_patent_titles[]
Methods of Using Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_patent_titles[]
Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space

# data[].attributes.field_technology_names[]
Interferon Gamma Inhibits Human Retinal Pigment Epithelium Proliferation And Migration

# data[].attributes.title
Gene Therapy for Leber Congenital Amaurosis

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations.

This technology includes an innovative gene therapy approach for treating Leber congenital amaurosis (LCA) caused by CEP290 mutations. LCA is a severe inherited eye disorder that leads to significant vision loss in infants, affecting approximately 20,000 individuals worldwide. Currently, there are no effective treatments available for LCA, particularly for the CEP290 mutation, which accounts for 20-25% of cases. Our research has identified a functional subunit of the CEP290 gene that can be effectively delivered to the retina using an adeno-associated viral (AAV) vector, overcoming the limitations of previous gene therapy attempts that struggled with the large size of the full-length CEP290 gene. This breakthrough offers hope for restoring vision in patients suffering from this debilitating condition.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations.

This technology includes an innovative gene therapy approach for treating Leber congenital amaurosis (LCA) caused by CEP290 mutations. LCA is a severe inherited eye disorder that leads to significant vision loss in infants, affecting approximately 20,000 individuals worldwide. Currently, there are no effective treatments available for LCA, particularly for the CEP290 mutation, which accounts for 20-25% of cases. Our research has identified a functional subunit of the CEP290 gene that can be effectively delivered to the retina using an adeno-associated viral (AAV) vector, overcoming the limitations of previous gene therapy attempts that struggled with the large size of the full-length CEP290 gene. This breakthrough offers hope for restoring vision in patients suffering from this debilitating condition.

# data[].attributes.field_commercial_applications.value
•	Therapeutic to treat Leber congenital amaurosis

# data[].attributes.field_commercial_applications.processed
•	Therapeutic to treat Leber congenital amaurosis

# data[].attributes.field_competitive_advantages.value
•	Established FDA approval route as gene therapy (based on Luxturna)
•	Previous attempts at treating CEP290-related LCA by gene therapy have been unsuccessful because of difficulty in delivering the full length CEP290 gene with a single vector. The present invention uses an AAV construct with a truncated portion of the CEP290 coding region that expresses functional protein to the photoreceptors.

# data[].attributes.field_competitive_advantages.processed
•	Established FDA approval route as gene therapy (based on Luxturna)
•	Previous attempts at treating CEP290-related LCA by gene therapy have been unsuccessful because of difficulty in delivering the full length CEP290 gene with a single vector. The present invention uses an AAV construct with a truncated portion of the CEP290 coding region that expresses functional protein to the photoreceptors.

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5107] Gene Therapy for Leber Congenital Amaurosis&body=Please send me information about technology [TAB-5107] Gene Therapy for Leber Congenital Amaurosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5107] Gene Therapy for Leber Congenital Amaurosis&body=Please send me information about technology [TAB-5107] Gene Therapy for Leber Congenital Amaurosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/042,703
Filed on 2014-08-27
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/042,703
Filed on 2014-08-27
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2015/047209
Filed on 2015-08-27
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2015/047209
Filed on 2015-08-27
Status: Expired

# data[].attributes.field_patents[].value
US Patent 10,351,844
Filed on 2017-02-24
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 10,351,844
Filed on 2017-02-24
Status: Issued

# data[].attributes.field_patents[].value
Canada
National Stage 2959540
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
Canada
National Stage 2959540
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].value
European Patent
National Stage 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].value
US Patent 11,421,219
Filed on 2019-05-28
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 11,421,219
Filed on 2019-05-28
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].value
Germany
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/042,703
Filed on 2014-08-27
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2015/047209
Filed on 2015-08-27
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 10,351,844
Filed on 2017-02-24
Status: Issued

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2959540
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 11,421,219
Filed on 2019-05-28
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 15760025.5
Filed on 2015-08-27
Status: Issued

# data[].attributes.field_patent_titles[]
METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_patent_titles[]
Methods and Compositions for Treating Leber Congenital Amaurosis

# data[].attributes.field_publications[].value
Mookherjee S, et al., 2018 (PMID: 30332642)

# data[].attributes.field_publications[].processed
Mookherjee S, et al., 2018 (PMID: 30332642)

# data[].attributes.field_technology_names[]
A Novel Gene Therapy Vector For Treating CEP290-associated Leber Congenital Amaurosis

# data[].attributes.title
Immunosuppressive Exosomes for Treating Autoimmune Diseases

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases.

This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing regulatory B cells (Bregs) as a therapeutic treatment for autoimmune diseases such as uveitis and multiple sclerosis. Current therapies face challenges with dosing and bioavailability of IL-35, which is a weakly associated heterodimer that can easily dissociate. Our innovative approach utilizes exosomes that encapsulate both subunits of IL-27 and IL-35, ensuring a stable and effective delivery mechanism. This advancement addresses the critical need for reliable dosing and bioavailability in immunotherapy, making it a significant improvement over existing treatments.

The technical solution involves the isolation and application of exosomes that contain biologically active IL-27 and IL-35, which have shown efficacy in preclinical models by suppressing neuroinflammation and promoting regulatory immune responses. This technology is particularly relevant for C-level executives and directors in the biotech and pharmaceutical industries, as it opens new avenues for treating challenging autoimmune conditions with a novel delivery system that overcomes existing barriers in therapeutic administration.

We are seeking licensing opportunities for this groundbreaking technology, which has the potential to transform the treatment landscape for autoimmune diseases. Collaborators and licensees will benefit from access to a unique therapeutic platform that is ready for further development and commercialization. We invite interested parties to engage in discussions regarding potential partnerships and licensing agreements to bring this innovative therapy to market.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases.

This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing regulatory B cells (Bregs) as a therapeutic treatment for autoimmune diseases such as uveitis and multiple sclerosis. Current therapies face challenges with dosing and bioavailability of IL-35, which is a weakly associated heterodimer that can easily dissociate. Our innovative approach utilizes exosomes that encapsulate both subunits of IL-27 and IL-35, ensuring a stable and effective delivery mechanism. This advancement addresses the critical need for reliable dosing and bioavailability in immunotherapy, making it a significant improvement over existing treatments.

The technical solution involves the isolation and application of exosomes that contain biologically active IL-27 and IL-35, which have shown efficacy in preclinical models by suppressing neuroinflammation and promoting regulatory immune responses. This technology is particularly relevant for C-level executives and directors in the biotech and pharmaceutical industries, as it opens new avenues for treating challenging autoimmune conditions with a novel delivery system that overcomes existing barriers in therapeutic administration.

We are seeking licensing opportunities for this groundbreaking technology, which has the potential to transform the treatment landscape for autoimmune diseases. Collaborators and licensees will benefit from access to a unique therapeutic platform that is ready for further development and commercialization. We invite interested parties to engage in discussions regarding potential partnerships and licensing agreements to bring this innovative therapy to market.

# data[].attributes.field_commercial_applications.value
•	Treatment for autoimmune diseases such as uveitis and multiple sclerosis
•	Potential applications in therapies for other inflammatory conditions like arthritis and graft-versus-host disease (GVHD)
•	Development of exosome-based immunotherapies for various neurological disorders

# data[].attributes.field_commercial_applications.processed
•	Treatment for autoimmune diseases such as uveitis and multiple sclerosis
•	Potential applications in therapies for other inflammatory conditions like arthritis and graft-versus-host disease (GVHD)
•	Development of exosome-based immunotherapies for various neurological disorders

# data[].attributes.field_competitive_advantages.value
•	Exosomes provide a stable delivery system for IL-27 and IL-35, overcoming dosing challenges associated with traditional therapies
•	The small size of exosomes (30-150 nm) allows for effective delivery across the blood-brain and blood-ocular barriers, enhancing therapeutic potential in neuroinflammatory diseases
•	Preclinical studies demonstrate significant efficacy in suppressing autoimmune responses and promoting regulatory immune cell expansion

# data[].attributes.field_competitive_advantages.processed
•	Exosomes provide a stable delivery system for IL-27 and IL-35, overcoming dosing challenges associated with traditional therapies
•	The small size of exosomes (30-150 nm) allows for effective delivery across the blood-brain and blood-ocular barriers, enhancing therapeutic potential in neuroinflammatory diseases
•	Preclinical studies demonstrate significant efficacy in suppressing autoimmune responses and promoting regulatory immune cell expansion

# data[].attributes.field_licensingcontact_htmls[]
Baxter, Merissa
merissa.baxter@nih.gov

# data[].attributes.field_licensing_contacts[].value
Baxter, Merissa
merissa.baxter@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Baxter, Merissa
merissa.baxter@nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/135,833
Filed on 2021-01-11
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/135,833
Filed on 2021-01-11
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2021/034778
Filed on 2021-05-28
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2021/034778
Filed on 2021-05-28
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2023-541862
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2023-541862
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3204551
Filed on 2023-07-07
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3204551
Filed on 2023-07-07
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2021417166
Filed on 2023-07-21
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2021417166
Filed on 2023-07-21
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/271,583
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/271,583
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 21742557.8
Filed on 2023-07-26
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 21742557.8
Filed on 2023-07-26
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/135,833
Filed on 2021-01-11
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2021/034778
Filed on 2021-05-28
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2023-541862
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3204551
Filed on 2023-07-07
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2021417166
Filed on 2023-07-21
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/271,583
Filed on 2023-07-10
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 21742557.8
Filed on 2023-07-26
Status: Pending

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_patent_titles[]
EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF

# data[].attributes.field_publications[].value
Choi JK, et al., 2025 (PMID: 40093899)

# data[].attributes.field_publications[].processed
Choi JK, et al., 2025 (PMID: 40093899)

# data[].attributes.field_publications[].value
Kang M, et al., 2020 (PMID: 32547555)

# data[].attributes.field_publications[].processed
Kang M, et al., 2020 (PMID: 32547555)

# data[].attributes.field_technology_names[]
Immunosuppressive Interleukin 35 And Interleukin 27- Producing Exosomes As A Therapeutic Treatment

# data[].attributes.title
Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.

This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1), a protein crucial for retinal health, which has potential therapeutic applications for X-Linked Retinoschisis (XLRS). XLRS is a genetic condition that leads to severe vision loss due to the malfunction of the RS1 protein. Current treatment options are limited, and this technology aims to provide a novel approach by producing RS1 in a human cell line, ensuring proper post-translational modifications and reducing immunogenicity. The stable cell line, derived from ARPE-19 cells, allows for consistent and high-yield production of RS1, which can be utilized for both therapeutic and research purposes.

The technical solution involves the use of human ARPE-19 cells, which are known for their ability to produce and secrete proteins effectively. This cell line has been optimized to express RS1 and its variants, including mutant forms, under serum-free conditions, which is essential for therapeutic applications. The significance of this technology lies in its potential to improve patient outcomes for those suffering from XLRS by providing a reliable source of RS1 for treatment.

The licensing opportunity for this technology is open for collaboration with industry partners interested in ocular therapeutics. The inventors are seeking partners who can assist in further development and commercialization of the RS1 protein and its delivery systems, including encapsulated cell-based therapies and nanoparticle formulations for targeted delivery to the retina.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.

This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1), a protein crucial for retinal health, which has potential therapeutic applications for X-Linked Retinoschisis (XLRS). XLRS is a genetic condition that leads to severe vision loss due to the malfunction of the RS1 protein. Current treatment options are limited, and this technology aims to provide a novel approach by producing RS1 in a human cell line, ensuring proper post-translational modifications and reducing immunogenicity. The stable cell line, derived from ARPE-19 cells, allows for consistent and high-yield production of RS1, which can be utilized for both therapeutic and research purposes.

The technical solution involves the use of human ARPE-19 cells, which are known for their ability to produce and secrete proteins effectively. This cell line has been optimized to express RS1 and its variants, including mutant forms, under serum-free conditions, which is essential for therapeutic applications. The significance of this technology lies in its potential to improve patient outcomes for those suffering from XLRS by providing a reliable source of RS1 for treatment.

The licensing opportunity for this technology is open for collaboration with industry partners interested in ocular therapeutics. The inventors are seeking partners who can assist in further development and commercialization of the RS1 protein and its delivery systems, including encapsulated cell-based therapies and nanoparticle formulations for targeted delivery to the retina.

# data[].attributes.field_commercial_applications.value
•	Treatment for X-Linked Retinoschisis (XLRS)
•	Research applications in retinal cell biology
•	Development of protein delivery systems for ocular therapies
•	Large-scale production of RS1 for pharmaceutical use
•	Study of RS1 structure and function in various cellular contexts

# data[].attributes.field_commercial_applications.processed
•	Treatment for X-Linked Retinoschisis (XLRS)
•	Research applications in retinal cell biology
•	Development of protein delivery systems for ocular therapies
•	Large-scale production of RS1 for pharmaceutical use
•	Study of RS1 structure and function in various cellular contexts

# data[].attributes.field_competitive_advantages.value
•	High-yield production of human Retinoschisin (RS1) in a stable cell line
•	Utilization of human ARPE-19 cells ensures proper post-translational modifications
•	Serum-free production reduces immunogenicity risks
•	Potential for both therapeutic and research applications in retinal diseases
•	Ability to produce mutant forms of RS1 for functional studies

# data[].attributes.field_competitive_advantages.processed
•	High-yield production of human Retinoschisin (RS1) in a stable cell line
•	Utilization of human ARPE-19 cells ensures proper post-translational modifications
•	Serum-free production reduces immunogenicity risks
•	Potential for both therapeutic and research applications in retinal diseases
•	Ability to produce mutant forms of RS1 for functional studies

# data[].attributes.field_inventor_companies[]
National Institute on Deafness and Other Communication Disorders (NIDCD)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy&body=Please send me information about technology [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy&body=Please send me information about technology [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/049,749
Filed on 2020-07-09
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/049,749
Filed on 2020-07-09
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2021/040790
Filed on 2021-07-08
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2021/040790
Filed on 2021-07-08
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/049,749
Filed on 2020-07-09
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2021/040790
Filed on 2021-07-08
Status: Expired

# data[].attributes.field_patent_titles[]
CELL LINES THAT PRODUCE HUMAN RETINOSCHISIN PROTEINS AND USES THEREOF

# data[].attributes.field_patent_titles[]
Cell Lines that Produce Human Retinoschisin Proteins and Uses Thereof

# data[].attributes.field_technology_names[]
Stable Cell Line For Large Scale Production Of Serum Free Human Retinoschisin And Its Mutant/discoidin Domain Variants In Mammalian Cell System, And Its Therapeutic Application For Ocular Cell/protein Therapy In XLRS

# data[].attributes.field_technology_owners[]
National Eye Institute (NEI), National Institute on Deafness and Other Communication Disorders (NIDCD)

# data[].attributes.title
Advanced Gene Editing Technology for Therapeutic Applications

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications.

This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited, often resulting in lifelong management rather than a cure. This technology offers a precise and efficient method to modify genes, potentially correcting the underlying causes of these disorders. By utilizing cutting-edge CRISPR technology, this solution not only enhances the accuracy of gene editing but also minimizes off-target effects, making it a safer option for therapeutic use. Stakeholders in the healthcare and biotechnology sectors should care about this technology as it represents a significant advancement in the pursuit of curative treatments for previously untreatable conditions. The licensing opportunity for this technology is open for collaboration with industry partners who are interested in further developing and commercializing these innovative therapeutic solutions. We are looking for partners who can contribute to the next stages of development and bring these therapies to market.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications.

This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited, often resulting in lifelong management rather than a cure. This technology offers a precise and efficient method to modify genes, potentially correcting the underlying causes of these disorders. By utilizing cutting-edge CRISPR technology, this solution not only enhances the accuracy of gene editing but also minimizes off-target effects, making it a safer option for therapeutic use. Stakeholders in the healthcare and biotechnology sectors should care about this technology as it represents a significant advancement in the pursuit of curative treatments for previously untreatable conditions. The licensing opportunity for this technology is open for collaboration with industry partners who are interested in further developing and commercializing these innovative therapeutic solutions. We are looking for partners who can contribute to the next stages of development and bring these therapies to market.

# data[].attributes.field_commercial_applications.value
•	Treatment of genetic disorders
•	Development of personalized medicine
•	Research in gene function and regulation
•	Innovative therapeutic strategies for rare diseases

# data[].attributes.field_commercial_applications.processed
•	Treatment of genetic disorders
•	Development of personalized medicine
•	Research in gene function and regulation
•	Innovative therapeutic strategies for rare diseases

# data[].attributes.field_competitive_advantages.value
•	High precision in gene editing
•	Reduced off-target effects
•	Potential for curative therapies
•	Broad applicability across various genetic disorders

# data[].attributes.field_competitive_advantages.processed
•	High precision in gene editing
•	Reduced off-target effects
•	Potential for curative therapies
•	Broad applicability across various genetic disorders

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications&body=Please send me information about technology [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications&body=Please send me information about technology [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_technology_names[]
Pure IPCS-derived RPE Progenitor Cells For Drug Discovery And Disease Modeling

# data[].attributes.title
Innovative Gene Therapy for Retinal Diseases

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.

This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, affect millions of people worldwide and currently have limited treatment options. Our gene therapy targets the underlying genetic causes of these diseases, offering a potential cure rather than just symptomatic relief.

The technical solution involves the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to retinal cells. This method is significant because it not only addresses the root cause of the disease but also has the potential for long-lasting effects, reducing the need for frequent treatments. You should care about this technology because it represents a breakthrough in the field of ophthalmology, with the potential to restore vision and improve the quality of life for patients suffering from debilitating retinal conditions.

We are seeking licensing partners who are interested in co-developing this groundbreaking technology. The ideal partner would have experience in gene therapy and a commitment to advancing innovative treatments in ophthalmology. We are open to discussions regarding collaboration and are eager to explore opportunities that align with our goals for this technology.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.

This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, affect millions of people worldwide and currently have limited treatment options. Our gene therapy targets the underlying genetic causes of these diseases, offering a potential cure rather than just symptomatic relief.

The technical solution involves the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to retinal cells. This method is significant because it not only addresses the root cause of the disease but also has the potential for long-lasting effects, reducing the need for frequent treatments. You should care about this technology because it represents a breakthrough in the field of ophthalmology, with the potential to restore vision and improve the quality of life for patients suffering from debilitating retinal conditions.

We are seeking licensing partners who are interested in co-developing this groundbreaking technology. The ideal partner would have experience in gene therapy and a commitment to advancing innovative treatments in ophthalmology. We are open to discussions regarding collaboration and are eager to explore opportunities that align with our goals for this technology.

# data[].attributes.field_commercial_applications.value
•	Treatment of age-related macular degeneration
•	Therapy for retinitis pigmentosa
•	Potential applications in other retinal disorders
•	Development of combination therapies with existing treatments

# data[].attributes.field_commercial_applications.processed
•	Treatment of age-related macular degeneration
•	Therapy for retinitis pigmentosa
•	Potential applications in other retinal disorders
•	Development of combination therapies with existing treatments

# data[].attributes.field_competitive_advantages.value
•	Targeted gene delivery using AAV vectors
•	Potential for long-lasting therapeutic effects
•	Addresses the root cause of retinal diseases
•	High safety profile with minimal side effects
•	Opportunity to significantly improve patient outcomes

# data[].attributes.field_competitive_advantages.processed
•	Targeted gene delivery using AAV vectors
•	Potential for long-lasting therapeutic effects
•	Addresses the root cause of retinal diseases
•	High safety profile with minimal side effects
•	Opportunity to significantly improve patient outcomes

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5116] Innovative Gene Therapy for Retinal Diseases&body=Please send me information about technology [TAB-5116] Innovative Gene Therapy for Retinal Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5116] Innovative Gene Therapy for Retinal Diseases&body=Please send me information about technology [TAB-5116] Innovative Gene Therapy for Retinal Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_publications[].value
Redmond TM, et al., 2000 (PMID: 10800710)

# data[].attributes.field_publications[].processed
Redmond TM, et al., 2000 (PMID: 10800710)

# data[].attributes.title
Snapwell Shipping Container for Live Cell Cultures

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.

This technology includes a specialized container designed for the secure shipping of fragile cell cultures grown on the Snapwell insert system, preventing media splashing that can damage the cells. The problem this invention addresses is the lack of reliable shipping options for sensitive tissues that cannot be frozen, which are increasingly used in tissue transplantation applications. Current methods do not adequately protect these tissues during transport, leading to potential damage and loss of viability.

The technical solution involves a series of thermo-molded inserts placed within standard 50ml containers, which create smaller protective compartments around the living cells. This design minimizes the movement of surrounding media, thereby reducing the risk of damage to the cell layer. This innovation is particularly relevant for academic institutions, biotechnology companies, and military applications, all of which are exploring new tissue transplantation technologies and require dependable shipping solutions.

We are seeking licensing opportunities for this technology, which has the potential for significant impact in the transplantation field. The prototype is ready for testing in research settings, and we are open to collaboration with partners interested in commercializing this invention.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.

This technology includes a specialized container designed for the secure shipping of fragile cell cultures grown on the Snapwell insert system, preventing media splashing that can damage the cells. The problem this invention addresses is the lack of reliable shipping options for sensitive tissues that cannot be frozen, which are increasingly used in tissue transplantation applications. Current methods do not adequately protect these tissues during transport, leading to potential damage and loss of viability.

The technical solution involves a series of thermo-molded inserts placed within standard 50ml containers, which create smaller protective compartments around the living cells. This design minimizes the movement of surrounding media, thereby reducing the risk of damage to the cell layer. This innovation is particularly relevant for academic institutions, biotechnology companies, and military applications, all of which are exploring new tissue transplantation technologies and require dependable shipping solutions.

We are seeking licensing opportunities for this technology, which has the potential for significant impact in the transplantation field. The prototype is ready for testing in research settings, and we are open to collaboration with partners interested in commercializing this invention.

# data[].attributes.field_commercial_applications.value
•	Shipping live cell cultures for research and clinical applications
•	Transporting sensitive tissues for transplantation
•	Use in academic and commercial laboratories focused on cell culture
•	Military applications requiring secure transport of biological materials
•	Development of specialized shipping solutions for biopharmaceutical companies

# data[].attributes.field_commercial_applications.processed
•	Shipping live cell cultures for research and clinical applications
•	Transporting sensitive tissues for transplantation
•	Use in academic and commercial laboratories focused on cell culture
•	Military applications requiring secure transport of biological materials
•	Development of specialized shipping solutions for biopharmaceutical companies

# data[].attributes.field_competitive_advantages.value
•	Provides a simple and cost-effective solution for shipping live cells without freezing
•	Protects fragile cell cultures from damage during transport
•	Customizable insert configurations to fit various container types
•	Utilizes FDA-approved materials for safety and compliance
•	Addresses a critical gap in the market for reliable tissue transportation

# data[].attributes.field_competitive_advantages.processed
•	Provides a simple and cost-effective solution for shipping live cells without freezing
•	Protects fragile cell cultures from damage during transport
•	Customizable insert configurations to fit various container types
•	Utilizes FDA-approved materials for safety and compliance
•	Addresses a critical gap in the market for reliable tissue transportation

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5118] Snapwell Shipping Container for Live Cell Cultures&body=Please send me information about technology [TAB-5118] Snapwell Shipping Container for Live Cell Cultures.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5118] Snapwell Shipping Container for Live Cell Cultures&body=Please send me information about technology [TAB-5118] Snapwell Shipping Container for Live Cell Cultures.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/524,434
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/524,434
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2024/035854
Filed on 2024-06-27
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2024/035854
Filed on 2024-06-27
Status: Expired

# data[].attributes.field_patents[].value
Canada
National Stage 3297165
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3297165
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2024308721
Filed on 2026-01-06
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2024308721
Filed on 2026-01-06
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 19/498,146
Filed on 2025-12-30
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 19/498,146
Filed on 2025-12-30
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 24746096.7
Filed on 2026-01-14
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 24746096.7
Filed on 2026-01-14
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/524,434
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2024/035854
Filed on 2024-06-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3297165
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2024308721
Filed on 2026-01-06
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 19/498,146
Filed on 2025-12-30
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 24746096.7
Filed on 2026-01-14
Status: Pending

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_patent_titles[]
SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS

# data[].attributes.field_technology_names[]
Container for shipping live cells on Snapwell

# data[].attributes.title
Targeted Disruption of Rpe65 Gene for Retinal Disease Research

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.

This technology includes the targeted disruption of the Rpe65 gene in mice, which serves as a crucial model for studying inherited retinal diseases and testing potential therapies. The RPE65 protein is essential for converting dietary vitamin A into the 11-cis isomer, a vital component for vision. The absence of this protein in our mouse model leads to a complete lack of 11-cis retinoids, resulting in blindness, thus confirming its role in the visual cycle. This innovative genetic strategy not only provides insights into the biochemical processes of vision but also opens avenues for developing treatments for RPE65-related retinal disorders.

The technical solution involves creating a genetically modified mouse model that lacks the Rpe65 gene, allowing researchers to observe the resulting phenotype and understand the implications of RPE65 mutations in human diseases. This model is particularly valuable for pharmaceutical companies and research institutions focused on ocular health, as it enables the testing of new drugs and therapies aimed at restoring vision in patients with RPE65 mutations. By utilizing this model, stakeholders can accelerate the development of effective treatments for retinal diseases, ultimately benefiting patients suffering from vision loss.

We are seeking licensing opportunities for this groundbreaking technology, which has already garnered interest from companies such as Acucela Inc. Collaborators can expect a mutually beneficial partnership that leverages our expertise in genetic engineering and retinal biology to advance therapeutic solutions. Licensing this technology will provide access to a unique research tool that can significantly impact the field of ophthalmology and vision science.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.

This technology includes the targeted disruption of the Rpe65 gene in mice, which serves as a crucial model for studying inherited retinal diseases and testing potential therapies. The RPE65 protein is essential for converting dietary vitamin A into the 11-cis isomer, a vital component for vision. The absence of this protein in our mouse model leads to a complete lack of 11-cis retinoids, resulting in blindness, thus confirming its role in the visual cycle. This innovative genetic strategy not only provides insights into the biochemical processes of vision but also opens avenues for developing treatments for RPE65-related retinal disorders.

The technical solution involves creating a genetically modified mouse model that lacks the Rpe65 gene, allowing researchers to observe the resulting phenotype and understand the implications of RPE65 mutations in human diseases. This model is particularly valuable for pharmaceutical companies and research institutions focused on ocular health, as it enables the testing of new drugs and therapies aimed at restoring vision in patients with RPE65 mutations. By utilizing this model, stakeholders can accelerate the development of effective treatments for retinal diseases, ultimately benefiting patients suffering from vision loss.

We are seeking licensing opportunities for this groundbreaking technology, which has already garnered interest from companies such as Acucela Inc. Collaborators can expect a mutually beneficial partnership that leverages our expertise in genetic engineering and retinal biology to advance therapeutic solutions. Licensing this technology will provide access to a unique research tool that can significantly impact the field of ophthalmology and vision science.

# data[].attributes.field_commercial_applications.value
•	Research into inherited retinal diseases
•	Testing of therapeutic compounds for RPE65 mutations
•	Development of gene therapies for vision restoration
•	Pharmaceutical research and development
•	Ocular health diagnostics and treatments

# data[].attributes.field_commercial_applications.processed
•	Research into inherited retinal diseases
•	Testing of therapeutic compounds for RPE65 mutations
•	Development of gene therapies for vision restoration
•	Pharmaceutical research and development
•	Ocular health diagnostics and treatments

# data[].attributes.field_competitive_advantages.value
•	First targeted disruption of the RPE65 gene
•	Provides a novel model for studying retinal diseases
•	Facilitates drug testing for RPE65-associated conditions
•	Offers insights into the visual cycle and vitamin A metabolism
•	Potential for collaboration with industry leaders

# data[].attributes.field_competitive_advantages.processed
•	First targeted disruption of the RPE65 gene
•	Provides a novel model for studying retinal diseases
•	Facilitates drug testing for RPE65-associated conditions
•	Offers insights into the visual cycle and vitamin A metabolism
•	Potential for collaboration with industry leaders

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research&body=Please send me information about technology [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research&body=Please send me information about technology [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_publications[].value
Redmond, T.M., et al., 1998 (PMID: 9843205)

# data[].attributes.field_publications[].processed
Redmond, T.M., et al., 1998 (PMID: 9843205)

# data[].attributes.field_technology_names[]
Targeted Disruption Of Rpe65 Gene In Mouse

# data[].attributes.title
Detection of Organomercurial Compound Biosynthesis in Microbial Communities

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.

This technology includes a novel method for detecting organomercurial compound biosynthesis, which poses significant health risks due to mercury contamination. Current detection methods primarily focus on the HgcAB system, which is limited in scope and effectiveness. Our approach leverages sequence-based techniques to identify a new family of radical SAM proteins that are likely involved in the formation of organomercurials through an unknown mechanism. This advancement allows for a more comprehensive and accurate identification of mercury-methylating organisms, which is crucial for assessing environmental and health risks.

The technical solution involves the construction of a hidden Markov model (HMM) named NF040546, which serves as a search tool to identify members of this novel enzyme family. This is important because it opens new avenues for understanding microbial mercury methylation pathways, which have been inadequately characterized by existing methods. By improving detection capabilities, this technology can significantly enhance environmental monitoring and public health safety, making it a valuable asset for researchers and industries concerned with mercury contamination.

We are seeking licensing opportunities for this technology, which has the potential to be developed into commercial products or services aimed at environmental monitoring and health risk assessment. Collaborators or licensees can expect to engage in a mutually beneficial partnership that leverages our innovative detection methods and their applications in various fields, including agriculture and public health.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.

This technology includes a novel method for detecting organomercurial compound biosynthesis, which poses significant health risks due to mercury contamination. Current detection methods primarily focus on the HgcAB system, which is limited in scope and effectiveness. Our approach leverages sequence-based techniques to identify a new family of radical SAM proteins that are likely involved in the formation of organomercurials through an unknown mechanism. This advancement allows for a more comprehensive and accurate identification of mercury-methylating organisms, which is crucial for assessing environmental and health risks.

The technical solution involves the construction of a hidden Markov model (HMM) named NF040546, which serves as a search tool to identify members of this novel enzyme family. This is important because it opens new avenues for understanding microbial mercury methylation pathways, which have been inadequately characterized by existing methods. By improving detection capabilities, this technology can significantly enhance environmental monitoring and public health safety, making it a valuable asset for researchers and industries concerned with mercury contamination.

We are seeking licensing opportunities for this technology, which has the potential to be developed into commercial products or services aimed at environmental monitoring and health risk assessment. Collaborators or licensees can expect to engage in a mutually beneficial partnership that leverages our innovative detection methods and their applications in various fields, including agriculture and public health.

# data[].attributes.field_commercial_applications.value
•	Sequencing and analysis methods for detecting mercury-methylated microbes in agricultural and human microbiomes
•	Development of probiotic microbes or prebiotic supplements to reduce mercury-methylating microbes in human gut microbiomes
•	Environmental monitoring tools for assessing mercury contamination risks in various ecosystems

# data[].attributes.field_commercial_applications.processed
•	Sequencing and analysis methods for detecting mercury-methylated microbes in agricultural and human microbiomes
•	Development of probiotic microbes or prebiotic supplements to reduce mercury-methylating microbes in human gut microbiomes
•	Environmental monitoring tools for assessing mercury contamination risks in various ecosystems

# data[].attributes.field_competitive_advantages.value
•	Novel detection method for organomercurial biosynthesis that surpasses existing technologies
•	Utilizes sequence-based methods to identify previously uncharacterized microbial pathways
•	Enhances accuracy and thoroughness in identifying mercury-methylating organisms
•	Potential for broad applications in environmental monitoring and public health safety

# data[].attributes.field_competitive_advantages.processed
•	Novel detection method for organomercurial biosynthesis that surpasses existing technologies
•	Utilizes sequence-based methods to identify previously uncharacterized microbial pathways
•	Enhances accuracy and thoroughness in identifying mercury-methylating organisms
•	Potential for broad applications in environmental monitoring and public health safety

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/642,512
Filed on 2024-05-03
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/642,512
Filed on 2024-05-03
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/027781
Filed on 2025-05-05
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/027781
Filed on 2025-05-05
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/642,512
Filed on 2024-05-03
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/027781
Filed on 2025-05-05
Status: Pending

# data[].attributes.field_patent_titles[]
CORYNEBACTERIUM MASTITIDIS-DERIVED MYCOLATES FOR TREATING OCULAR SURFACE DISEASES

# data[].attributes.field_publications[].value
Xiaoyan Xu, et al., 2026 (PMID 41558487)

# data[].attributes.field_publications[].processed
Xiaoyan Xu, et al., 2026 (PMID 41558487)

# data[].attributes.field_technology_names[]
Corynebacterium mastitidis-derived mycolates for treating ocular surface diseases

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation.

This technology includes a dual-layer biodegradable tissue scaffold designed for the transplantation of multiple tissue types, such as retinal pigment epithelium (RPE) and photoreceptors. The current challenge in tissue transplantation is the lack of mechanical strength in existing scaffolds, which often leads to separation during handling and implantation. This innovative scaffold addresses these issues by utilizing a unique structure made from poly(lactic-co-glycolic acid) (PLGA) that combines a lower support layer with a secondary matrix of lactide-rich loops, enhancing stability and facilitating cell adhesion and polarization.

The technical solution involves a temperature-fused design that creates a robust scaffold with minimal capillary forces, allowing for better integration of the two tissue layers. This is particularly important for complex eye surgeries where multiple tissues are affected. By providing a supportive environment for weakly adherent cells, this scaffold can significantly improve the outcomes of retinal and choroidal transplants, making it a valuable tool for restoring vision in patients with advanced eye diseases.

The licensing opportunity for this technology is open for collaboration with industry partners interested in advancing tissue engineering and transplantation techniques. The inventor seeks partnerships that can help bring this innovative scaffold to market, focusing on its application in regenerative medicine and ophthalmology.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation.

This technology includes a dual-layer biodegradable tissue scaffold designed for the transplantation of multiple tissue types, such as retinal pigment epithelium (RPE) and photoreceptors. The current challenge in tissue transplantation is the lack of mechanical strength in existing scaffolds, which often leads to separation during handling and implantation. This innovative scaffold addresses these issues by utilizing a unique structure made from poly(lactic-co-glycolic acid) (PLGA) that combines a lower support layer with a secondary matrix of lactide-rich loops, enhancing stability and facilitating cell adhesion and polarization.

The technical solution involves a temperature-fused design that creates a robust scaffold with minimal capillary forces, allowing for better integration of the two tissue layers. This is particularly important for complex eye surgeries where multiple tissues are affected. By providing a supportive environment for weakly adherent cells, this scaffold can significantly improve the outcomes of retinal and choroidal transplants, making it a valuable tool for restoring vision in patients with advanced eye diseases.

The licensing opportunity for this technology is open for collaboration with industry partners interested in advancing tissue engineering and transplantation techniques. The inventor seeks partnerships that can help bring this innovative scaffold to market, focusing on its application in regenerative medicine and ophthalmology.

# data[].attributes.field_commercial_applications.value
•	Retinal and choroidal tissue transplantation
•	Regenerative medicine for ocular diseases
•	Development of multi-tissue implants for complex surgical procedures
•	Research applications in tissue engineering and biomaterials
•	Potential use in other organ systems requiring scaffold support

# data[].attributes.field_commercial_applications.processed
•	Retinal and choroidal tissue transplantation
•	Regenerative medicine for ocular diseases
•	Development of multi-tissue implants for complex surgical procedures
•	Research applications in tissue engineering and biomaterials
•	Potential use in other organ systems requiring scaffold support

# data[].attributes.field_competitive_advantages.value
•	Biodegradable material ensures anatomical integrity post-transplant
•	Enhanced mechanical strength through fused fibers and loop structures
•	Reduced capillary forces improve cell integration and function
•	Facilitates the transplantation of multiple tissue types simultaneously
•	Customizable for various tissue engineering applications

# data[].attributes.field_competitive_advantages.processed
•	Biodegradable material ensures anatomical integrity post-transplant
•	Enhanced mechanical strength through fused fibers and loop structures
•	Reduced capillary forces improve cell integration and function
•	Facilitates the transplantation of multiple tissue types simultaneously
•	Customizable for various tissue engineering applications

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/194,770
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/194,770
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/031107
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/031107
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2023-572792
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2023-572792
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3220433
Filed on 2023-11-28
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3220433
Filed on 2023-11-28
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2022282379
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2022282379
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/290,396
Filed on 2023-11-13
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/290,396
Filed on 2023-11-13
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Spain
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Spain
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Italy
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Italy
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Germany
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Denmark
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Denmark
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Belgium
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Belgium
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Sweden
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Sweden
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
Switzerland
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
Switzerland
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].value
The Netherlands
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patents[].processed
The Netherlands
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/194,770
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/031107
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2023-572792
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3220433
Filed on 2023-11-28
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2022282379
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/290,396
Filed on 2023-11-13
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Spain
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Italy
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Denmark
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Belgium
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Sweden
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
Switzerland
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_htmls[]
The Netherlands
European patent (EP) 22732802.8
Filed on 2023-12-14
Status: Issued

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_patent_titles[]
BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST

# data[].attributes.field_technology_names[]
Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells

# data[].attributes.title
A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.

This technology includes a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells, which are crucial for developing targeted cell therapies and drug discovery for retinal degenerative diseases. The problem lies in the lack of in vitro models that accurately reproduce the regional diversity and vulnerability of RPE cells, particularly in conditions like age-related macular degeneration (AMD) and retinitis pigmentosa. Our innovative approach utilizes two specific drugs, AGN 193109 and endo-IWR 1, to induce distinct macular and peripheral RPE phenotypes from induced pluripotent stem cells (iPSCs), enabling the study of regional RPE defects and high-throughput drug screening for specific retinal conditions.

The technical solution leverages the unique properties of iPSC-derived RPE cells, which can be manipulated to reflect the diverse characteristics of human RPE. This is significant because it allows researchers and clinicians to better understand the mechanisms underlying retinal diseases and to develop targeted therapies. By creating a high-throughput platform for generating various RPE cell types, we can facilitate the discovery of disease-specific pathways and drug candidates, ultimately leading to improved treatment options for patients suffering from retinal degenerative diseases.

We are seeking licensing opportunities for this technology, which has the potential to revolutionize the field of retinal research and therapy. Collaborators and licensees will benefit from access to a cutting-edge platform that addresses a critical gap in current RPE research and therapeutic development. We are open to discussions regarding potential partnerships and collaborations to further advance this technology.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.

This technology includes a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells, which are crucial for developing targeted cell therapies and drug discovery for retinal degenerative diseases. The problem lies in the lack of in vitro models that accurately reproduce the regional diversity and vulnerability of RPE cells, particularly in conditions like age-related macular degeneration (AMD) and retinitis pigmentosa. Our innovative approach utilizes two specific drugs, AGN 193109 and endo-IWR 1, to induce distinct macular and peripheral RPE phenotypes from induced pluripotent stem cells (iPSCs), enabling the study of regional RPE defects and high-throughput drug screening for specific retinal conditions.

The technical solution leverages the unique properties of iPSC-derived RPE cells, which can be manipulated to reflect the diverse characteristics of human RPE. This is significant because it allows researchers and clinicians to better understand the mechanisms underlying retinal diseases and to develop targeted therapies. By creating a high-throughput platform for generating various RPE cell types, we can facilitate the discovery of disease-specific pathways and drug candidates, ultimately leading to improved treatment options for patients suffering from retinal degenerative diseases.

We are seeking licensing opportunities for this technology, which has the potential to revolutionize the field of retinal research and therapy. Collaborators and licensees will benefit from access to a cutting-edge platform that addresses a critical gap in current RPE research and therapeutic development. We are open to discussions regarding potential partnerships and collaborations to further advance this technology.

# data[].attributes.field_commercial_applications.value
•	Development of macular and peripheral RPE patches for cell therapy
•	High-throughput drug screening for retinal diseases
•	In vitro modeling of retinal degenerative diseases
•	Research on regional RPE defects in various conditions
•	Discovery of disease-specific pathways and drug candidates

# data[].attributes.field_commercial_applications.processed
•	Development of macular and peripheral RPE patches for cell therapy
•	High-throughput drug screening for retinal diseases
•	In vitro modeling of retinal degenerative diseases
•	Research on regional RPE defects in various conditions
•	Discovery of disease-specific pathways and drug candidates

# data[].attributes.field_competitive_advantages.value
•	Unique ability to generate macular and peripheral RPE cells in vitro
•	Addresses a significant gap in current retinal research models
•	Enables high-throughput drug screening for specific retinal diseases
•	Provides a platform for studying regional RPE defects and disease mechanisms
•	Potential for developing targeted cell therapies for retinal degenerative diseases

# data[].attributes.field_competitive_advantages.processed
•	Unique ability to generate macular and peripheral RPE cells in vitro
•	Addresses a significant gap in current retinal research models
•	Enables high-throughput drug screening for specific retinal diseases
•	Provides a platform for studying regional RPE defects and disease mechanisms
•	Potential for developing targeted cell therapies for retinal degenerative diseases

# data[].attributes.field_licensingcontact_hrefs[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/194,774
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/194,774
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
Patent Cooperation Treaty Combined (PCT COMB) PCT/US2022/031136
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
Patent Cooperation Treaty Combined (PCT COMB) PCT/US2022/031136
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2023-572794
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2023-572794
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3220602
Filed on 2023-11-17
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3220602
Filed on 2023-11-17
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 22736412.2
Filed on 2023-12-19
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 22736412.2
Filed on 2023-12-19
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2022280062
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2022280062
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/562,806
Filed on 2023-11-20
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/562,806
Filed on 2023-11-20
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/194,774
Filed on 2021-05-28
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
Patent Cooperation Treaty Combined (PCT COMB) PCT/US2022/031136
Filed on 2022-05-26
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2023-572794
Filed on 2023-11-24
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3220602
Filed on 2023-11-17
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 22736412.2
Filed on 2023-12-19
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2022280062
Filed on 2023-11-10
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/562,806
Filed on 2023-11-20
Status: Pending

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_patent_titles[]
METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS

# data[].attributes.field_publications[].value
Ortolan D, et al., 2022 (PMID: 35522714)

# data[].attributes.field_publications[].processed
Ortolan D, et al., 2022 (PMID: 35522714)

# data[].attributes.field_technology_names[]
A Robust Method To Generate Macular Vs Peripheral RPE Cells Of Cell Therapy And Drug Discovery

# data[].attributes.title
Mini-Bioreactor for Enhanced Organoid Culture

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.

This technology includes a mini-bioreactor designed to improve organoid outcomes in cell culture applications. The bioreactor system is a multi-well, 3D-printed device that fits standard 100 mm cell culture dishes and utilizes a central stirring mechanism to create a controlled laminar flow. This innovative design addresses the common challenges in organoid culture, such as non-specific adherence and fusion, while enhancing mass transfer without the shear stress typically associated with other bioreactor systems.

The technical solution provided by this bioreactor is significant because it simplifies the organoid culture process by integrating a single-component system that is compatible with standard lab equipment. This means that researchers can easily adopt this technology without needing specialized training or additional components. The ability to track individual organoids longitudinally further enhances its utility in research settings, making it an attractive option for laboratories focused on organoid studies.

The licensing opportunity for this technology is promising, as it can be developed and produced in less than two years. Companies that manufacture cell culture vessels, such as Corning, Thermo Fisher, and VWR, may find this bioreactor particularly appealing for their product lines. Collaboration with the inventors is encouraged to explore the full commercial potential of this innovative bioreactor system.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.

This technology includes a mini-bioreactor designed to improve organoid outcomes in cell culture applications. The bioreactor system is a multi-well, 3D-printed device that fits standard 100 mm cell culture dishes and utilizes a central stirring mechanism to create a controlled laminar flow. This innovative design addresses the common challenges in organoid culture, such as non-specific adherence and fusion, while enhancing mass transfer without the shear stress typically associated with other bioreactor systems.

The technical solution provided by this bioreactor is significant because it simplifies the organoid culture process by integrating a single-component system that is compatible with standard lab equipment. This means that researchers can easily adopt this technology without needing specialized training or additional components. The ability to track individual organoids longitudinally further enhances its utility in research settings, making it an attractive option for laboratories focused on organoid studies.

The licensing opportunity for this technology is promising, as it can be developed and produced in less than two years. Companies that manufacture cell culture vessels, such as Corning, Thermo Fisher, and VWR, may find this bioreactor particularly appealing for their product lines. Collaboration with the inventors is encouraged to explore the full commercial potential of this innovative bioreactor system.

# data[].attributes.field_commercial_applications.value
•	Organoid culture for drug testing and development
•	Research in regenerative medicine and tissue engineering
•	Applications in personalized medicine and disease modeling
•	Use in academic and industrial research laboratories

# data[].attributes.field_commercial_applications.processed
•	Organoid culture for drug testing and development
•	Research in regenerative medicine and tissue engineering
•	Applications in personalized medicine and disease modeling
•	Use in academic and industrial research laboratories

# data[].attributes.field_competitive_advantages.value
•	Simplified design with a single component, reducing complexity in organoid culture
•	Compatible with standard 100 mm cell culture dishes and existing lab equipment
•	Enhanced mass transfer without the shear stress associated with traditional bioreactors
•	Longitudinal tracking of individual organoids for improved research outcomes
•	Potential for rapid commercialization within two years

# data[].attributes.field_competitive_advantages.processed
•	Simplified design with a single component, reducing complexity in organoid culture
•	Compatible with standard 100 mm cell culture dishes and existing lab equipment
•	Enhanced mass transfer without the shear stress associated with traditional bioreactors
•	Longitudinal tracking of individual organoids for improved research outcomes
•	Potential for rapid commercialization within two years

# data[].attributes.field_licensingcontact_htmls[]
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].value
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Fenn, Edward (Tedd)
tedd.fenn@nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/541,656
Filed on 2023-09-29
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/541,656
Filed on 2023-09-29
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2024/049060
Filed on 2024-09-27
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2024/049060
Filed on 2024-09-27
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2026-519253
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2026-519253
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patents[].value
Australia
National Stage 2024353162
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2024353162
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 19/524,229
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 19/524,229
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 24790765.2
Filed on 2026-04-29
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 24790765.2
Filed on 2026-04-29
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3305823
Filed on 2026-03-23
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3305823
Filed on 2026-03-23
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/541,656
Filed on 2023-09-29
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2024/049060
Filed on 2024-09-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2026-519253
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2024353162
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 19/524,229
Filed on 2026-03-27
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 24790765.2
Filed on 2026-04-29
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3305823
Filed on 2026-03-23
Status: Pending

# data[].attributes.field_technology_names[]
Mini-bioreactor to improve organoid outcomes

# data[].attributes.field_technology_owners[]
National Eye Institute (NEI), National Eye Institute (NEI)

# data[].attributes.title
RPGR Gene Therapy for Retinitis Pigmentosa

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.

This technology includes an abbreviated version of the RPGR gene that is effective in gene replacement therapy for treating X-linked Retinitis Pigmentosa (XLRP). This condition is a genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells in the retina. The current version of RPGR is known to be unstable and can undergo changes in vivo, which may be harmful to recipient cells. The abbreviated RPGR retains its function, rescues the disease, and is stabilized, making it a safer option for gene therapy.

The technical solution involves using an adeno-associated viral vector that carries the abbreviated human RPGR cDNA. This vector supplies functional RPGR proteins to treat inherited ocular disorders related to RPGR mutations. This technology is significant because it addresses the instability issues of the current RPGR gene therapy approaches, providing a more reliable and effective treatment option for patients suffering from XLRP. Stakeholders in the ophthalmology and gene therapy fields should care about this innovation as it represents a potential breakthrough in treating a debilitating condition.

The licensing opportunity for this technology is open for collaboration with interested parties who are looking to develop and commercialize this gene therapy. The inventors are seeking partners who can assist in further development and potential market entry, ensuring that this promising therapy reaches those in need.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.

This technology includes an abbreviated version of the RPGR gene that is effective in gene replacement therapy for treating X-linked Retinitis Pigmentosa (XLRP). This condition is a genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells in the retina. The current version of RPGR is known to be unstable and can undergo changes in vivo, which may be harmful to recipient cells. The abbreviated RPGR retains its function, rescues the disease, and is stabilized, making it a safer option for gene therapy.

The technical solution involves using an adeno-associated viral vector that carries the abbreviated human RPGR cDNA. This vector supplies functional RPGR proteins to treat inherited ocular disorders related to RPGR mutations. This technology is significant because it addresses the instability issues of the current RPGR gene therapy approaches, providing a more reliable and effective treatment option for patients suffering from XLRP. Stakeholders in the ophthalmology and gene therapy fields should care about this innovation as it represents a potential breakthrough in treating a debilitating condition.

The licensing opportunity for this technology is open for collaboration with interested parties who are looking to develop and commercialize this gene therapy. The inventors are seeking partners who can assist in further development and potential market entry, ensuring that this promising therapy reaches those in need.

# data[].attributes.field_commercial_applications.value
•	Treatment for X-linked Retinitis Pigmentosa
•	Gene therapy for other inherited retinal diseases
•	Research applications in gene therapy and ophthalmology

# data[].attributes.field_commercial_applications.processed
•	Treatment for X-linked Retinitis Pigmentosa
•	Gene therapy for other inherited retinal diseases
•	Research applications in gene therapy and ophthalmology

# data[].attributes.field_competitive_advantages.value
•	Abbreviated RPGR gene is more stable than the current version
•	Effective in rescuing photoreceptor function in XLRP models
•	Utilizes a safe adeno-associated viral vector for delivery
•	Potential for broader applications in other RPGR-related ocular disorders

# data[].attributes.field_competitive_advantages.processed
•	Abbreviated RPGR gene is more stable than the current version
•	Effective in rescuing photoreceptor function in XLRP models
•	Utilizes a safe adeno-associated viral vector for delivery
•	Potential for broader applications in other RPGR-related ocular disorders

# data[].attributes.field_inventor_companies[]
Massachusetts Eye & Ear Infirmary (MEEI)

# data[].attributes.field_inventor_companies[]
Massachusetts Eye & Ear Infirmary (MEEI)

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa&body=Please send me information about technology [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa&body=Please send me information about technology [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/028,638
Filed on 2014-07-24
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/028,638
Filed on 2014-07-24
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2015/040866
Filed on 2015-07-17
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2015/040866
Filed on 2015-07-17
Status: Expired

# data[].attributes.field_patents[].value
China
National Stage 201580051512.3
Filed on 2015-07-17
Status: Pending

# data[].attributes.field_patents[].processed
China
National Stage 201580051512.3
Filed on 2015-07-17
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 2991750
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Canada
National Stage 2991750
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
European Patent
National Stage 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
National Stage 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Japan
National Stage 2017-525514
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Japan
National Stage 2017-525514
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
US Patent 10,314,924
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 10,314,924
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
US Patent 11,045,558
Filed on 2019-06-10
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 11,045,558
Filed on 2019-06-10
Status: Issued

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2019-235539
Filed on 2019-12-26
Status: Issued

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2019-235539
Filed on 2019-12-26
Status: Issued

# data[].attributes.field_patents[].value
European Patent
Divisional (DIV) 20199208.8
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
European Patent
Divisional (DIV) 20199208.8
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Belgium
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Belgium
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Bulgaria
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Bulgaria
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Germany
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Denmark
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Denmark
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Estonia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Estonia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Spain
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Spain
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Finland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Finland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
France
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
France
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Iceland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Iceland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Italy
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Italy
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Luxembourg
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Luxembourg
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Latvia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Latvia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
The Netherlands
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
The Netherlands
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Portugal
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Portugal
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Sweden
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Sweden
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Turkey
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Turkey
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Cyprus
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Cyprus
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Greece
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Greece
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Hungary
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Hungary
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Malta
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].processed
Malta
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2021-172128
Filed on 2021-10-21
Status: Issued

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2021-172128
Filed on 2021-10-21
Status: Issued

# data[].attributes.field_patents[].value
Hong Kong
European patent (EP) 42021042687.0
Filed on 2021-11-18
Status: Pending

# data[].attributes.field_patents[].processed
Hong Kong
European patent (EP) 42021042687.0
Filed on 2021-11-18
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/028,638
Filed on 2014-07-24
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2015/040866
Filed on 2015-07-17
Status: Expired

# data[].attributes.field_patent_htmls[]
China
National Stage 201580051512.3
Filed on 2015-07-17
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2991750
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2017-525514
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 10,314,924
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 11,045,558
Filed on 2019-06-10
Status: Issued

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2019-235539
Filed on 2019-12-26
Status: Issued

# data[].attributes.field_patent_htmls[]
European Patent
Divisional (DIV) 20199208.8
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Belgium
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Bulgaria
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Denmark
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Estonia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Spain
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Finland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Iceland
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Italy
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Luxembourg
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Latvia
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
The Netherlands
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Portugal
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Sweden
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Turkey
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Cyprus
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Greece
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Hungary
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Malta
European patent (EP) 15825383.1
Filed on 2015-07-17
Status: Issued

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2021-172128
Filed on 2021-10-21
Status: Issued

# data[].attributes.field_patent_htmls[]
Hong Kong
European patent (EP) 42021042687.0
Filed on 2021-11-18
Status: Pending

# data[].attributes.field_patent_titles[]
THE RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA

# data[].attributes.field_patent_titles[]
Abbreviated Version Of RPGR Is Effective In Gene Replacement Therapy

# data[].attributes.field_patent_titles[]
RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA

# data[].attributes.field_technology_names[]
Abbreviated Version Of RPGR Is Effective In Gene Replacement Therapy

# data[].attributes.field_technology_owners[]
Massachusetts Eye & Ear Infirmary (MEEI), Medical Research Council, National Eye Institute (NEI), University College London

# data[].attributes.title
AI Based Workflow for Single Cell Analysis

# data[].attributes.body.value
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.

This technology includes SCassist, an innovative open-source R package designed to enhance single-cell RNA sequencing (scRNA-seq) data analysis. The complexity of scRNA-seq workflows often requires extensive expertise, making it challenging for many researchers to fully explore their data. This limitation can hinder scientific discovery and innovation, as researchers may struggle to navigate through the intricate stages of data filtering, normalization, clustering, and interpretation. SCassist addresses these challenges by leveraging large language models (LLMs) to provide intelligent recommendations and interpretations throughout the analysis process, making advanced scRNA-seq analysis accessible to researchers at all levels.

SCassist integrates LLMs into key workflow steps, offering guidance on filtering, normalization, clustering parameters, and insightful interpretations of variable features and principal components. It also performs cell type annotations and provides a system-level view through network representations based on pathway and ontology enrichment analyses. This user-friendly interface allows researchers to incorporate AI-driven insights into their scRNA-seq analysis, ultimately accelerating their workflow and uncovering deeper biological understanding. By democratizing scRNA-seq analysis, SCassist empowers researchers to navigate complexities and make the most of their valuable data.

The National Eye Institute (NEI) is seeking licensing opportunities and collaborative partnerships to further develop and expand the capabilities of SCassist. This technology has the potential to be utilized across various fields, including genomics, proteomics, and metabolomics, enabling researchers to gain novel insights into their ‘omics’ scale data. The NEI welcomes inquiries from potential partners interested in leveraging SCassist to enhance their research capabilities and drive scientific innovation.

# data[].attributes.body.processed
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.

This technology includes SCassist, an innovative open-source R package designed to enhance single-cell RNA sequencing (scRNA-seq) data analysis. The complexity of scRNA-seq workflows often requires extensive expertise, making it challenging for many researchers to fully explore their data. This limitation can hinder scientific discovery and innovation, as researchers may struggle to navigate through the intricate stages of data filtering, normalization, clustering, and interpretation. SCassist addresses these challenges by leveraging large language models (LLMs) to provide intelligent recommendations and interpretations throughout the analysis process, making advanced scRNA-seq analysis accessible to researchers at all levels.

SCassist integrates LLMs into key workflow steps, offering guidance on filtering, normalization, clustering parameters, and insightful interpretations of variable features and principal components. It also performs cell type annotations and provides a system-level view through network representations based on pathway and ontology enrichment analyses. This user-friendly interface allows researchers to incorporate AI-driven insights into their scRNA-seq analysis, ultimately accelerating their workflow and uncovering deeper biological understanding. By democratizing scRNA-seq analysis, SCassist empowers researchers to navigate complexities and make the most of their valuable data.

The National Eye Institute (NEI) is seeking licensing opportunities and collaborative partnerships to further develop and expand the capabilities of SCassist. This technology has the potential to be utilized across various fields, including genomics, proteomics, and metabolomics, enabling researchers to gain novel insights into their ‘omics’ scale data. The NEI welcomes inquiries from potential partners interested in leveraging SCassist to enhance their research capabilities and drive scientific innovation.

# data[].attributes.field_commercial_applications.value
•	Basic researchers
•	Biomarker identification, toxicology studies, cell therapy development
•	Companies specializing in single cell sequencing technologies can incorporate SCassist into their product offerings, enhancing the analytical capabilities and value of their platforms
•	Companies providing sequencing services can integrate an analysis platform for customers

# data[].attributes.field_commercial_applications.processed
•	Basic researchers
•	Biomarker identification, toxicology studies, cell therapy development
•	Companies specializing in single cell sequencing technologies can incorporate SCassist into their product offerings, enhancing the analytical capabilities and value of their platforms
•	Companies providing sequencing services can integrate an analysis platform for customers

# data[].attributes.field_competitive_advantages.value
•	Makes scRNA-seq analysis accessible to researchers at all levels by providing user guidance in a user-friendly interface
•	Incorporation of artificial intelligence assistance for parameter selections
•	Seamlessly integrates LLMs into the standard single cell analysis workflow, providing LLM-guided interpretations, cell type annotations, and enrichment analysis
•	Addresses the computational challenges associated with single-cell RNA-seq data analysis, regardless of how libraries and data are generated
•	All encompassing workflow from start to finish

# data[].attributes.field_competitive_advantages.processed
•	Makes scRNA-seq analysis accessible to researchers at all levels by providing user guidance in a user-friendly interface
•	Incorporation of artificial intelligence assistance for parameter selections
•	Seamlessly integrates LLMs into the standard single cell analysis workflow, providing LLM-guided interpretations, cell type annotations, and enrichment analysis
•	Addresses the computational challenges associated with single-cell RNA-seq data analysis, regardless of how libraries and data are generated
•	All encompassing workflow from start to finish

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5104] AI Based Workflow for Single Cell Analysis&body=Please send me information about technology [TAB-5104] AI Based Workflow for Single Cell Analysis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5104] AI Based Workflow for Single Cell Analysis&body=Please send me information about technology [TAB-5104] AI Based Workflow for Single Cell Analysis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/739,320
Filed on 2024-12-27
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/739,320
Filed on 2024-12-27
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/061495
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/061495
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/739,320
Filed on 2024-12-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/061495
Filed on 2025-12-29
Status: Pending

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE BASED WORKFLOW ASSISTANT FOR SINGLE CELL ANALYSIS

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE BASED WORKFLOW ASSISTANT FOR SINGLE CELL ANALYSIS

# data[].attributes.field_publications[].value
Nagarajan V, et al., 2005 (PMID 40093069)

# data[].attributes.field_publications[].processed
Nagarajan V, et al., 2005 (PMID 40093069)

# data[].attributes.field_technology_names[]
AI Based Workflow Assistant for Single Cell Analysis

# data[].attributes.title
EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques

# data[].attributes.body.value
Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic interventions targeting this virus.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID) have identified four monoclonal antibodies that potently bind and neutralize multiple subclades of EV-D68, including B3 and A2 variants. Animal studies have indicated that these Rhesus macaque-derived monoclonal antibodies (mAbs) are likely to confer protection against respiratory illness in young children (particularly those under age 5) and in individuals with respiratory or immunocompromising conditions. Analyses conducted using standard techniques such as cryo-EM have enabled the inventors to further characterize the epitopes of two unique EV-D68-specific antibodies, suggesting the value of this technology for developing multi-specific approaches that confer broad protection against EV-D68.

Humanization and combination of these mAbs with other antibodies exhibiting unique epitope specificities may prove beneficial for therapeutic or prophylactic purposes, especially within the context of a broader pandemic preparedness program. Further, these antibodies could be incorporated into diagnostic assays/kits for the rapid and accurate detection of EV-D68 in clinical or non-clinical settings.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

# data[].attributes.body.processed
Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic interventions targeting this virus.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID) have identified four monoclonal antibodies that potently bind and neutralize multiple subclades of EV-D68, including B3 and A2 variants. Animal studies have indicated that these Rhesus macaque-derived monoclonal antibodies (mAbs) are likely to confer protection against respiratory illness in young children (particularly those under age 5) and in individuals with respiratory or immunocompromising conditions. Analyses conducted using standard techniques such as cryo-EM have enabled the inventors to further characterize the epitopes of two unique EV-D68-specific antibodies, suggesting the value of this technology for developing multi-specific approaches that confer broad protection against EV-D68.

Humanization and combination of these mAbs with other antibodies exhibiting unique epitope specificities may prove beneficial for therapeutic or prophylactic purposes, especially within the context of a broader pandemic preparedness program. Further, these antibodies could be incorporated into diagnostic assays/kits for the rapid and accurate detection of EV-D68 in clinical or non-clinical settings.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

# data[].attributes.field_commercial_applications.value
Prevention or treatment of EV-D68 infection

Development of diagnostic assays for rapid, accurate EV-D68 detection in clinical and non-clinical settings

# data[].attributes.field_commercial_applications.processed
Prevention or treatment of EV-D68 infection

Development of diagnostic assays for rapid, accurate EV-D68 detection in clinical and non-clinical settings

# data[].attributes.field_competitive_advantages.value
Development of prophylactic or therapeutic interventions against EV-D68 that effectively induce broad protection against multiple circulating subclades

# data[].attributes.field_competitive_advantages.processed
Development of prophylactic or therapeutic interventions against EV-D68 that effectively induce broad protection against multiple circulating subclades

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques&body=Please send me information about technology [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques.

# data[].attributes.field_licensingcontact_htmls[]
Bailey, Brian
bbailey@mail.nih.gov

# data[].attributes.field_licensing_contacts[].value
Bailey, Brian
bbailey@mail.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Bailey, Brian
bbailey@mail.nih.gov

# data[].attributes.field_licensing_contacts_uris[]
bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques&body=Please send me information about technology [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/640,619
Filed on 2024-04-30
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/640,619
Filed on 2024-04-30
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/027110
Filed on 2025-04-30
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/027110
Filed on 2025-04-30
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/640,619
Filed on 2024-04-30
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/027110
Filed on 2025-04-30
Status: Pending

# data[].attributes.field_publications[].value
Krug et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9:eadg6076. https://doi.org/10.1126/sciadv.adg6076

# data[].attributes.field_publications[].processed
Krug et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9:eadg6076. https://doi.org/10.1126/sciadv.adg6076

# data[].attributes.field_technology_names[]
EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIH - NIAID

# data[].attributes.title
Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration

# data[].attributes.body.value
Summary:

The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.

Description of Technology:

Inherited Retinal Degenerations (IRD), such as Leber Congenital Amaurosis (LCA) and retinitis pigmentosa (RP), are characterized by a progressive loss of photo-sensitive cells in the retina. Most forms of IRD have no therapeutic options available due to their genetic heterogeneity and/or lack of mechanistic understanding. In particular, LCA represents roughly 5% of all retinal dystrophies and results in severe vision loss at an early age. There is an FDA-approved treatment for one form of LCA caused by mutations in the RPE 65 gene. This involves injection of an adenovirus vector containing the normal copy of the RPE65 gene. Long-term data for the gene therapy achieved only transient results: progressive reduction in visual acuity, sensitivity and function occurred following an initial gain seen 6-12 months post-treatment.

RP is a collection of rare eye diseases that affect roughly 1 in 4000 people worldwide. Currently, as there are no treatments, a majority of affected individuals lose most of their sight.

By 2040, age-related macular degeneration (AMD) will affect ~288 million people worldwide. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.

Scientists at the National Eye Institute (NEI) have developed a mutation-independent method to treat LCA, RP, other IRDs, and AMD using the FDA-approved small molecule, Halofantrine (NCGC00016833-01). Halofantrine, which was previously approved to treat malaria, helped protect photoreceptors from cell death in three different IRD model systems in 1) retinal organoid model systems, 2) two different mouse models, and 3) rat models. Furthermore, packaging Halofantrine and other potential candidate compounds for conjunctival delivery into the eye via eye drops is under development.

These small molecules act by targeting several cellular pathways which are also affected in diseases of other organs, suggesting that they may be useful in treating other, mutation independent ocular diseases.

Potential Commercial Applications:

Therapeutic to treat Leber congenital amaurosis

Therapeutic to treat Inherited Retinal Disorders associated with photoreceptor degeneration

Therapeutic to treat AMD

Therapeutic to treat mutation-independent ocular diseases

Competitive Advantages:

Less time-consuming, costly and labor intensive versus the development of individualized gene therapies

Small molecules are scalable with cost-effective manufacturing

Small molecules are highly penetrant with easy routes of administration

Small molecules can be delivered via eye drops or as intra-vitreal injection

Less intrusive and easy administration route

Conjunctival delivery and eye drop formulation more accessible than retinal implant or injection

# data[].attributes.body.processed
Summary:

The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.

Description of Technology:

Inherited Retinal Degenerations (IRD), such as Leber Congenital Amaurosis (LCA) and retinitis pigmentosa (RP), are characterized by a progressive loss of photo-sensitive cells in the retina. Most forms of IRD have no therapeutic options available due to their genetic heterogeneity and/or lack of mechanistic understanding. In particular, LCA represents roughly 5% of all retinal dystrophies and results in severe vision loss at an early age. There is an FDA-approved treatment for one form of LCA caused by mutations in the RPE 65 gene. This involves injection of an adenovirus vector containing the normal copy of the RPE65 gene. Long-term data for the gene therapy achieved only transient results: progressive reduction in visual acuity, sensitivity and function occurred following an initial gain seen 6-12 months post-treatment.

RP is a collection of rare eye diseases that affect roughly 1 in 4000 people worldwide. Currently, as there are no treatments, a majority of affected individuals lose most of their sight.

By 2040, age-related macular degeneration (AMD) will affect ~288 million people worldwide. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.

Scientists at the National Eye Institute (NEI) have developed a mutation-independent method to treat LCA, RP, other IRDs, and AMD using the FDA-approved small molecule, Halofantrine (NCGC00016833-01). Halofantrine, which was previously approved to treat malaria, helped protect photoreceptors from cell death in three different IRD model systems in 1) retinal organoid model systems, 2) two different mouse models, and 3) rat models. Furthermore, packaging Halofantrine and other potential candidate compounds for conjunctival delivery into the eye via eye drops is under development.

These small molecules act by targeting several cellular pathways which are also affected in diseases of other organs, suggesting that they may be useful in treating other, mutation independent ocular diseases.

Potential Commercial Applications:

Therapeutic to treat Leber congenital amaurosis

Therapeutic to treat Inherited Retinal Disorders associated with photoreceptor degeneration

Therapeutic to treat AMD

Therapeutic to treat mutation-independent ocular diseases

Competitive Advantages:

Less time-consuming, costly and labor intensive versus the development of individualized gene therapies

Small molecules are scalable with cost-effective manufacturing

Small molecules are highly penetrant with easy routes of administration

Small molecules can be delivered via eye drops or as intra-vitreal injection

Less intrusive and easy administration route

Conjunctival delivery and eye drop formulation more accessible than retinal implant or injection

# data[].attributes.field_collaboration_description.value
Researchers at the NEI seek licensing and/or co-development research collaborations  for a therapy using an FDA-approved small molecule drug reserpine and related compounds (such as halofantrine) that prevents retinal degeneration.

# data[].attributes.field_collaboration_description.processed
Researchers at the NEI seek licensing and/or co-development research collaborations  for a therapy using an FDA-approved small molecule drug reserpine and related compounds (such as halofantrine) that prevents retinal degeneration.

# data[].attributes.field_licensingcontact_hrefs[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pollard, Ricquita
ricquita.pollard@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/047,858
Filed on 2020-07-02
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/047,858
Filed on 2020-07-02
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2021/040157
Filed on 2021-07-01
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2021/040157
Filed on 2021-07-01
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 2021300425
Filed on 2022-12-08
Status: Pending

# data[].attributes.field_patents[].processed
Australia
National Stage 2021300425
Filed on 2022-12-08
Status: Pending

# data[].attributes.field_patents[].value
Canada
National Stage 3186586
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3186586
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 21751672.3
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 21751672.3
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patents[].value
Japan
National Stage 2022-581456
Filed on 2022-12-28
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2022-581456
Filed on 2022-12-28
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/014,045
Filed on 2022-12-30
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/014,045
Filed on 2022-12-30
Status: Pending

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2026-019246
Filed on 2026-02-09
Status: Pending

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2026-019246
Filed on 2026-02-09
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/047,858
Filed on 2020-07-02
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2021/040157
Filed on 2021-07-01
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2021300425
Filed on 2022-12-08
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3186586
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 21751672.3
Filed on 2021-07-01
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2022-581456
Filed on 2022-12-28
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/014,045
Filed on 2022-12-30
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2026-019246
Filed on 2026-02-09
Status: Pending

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_patent_titles[]
CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_patent_titles[]
CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_patent_titles[]
CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION

# data[].attributes.field_patent_titles[]
COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME

# data[].attributes.field_publications[].value
Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211)

# data[].attributes.field_publications[].processed
Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211)

# data[].attributes.field_technology_names[]
Small Molecule Drug Candidates And Disease-associated Signature Genes For Therapeutic Interventions In Retinal Degeneration

# data[].attributes.field_technology_owners[]
National Eye Institute (NEI), NCATS - NCGC

# data[].attributes.title
First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)

# data[].attributes.body.value
It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF.

The present invention is directed to novel relaxin receptor (RFXP1 receptor) small molecule agonists useful for treating relaxin-related disorders including fibrosis, certain cancers, vascular calcifications, including atherosclerosis, and heart failure. The RFXP1 agonists of this disclosure possess a number of advantages not found in earlier RFXP1 agonists. These properties include, for example, improved bioavailability, low toxicity, and better activity in RXFP1-dependent biological functional assays.

NCATS in collaboration with Florida International University (FIU) and University of South Florida (USF) has identified low molecular weight, highly potent, and efficient full RXFP1 agonists with low cytotoxicity. The identification and characterization of these compounds may lead to the development of a new class of cost-effective drugs for the treatment of numerous cancers, fibrotic, and vascular disorders.

NCATS is actively seeking licensing to develop therapeutic interventions for cancers, fibrotic and vascular disease including but not limited to breast cancer, solid tumors, atherosclerosis, and liver fibrosis.

# data[].attributes.body.processed
It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF.

The present invention is directed to novel relaxin receptor (RFXP1 receptor) small molecule agonists useful for treating relaxin-related disorders including fibrosis, certain cancers, vascular calcifications, including atherosclerosis, and heart failure. The RFXP1 agonists of this disclosure possess a number of advantages not found in earlier RFXP1 agonists. These properties include, for example, improved bioavailability, low toxicity, and better activity in RXFP1-dependent biological functional assays.

NCATS in collaboration with Florida International University (FIU) and University of South Florida (USF) has identified low molecular weight, highly potent, and efficient full RXFP1 agonists with low cytotoxicity. The identification and characterization of these compounds may lead to the development of a new class of cost-effective drugs for the treatment of numerous cancers, fibrotic, and vascular disorders.

NCATS is actively seeking licensing to develop therapeutic interventions for cancers, fibrotic and vascular disease including but not limited to breast cancer, solid tumors, atherosclerosis, and liver fibrosis.

# data[].attributes.field_collaboration_description.value
Researchers at the National Center for Advancing Translational Sciences (NCATS) seek to license these molecules.

Licensing Contact: 
Jasmine Kalsi, M.S.
Email: jasmine.kalsi@nih.gov
Telephone: 301.435.0129

# data[].attributes.field_collaboration_description.processed
Researchers at the National Center for Advancing Translational Sciences (NCATS) seek to license these molecules.

Licensing Contact: 
Jasmine Kalsi, M.S.
Email: jasmine.kalsi@nih.gov
Telephone: 301.435.0129

# data[].attributes.field_commercial_applications.value
Vascular health

Fibrotic diseases

Cancers

Human reproductive health

# data[].attributes.field_commercial_applications.processed
Vascular health

Fibrotic diseases

Cancers

Human reproductive health

# data[].attributes.field_competitive_advantages.value
First and only small molecule agonists of RXFP1

Potent and highly selective

Bioavailable with excellent exposure

Easy to synthesize and scale-up

# data[].attributes.field_competitive_advantages.processed
First and only small molecule agonists of RXFP1

Potent and highly selective

Bioavailable with excellent exposure

Easy to synthesize and scale-up

# data[].attributes.field_inventor_companies[]
National Center for Advancing Translational Sciences

# data[].attributes.field_inventor_companies[]
National Center for Advancing Translational Sciences

# data[].attributes.field_licensingcontact_hrefs[]
jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02).

# data[].attributes.field_licensingcontact_htmls[]
Kalsi, Jasmine
jasmine.kalsi@nih.gov

# data[].attributes.field_licensing_contacts[].value
Kalsi, Jasmine
jasmine.kalsi@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Kalsi, Jasmine
jasmine.kalsi@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02).

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/757,235
Filed on 2025-02-11
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/757,235
Filed on 2025-02-11
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/780,976
Filed on 2025-03-31
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/780,976
Filed on 2025-03-31
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2026/021648
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2026/021648
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/757,235
Filed on 2025-02-11
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/780,976
Filed on 2025-03-31
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2026/021648
Filed on 2026-03-31
Status: Pending

# data[].attributes.field_technology_names[]
NCGC00846044 is a novel functionally selective RXFP1 agonist with exceptional properties

# data[].attributes.field_technology_owners[]
Florida International University (FIU), National Center for Advancing Translational Sciences, National Center for Advancing Translational Sciences, National Center for Advancing Translational Sciences, NCATS - NCGC, NCATS - NCGC, NCATS - TRND, University of South Florida

# data[].attributes.title
48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio

# data[].attributes.body.value
CDC scientists have developed a new design for a multi-well dialysis microplate for equilibrium dialysis. The unique design accommodates a 1:1 buffer to sample ratio and provides additional room at the base of the well to enable optimal cartridge immersion and analyte diffusion. The microplate is readily adaptable into existing automated analytical systems and meets the criteria of American National Standards Institute (ANSI). The microplate is designed for measuring blood or other biological fluid samples over a wide range of sample volumes and may be used in a high throughput manner. Use of the microplate has been shown to reduce errors, while increasing accuracy, precision, and sensitivity.

Thus far, the microplate has been successfully used for free testosterone measurement. The microplate may also be used for measuring other analytes and has the potential to be used in both clinical and research settings.

# data[].attributes.body.processed
CDC scientists have developed a new design for a multi-well dialysis microplate for equilibrium dialysis. The unique design accommodates a 1:1 buffer to sample ratio and provides additional room at the base of the well to enable optimal cartridge immersion and analyte diffusion. The microplate is readily adaptable into existing automated analytical systems and meets the criteria of American National Standards Institute (ANSI). The microplate is designed for measuring blood or other biological fluid samples over a wide range of sample volumes and may be used in a high throughput manner. Use of the microplate has been shown to reduce errors, while increasing accuracy, precision, and sensitivity.

Thus far, the microplate has been successfully used for free testosterone measurement. The microplate may also be used for measuring other analytes and has the potential to be used in both clinical and research settings.

# data[].attributes.field_collaboration_description.value
The CDC-NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the multi-well dialysis microplate. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov; TTO@cdc.gov.

# data[].attributes.field_collaboration_description.processed
The CDC-NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the multi-well dialysis microplate. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov; TTO@cdc.gov.

# data[].attributes.field_commercial_applications.value
Diagnostics: Meets the criteria of American National Standards Institute (ANSI).

Research Materials.

# data[].attributes.field_commercial_applications.processed
Diagnostics: Meets the criteria of American National Standards Institute (ANSI).

Research Materials.

# data[].attributes.field_competitive_advantages.value
Diagnostics: Dialysis microplate for measuring free hormone analytes such as free testosterone, free thyroxine (FT4), triiodothyronine, as well as measuring unbound drugs such as dolutegravir in diagnostic or research settings.

Public Health: Use of the dialysis microplate to provide dialysis testing services for customers.

# data[].attributes.field_competitive_advantages.processed
Diagnostics: Dialysis microplate for measuring free hormone analytes such as free testosterone, free thyroxine (FT4), triiodothyronine, as well as measuring unbound drugs such as dolutegravir in diagnostic or research settings.

Public Health: Use of the dialysis microplate to provide dialysis testing services for customers.

# data[].attributes.field_licensingcontact_hrefs[]
dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio.

# data[].attributes.field_licensingcontact_htmls[]
Taylor-Mulneix, Dawn
dawn.taylor-mulneix@nih.gov

# data[].attributes.field_licensing_contacts[].value
Taylor-Mulneix, Dawn
dawn.taylor-mulneix@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Taylor-Mulneix, Dawn
dawn.taylor-mulneix@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/551,965
Filed on 2024-02-09
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/551,965
Filed on 2024-02-09
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/014980
Filed on 2025-02-07
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/014980
Filed on 2025-02-07
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/551,965
Filed on 2024-02-09
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/014980
Filed on 2025-02-07
Status: Pending

# data[].attributes.field_technology_names[]
48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio

# data[].attributes.title
T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias

# data[].attributes.body.value
Description of Technology:

CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface. TCRs are expected to overcome these resistance mechanisms as they use distinct target recognition mechanism. TCRs instead recognize epitopes derived from proteins processed intracellularly and presented in the context of Human Leukocyte Antigens (HLA), enabling detection of broad antigens inaccessible to antibodies or CAR-T’s – including neoantigens, cancer germline antigens, and intracellular viral oncoproteins.

Investigators at the National Cancer Institute (NCI) developed a TCR recognizing a CD22-derived epitope presented in context of the highly prevalent HLA-A*02:01. The TCR was not cross-reactive against unintended target antigens. T cells expressing the TCR (CD22 TCR-T cells) show anti-tumor activity at clinically-relevant doses without causing systemic cytokine elevation in pre-clinical, in vivo models. The inventors are translating their findings into the clinic.

NCI seeks parties interested in licensing and/or collaborations to further develop this technology.

Potential Commercial Applications:

Autologous adoptive cell therapy for patients with B-cell malignancies such as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

Off-the-shelf, allogeneic adoptive cell therapy for patients will B-cell malignancies.

Therapy alternative for patients with CD22-expressing malignancies that are resistant to antibody-based treatment, including chimeric antigen receptor (CAR)-based adoptive cell therapy.

Competitive Advantages:

Clinical stage asset with an established market need and regulatory path – following the Accelerated Approvals of inotuzumab ozogamicin (Aucatzyl) in 2017 and afamitresgene autoleucel (Tecelra) in 2024.

T cells engineered to express the CD22 TCR clear leukemia at clinically-relevant doses without causing systemic cytokine elevation.

TCR is highly specific to human CD22 and is expected to recognize its target under conditions that involve loss or modulation of cell surface expression.

TCR is restricted by the highly prevalent HLA A*02:01 allele, which has an approximate frequency of up to 43% within the United States population.

# data[].attributes.body.processed
Description of Technology:

CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface. TCRs are expected to overcome these resistance mechanisms as they use distinct target recognition mechanism. TCRs instead recognize epitopes derived from proteins processed intracellularly and presented in the context of Human Leukocyte Antigens (HLA), enabling detection of broad antigens inaccessible to antibodies or CAR-T’s – including neoantigens, cancer germline antigens, and intracellular viral oncoproteins.

Investigators at the National Cancer Institute (NCI) developed a TCR recognizing a CD22-derived epitope presented in context of the highly prevalent HLA-A*02:01. The TCR was not cross-reactive against unintended target antigens. T cells expressing the TCR (CD22 TCR-T cells) show anti-tumor activity at clinically-relevant doses without causing systemic cytokine elevation in pre-clinical, in vivo models. The inventors are translating their findings into the clinic.

NCI seeks parties interested in licensing and/or collaborations to further develop this technology.

Potential Commercial Applications:

Autologous adoptive cell therapy for patients with B-cell malignancies such as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

Off-the-shelf, allogeneic adoptive cell therapy for patients will B-cell malignancies.

Therapy alternative for patients with CD22-expressing malignancies that are resistant to antibody-based treatment, including chimeric antigen receptor (CAR)-based adoptive cell therapy.

Competitive Advantages:

Clinical stage asset with an established market need and regulatory path – following the Accelerated Approvals of inotuzumab ozogamicin (Aucatzyl) in 2017 and afamitresgene autoleucel (Tecelra) in 2024.

T cells engineered to express the CD22 TCR clear leukemia at clinically-relevant doses without causing systemic cytokine elevation.

TCR is highly specific to human CD22 and is expected to recognize its target under conditions that involve loss or modulation of cell surface expression.

TCR is restricted by the highly prevalent HLA A*02:01 allele, which has an approximate frequency of up to 43% within the United States population.

# data[].attributes.field_collaboration_description.value
Researchers at the NCI seek licensing and/or co-development research collaborations for a T-cell receptor (TCR) that specifically targets an HLA-A*02:01-restricted CD22 Epitope

# data[].attributes.field_collaboration_description.processed
Researchers at the NCI seek licensing and/or co-development research collaborations for a T-cell receptor (TCR) that specifically targets an HLA-A*02:01-restricted CD22 Epitope

# data[].attributes.field_keywords[]
Relapsed / refractory B-Lymphoid Malignancies

# data[].attributes.field_licensingcontact_hrefs[]
suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts[].value
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/016561
Filed on 2022-02-16
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/016561
Filed on 2022-02-16
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/149,795
Filed on 2021-02-16
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/149,795
Filed on 2021-02-16
Status: Abandoned

# data[].attributes.field_patents[].value
Canada
National Stage 3207989
Filed on 2023-08-10
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3207989
Filed on 2023-08-10
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/277,521
Filed on 2023-08-16
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/277,521
Filed on 2023-08-16
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 22709092.5
Filed on 2023-09-13
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 22709092.5
Filed on 2023-09-13
Status: Pending

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/016561
Filed on 2022-02-16
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/149,795
Filed on 2021-02-16
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3207989
Filed on 2023-08-10
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/277,521
Filed on 2023-08-16
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 22709092.5
Filed on 2023-09-13
Status: Pending

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_patent_titles[]
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22

# data[].attributes.field_publications[].value
Nguyen KA, et al. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. (PMID: 40203088)

# data[].attributes.field_publications[].processed
Nguyen KA, et al. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. (PMID: 40203088)

# data[].attributes.field_related_inventions[].processed
E-152-2020

# data[].attributes.field_technology_names[]
Discovery Of T Cell Receptors (TCR) Against HLA-A*02:01-restricted CD22 Epitope

# data[].attributes.title
Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense

# data[].attributes.body.value
The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent toxin-neutralizing activity, while the anti-capsule mAb efficiently kills anthrax bacteria. By merging these specificities into a single lgG framework, the resulting bispecific antibody can simultaneously neutralize toxins and kill bacteria, potentially offering comprehensive protection against anthrax infection. The bispecific antibody is produced from transfected mammalian cells, ensuring scalability for large-scale production. This technology represents a significant advancement in anthrax biodefense, providing a simpler, more effective approach for treatment following exposure to aerosolized B. anthracis spores.

# data[].attributes.body.processed
The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent toxin-neutralizing activity, while the anti-capsule mAb efficiently kills anthrax bacteria. By merging these specificities into a single lgG framework, the resulting bispecific antibody can simultaneously neutralize toxins and kill bacteria, potentially offering comprehensive protection against anthrax infection. The bispecific antibody is produced from transfected mammalian cells, ensuring scalability for large-scale production. This technology represents a significant advancement in anthrax biodefense, providing a simpler, more effective approach for treatment following exposure to aerosolized B. anthracis spores.

# data[].attributes.field_commercial_applications.value
The tetravalent bispecific antibody targeting anthrax toxins and capsule has significant potential applications in biodefense and anthrax treatment. It could be used as a post-exposure prophylactic following potential exposure to aerosolized B. anthracis spores, offering rapid and targeted protection. Additionally, this antibody may find utility in the treatment of anthrax infections, potentially improving outcomes and reducing the need for complex treatment regimens. Its ability to target multiple virulence factors simultaneously makes it a promising candidate for use in biodefense strategies against anthrax.

# data[].attributes.field_commercial_applications.processed
The tetravalent bispecific antibody targeting anthrax toxins and capsule has significant potential applications in biodefense and anthrax treatment. It could be used as a post-exposure prophylactic following potential exposure to aerosolized B. anthracis spores, offering rapid and targeted protection. Additionally, this antibody may find utility in the treatment of anthrax infections, potentially improving outcomes and reducing the need for complex treatment regimens. Its ability to target multiple virulence factors simultaneously makes it a promising candidate for use in biodefense strategies against anthrax.

# data[].attributes.field_competitive_advantages.value
The tetravalent bispecific antibody targeting anthrax toxins and capsule offers several competitive advantages over existing approaches. Unlike conventional monoclonal antibodies that target only one antigen, this bispecific antibody can simultaneously neutralize toxins and kill bacteria, providing comprehensive protection against anthrax infection. Additionally, the simplicity of using a single molecule instead of a combination of two monoclonal antibodies enhances efficacy and ease of administration. The ability to express and purify the antibody from transfected mammalian cells ensures scalability for large-scale production, further enhancing its potential as a biodefense tool.

# data[].attributes.field_competitive_advantages.processed
The tetravalent bispecific antibody targeting anthrax toxins and capsule offers several competitive advantages over existing approaches. Unlike conventional monoclonal antibodies that target only one antigen, this bispecific antibody can simultaneously neutralize toxins and kill bacteria, providing comprehensive protection against anthrax infection. Additionally, the simplicity of using a single molecule instead of a combination of two monoclonal antibodies enhances efficacy and ease of administration. The ability to express and purify the antibody from transfected mammalian cells ensures scalability for large-scale production, further enhancing its potential as a biodefense tool.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_depts[]
Technology Transfer and Intellectual Property Office

# data[].attributes.field_licensingcontact_hrefs[]
peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense&body=Please send me information about technology [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense.

# data[].attributes.field_licensingcontact_htmls[]
Soukas, Peter
peter.soukas@nih.gov

# data[].attributes.field_licensing_contacts[].value
Soukas, Peter
peter.soukas@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Soukas, Peter
peter.soukas@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense&body=Please send me information about technology [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense.

# data[].attributes.field_technology_names[]
Development Of A Bispecific Antibody With An Ability To Neutralize Anthrax Toxins And Kill The Bacteria

# data[].attributes.title
Interleukin-27 Producing B-Cell Population and Uses Thereof

# data[].attributes.body.value
Summary:

The National Eye Institute (NEI) seeks research co-development partners and/or licensees to advance the production and uses of interleukin-27 (IL-27) producing B-regulatory cell (i27-Breg) therapy for immune related autoimmune disorders. These disorders include but are not limited, to age-related macular degeneration (AMD), graft-versus-host disease (GVHD), multiple sclerosis (MS) and transplant rejection.

Description of Technology:

Autoimmune diseases in which the immune system attacks the body's own tissues or organs include: graft-vs-host disease (GVHD), age-related macular degeneration (AMD), multiple sclerosis (MS), uveitis and encephalomyelitis.  These diseases can result in blindness, paralysis, and significant morbidity impacting quality of life.  In GVHD, the allogeneic transplant views the recipient’s body as foreign, and the transplant attacks the body.  Uveitis is comprised of a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology.  Similarly, autoimmune processes contribute significantly to the progression of retinal degeneration associated with AMD.  MS is caused in part by immune cells that attack and/or destroy neurons, thereby interfering with normal neurological function. Steroids and monoclonal antibodies are temporarily effective therapies; serious adverse effects preclude their prolonged use. Therefore, an unmet need remains for safe, effective long-term therapies for autoimmune disorders.

The invention consists of an isolated population of mammal cells comprising about 75 % or higher B-1a regulatory cells and methods of preparation of such cell populations. i27-Bregs have distinct advantages over  systemic administration of interleukin-27 (IL-27) since the latter is costly to synthesize and rapidly degrades in the body. i27-Bregs provide several therapeutic advantages over current standard of care:  (i) self-renewal after administration and thereby sustained IL-27 production in host tissues; (ii) reprograms recipient lymphocytes into Bregs and Tregs (regulatory T cells) (iii) effective suppression of the host’s overreactive immune system; (iv) no requirement of prior activation, providing a potential therapeutic advantage over other disease-specific cell therapies. Immune system suppression by i27-Bregs administration can also be used in conjunction with solid organ or allogenic cell transplants to reduce potentially fatal transplant rejection.

This technology is available for development under a license for the above-mentioned disorders. Inventors at the National Eye Institute are interested in participating under a CRADA collaboration to further develop the technology toward clinical applications or will assist to transfer the technological know-how for licensing.

Potential Commercial Applications:

Cell therapy for severe CNS autoimmune disease, GVHD, transplants, encephalomyelitis, or multiple sclerosis

Competitive Advantages:

Can be co-administered with other currently approved therapies currently

No FDA approved B cell therapy for the treatment of auto immune disease

Self-renewing

Excreted interleukins following administration provide a longer-lasting effect than currently approved monoclonal antibody therapies

Potentially fewer side effects since IL-27 extended release avoids the systemic administration of monoclonal antibodies or immunosuppressive drugs

Ex-vivo preparation can be further genetically modified to enhance efficacy

Activation not required to inhibit autoimmunity

# data[].attributes.body.processed
Summary:

The National Eye Institute (NEI) seeks research co-development partners and/or licensees to advance the production and uses of interleukin-27 (IL-27) producing B-regulatory cell (i27-Breg) therapy for immune related autoimmune disorders. These disorders include but are not limited, to age-related macular degeneration (AMD), graft-versus-host disease (GVHD), multiple sclerosis (MS) and transplant rejection.

Description of Technology:

Autoimmune diseases in which the immune system attacks the body's own tissues or organs include: graft-vs-host disease (GVHD), age-related macular degeneration (AMD), multiple sclerosis (MS), uveitis and encephalomyelitis.  These diseases can result in blindness, paralysis, and significant morbidity impacting quality of life.  In GVHD, the allogeneic transplant views the recipient’s body as foreign, and the transplant attacks the body.  Uveitis is comprised of a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology.  Similarly, autoimmune processes contribute significantly to the progression of retinal degeneration associated with AMD.  MS is caused in part by immune cells that attack and/or destroy neurons, thereby interfering with normal neurological function. Steroids and monoclonal antibodies are temporarily effective therapies; serious adverse effects preclude their prolonged use. Therefore, an unmet need remains for safe, effective long-term therapies for autoimmune disorders.

The invention consists of an isolated population of mammal cells comprising about 75 % or higher B-1a regulatory cells and methods of preparation of such cell populations. i27-Bregs have distinct advantages over  systemic administration of interleukin-27 (IL-27) since the latter is costly to synthesize and rapidly degrades in the body. i27-Bregs provide several therapeutic advantages over current standard of care:  (i) self-renewal after administration and thereby sustained IL-27 production in host tissues; (ii) reprograms recipient lymphocytes into Bregs and Tregs (regulatory T cells) (iii) effective suppression of the host’s overreactive immune system; (iv) no requirement of prior activation, providing a potential therapeutic advantage over other disease-specific cell therapies. Immune system suppression by i27-Bregs administration can also be used in conjunction with solid organ or allogenic cell transplants to reduce potentially fatal transplant rejection.

This technology is available for development under a license for the above-mentioned disorders. Inventors at the National Eye Institute are interested in participating under a CRADA collaboration to further develop the technology toward clinical applications or will assist to transfer the technological know-how for licensing.

Potential Commercial Applications:

Cell therapy for severe CNS autoimmune disease, GVHD, transplants, encephalomyelitis, or multiple sclerosis

Competitive Advantages:

Can be co-administered with other currently approved therapies currently

No FDA approved B cell therapy for the treatment of auto immune disease

Self-renewing

Excreted interleukins following administration provide a longer-lasting effect than currently approved monoclonal antibody therapies

Potentially fewer side effects since IL-27 extended release avoids the systemic administration of monoclonal antibodies or immunosuppressive drugs

Ex-vivo preparation can be further genetically modified to enhance efficacy

Activation not required to inhibit autoimmunity

# data[].attributes.field_collaboration_description.value
Researchers at the NEI seek licensing and/or co-development research collaborations  to advance the production and uses of IL-27 producing B-regulatory cells (i27-Bregs) for autoimmune disorders, including but not limited to, graft-versus-host disease (GVHD), age-related macular degeneration (AMD); and transplant rejection.

# data[].attributes.field_collaboration_description.processed
Researchers at the NEI seek licensing and/or co-development research collaborations  to advance the production and uses of IL-27 producing B-regulatory cells (i27-Bregs) for autoimmune disorders, including but not limited to, graft-versus-host disease (GVHD), age-related macular degeneration (AMD); and transplant rejection.

# data[].attributes.field_licensingcontact_hrefs[]
merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof&body=Please send me information about technology [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Baxter, Merissa
merissa.baxter@nih.gov

# data[].attributes.field_licensing_contacts[].value
Baxter, Merissa
merissa.baxter@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Baxter, Merissa
merissa.baxter@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof&body=Please send me information about technology [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/863,054
Filed on 2019-06-18
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/863,054
Filed on 2019-06-18
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2020/038368
Filed on 2020-06-18
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2020/038368
Filed on 2020-06-18
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 2020295470
Filed on 2020-06-18
Status: Issued

# data[].attributes.field_patents[].processed
Australia
National Stage 2020295470
Filed on 2020-06-18
Status: Issued

# data[].attributes.field_patents[].value
Canada
National Stage 3143998
Filed on 2020-06-18
Status: Pending

# data[].attributes.field_patents[].processed
Canada
National Stage 3143998
Filed on 2020-06-18
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 20736554.5
Filed on 2020-06-18
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 20736554.5
Filed on 2020-06-18
Status: Pending

# data[].attributes.field_patents[].value
Japan
National Stage 2021-575486
Filed on 2021-12-17
Status: Issued

# data[].attributes.field_patents[].processed
Japan
National Stage 2021-575486
Filed on 2021-12-17
Status: Issued

# data[].attributes.field_patents[].value
US
National Stage 17/620,248
Filed on 2021-12-17
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 17/620,248
Filed on 2021-12-17
Status: Pending

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2025-061994
Filed on 2025-04-03
Status: Pending

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2025-061994
Filed on 2025-04-03
Status: Pending

# data[].attributes.field_patents[].value
Canada
Divisional (DIV) None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].processed
Canada
Divisional (DIV) None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].value
Australia
Divisional (DIV) 2026200686
Filed on 2026-01-30
Status: Pending

# data[].attributes.field_patents[].processed
Australia
Divisional (DIV) 2026200686
Filed on 2026-01-30
Status: Pending

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2026-096889
Filed on 2026-06-10
Status: Pending

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2026-096889
Filed on 2026-06-10
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/863,054
Filed on 2019-06-18
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2020/038368
Filed on 2020-06-18
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 2020295470
Filed on 2020-06-18
Status: Issued

# data[].attributes.field_patent_htmls[]
Canada
National Stage 3143998
Filed on 2020-06-18
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 20736554.5
Filed on 2020-06-18
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2021-575486
Filed on 2021-12-17
Status: Issued

# data[].attributes.field_patent_htmls[]
US
National Stage 17/620,248
Filed on 2021-12-17
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2025-061994
Filed on 2025-04-03
Status: Pending

# data[].attributes.field_patent_htmls[]
Canada
Divisional (DIV) None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_htmls[]
Australia
Divisional (DIV) 2026200686
Filed on 2026-01-30
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2026-096889
Filed on 2026-06-10
Status: Pending

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELL AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELL AND USES THEREOF

# data[].attributes.field_patent_titles[]
INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF

# data[].attributes.field_publications[].value
Choi JK, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. (PMID 34782464)

# data[].attributes.field_publications[].processed
Choi JK, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. (PMID 34782464)

# data[].attributes.field_related_inventions[].processed
E-036-2012

# data[].attributes.field_technology_names[]
A Novel IL-27-producing Innate B-1a Cell Population Regulates Neuroinflammation And Confers Protection
against Severe CNS Autoimmune Diseases

# data[].attributes.title
Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells

# data[].attributes.body.value
Regulatory T cells (Tregs) are immune cells that keep the immune system balanced and prevent autoimmunity. Tregs depend on a protein called Eos (Ikzf4) that helps turn genes on and off for their development and function, but until now, antibodies used to detect and study Eos were unreliable.

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have created monoclonal antibody 18H2 to accurately detect Eos in mouse and human Treg cells. To make 18H2, they immunized hamsters with a segment of the Eos protein and used advanced techniques to select the best antibody-producing cells. The resulting 18H2 antibody specifically detects Eos and does not react with cells lacking Eos.

The 18H2 antibody stands out by reliably detecting both human and mouse Eos and performing better in laboratory tests, such as flow cytometry, used to analyze Treg cells. This technology offers a powerful new way to study Treg cell development and how Eos helps protect against autoimmune conditions.

# data[].attributes.body.processed
Regulatory T cells (Tregs) are immune cells that keep the immune system balanced and prevent autoimmunity. Tregs depend on a protein called Eos (Ikzf4) that helps turn genes on and off for their development and function, but until now, antibodies used to detect and study Eos were unreliable.

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have created monoclonal antibody 18H2 to accurately detect Eos in mouse and human Treg cells. To make 18H2, they immunized hamsters with a segment of the Eos protein and used advanced techniques to select the best antibody-producing cells. The resulting 18H2 antibody specifically detects Eos and does not react with cells lacking Eos.

The 18H2 antibody stands out by reliably detecting both human and mouse Eos and performing better in laboratory tests, such as flow cytometry, used to analyze Treg cells. This technology offers a powerful new way to study Treg cell development and how Eos helps protect against autoimmune conditions.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include (a) application in pre-clinical models of autoimmunity, cancer, and transplantation, (b) development of diagnostic assays for immune monitoring and biomarker discovery, and (c) inclusion in high-throughput screening platforms for drug discovery targeting Treg pathways. For collaboration opportunities, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include (a) application in pre-clinical models of autoimmunity, cancer, and transplantation, (b) development of diagnostic assays for immune monitoring and biomarker discovery, and (c) inclusion in high-throughput screening platforms for drug discovery targeting Treg pathways. For collaboration opportunities, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov.

# data[].attributes.field_commercial_applications.value
Development of tests that track Treg cell function and Eos protein levels in patients and monitor Eos levels in autoimmune diseases, cancer treatments, and organ transplants.

# data[].attributes.field_commercial_applications.processed
Development of tests that track Treg cell function and Eos protein levels in patients and monitor Eos levels in autoimmune diseases, cancer treatments, and organ transplants.

# data[].attributes.field_competitive_advantages.value
Eos-specific detection, confirmed by lack of reactivity in cells that lack Eos.

Detection of both mouse and human Eos, enabling application to human research.

Precise detection and measurement of Treg cells in diverse sample types.

# data[].attributes.field_competitive_advantages.processed
Eos-specific detection, confirmed by lack of reactivity in cells that lack Eos.

Detection of both mouse and human Eos, enabling application to human research.

Precise detection and measurement of Treg cells in diverse sample types.

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells.

# data[].attributes.field_publications[].value
Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838)

# data[].attributes.field_publications[].processed
Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838)

# data[].attributes.field_technology_names[]
Anti-mouse Ikzf4 (Eos) Monoclonal Antibody

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR

# data[].attributes.body.value
Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide.

Researchers at NIAID’s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created by combining selected genes from human and bovine (cow) rotaviruses. This approach targets the most important rotavirus serotypes at once, including G1, G2, G3, and G4, with the potential to expand coverage to G5, G9, and G10.

These multivalent vaccine candidates trigger immune responses against multiple rotavirus serotypes in a single formulation at lower doses than earlier human-bovine vaccine approaches. The multivalent formulation does not cause the low-grade, short-lived fever seen with prior candidates.

# data[].attributes.body.processed
Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide.

Researchers at NIAID’s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created by combining selected genes from human and bovine (cow) rotaviruses. This approach targets the most important rotavirus serotypes at once, including G1, G2, G3, and G4, with the potential to expand coverage to G5, G9, and G10.

These multivalent vaccine candidates trigger immune responses against multiple rotavirus serotypes in a single formulation at lower doses than earlier human-bovine vaccine approaches. The multivalent formulation does not cause the low-grade, short-lived fever seen with prior candidates.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts at 240–669–5299, or elizabeth.pitts@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts at 240–669–5299, or elizabeth.pitts@nih.gov.

# data[].attributes.field_commercial_applications.value
Multivalent rotavirus vaccine that covers several clinically important rotavirus serotypes in a single product, including G1, G2, G3, and G4, with potential to expand coverage to the additional serotypes G5, G9, and G10.

# data[].attributes.field_commercial_applications.processed
Multivalent rotavirus vaccine that covers several clinically important rotavirus serotypes in a single product, including G1, G2, G3, and G4, with potential to expand coverage to the additional serotypes G5, G9, and G10.

# data[].attributes.field_competitive_advantages.value
Designed for lower-dose immunogenicity than earlier human-bovine reassortant approaches described in the literature.

No low-grade, transient fever observed compared with prior candidates.

Flexible reassortant design that may support addition of newly important rotavirus serotypes.

# data[].attributes.field_competitive_advantages.processed
Designed for lower-dose immunogenicity than earlier human-bovine reassortant approaches described in the literature.

No low-grade, transient fever observed compared with prior candidates.

Flexible reassortant design that may support addition of newly important rotavirus serotypes.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine.

# data[].attributes.field_licensingcontact_htmls[]
Pitts, Elizabeth
elizabeth.pitts@nih.gov

# data[].attributes.field_licensing_contacts[].value
Pitts, Elizabeth
elizabeth.pitts@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Pitts, Elizabeth
elizabeth.pitts@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/094,425
Filed on 1998-07-28
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/094,425
Filed on 1998-07-28
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US1999/017036
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US1999/017036
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
US Patent 7,932,074
Filed on 2001-01-04
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 7,932,074
Filed on 2001-01-04
Status: Expired

# data[].attributes.field_patents[].value
Australia
National Stage 53221/99
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Australia
National Stage 53221/99
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Brazil
National Stage PI9912485-8
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Brazil
National Stage PI9912485-8
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Canada
National Stage 2336875
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Canada
National Stage 2336875
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
China
National Stage 99810311.X
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
China
National Stage 99810311.X
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
European Patent
National Stage 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
European Patent
National Stage 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
India
National Stage IN/PCT/2001/0106/CHE
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
India
National Stage IN/PCT/2001/0106/CHE
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Japan
National Stage 2000-562050
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Japan
National Stage 2000-562050
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
South Korea
National Stage 10-2001-7001236
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
South Korea
National Stage 10-2001-7001236
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Germany
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Germany
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
France
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
France
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
United Kingdom
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
United Kingdom
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Ireland
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Ireland
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
Italy
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].processed
Italy
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patents[].value
China
Divisional (DIV) 200810090397.2
Filed on 2008-04-11
Status: Expired

# data[].attributes.field_patents[].processed
China
Divisional (DIV) 200810090397.2
Filed on 2008-04-11
Status: Expired

# data[].attributes.field_patents[].value
Japan
Divisional (DIV) 2009-148918
Filed on 2009-06-23
Status: Abandoned

# data[].attributes.field_patents[].processed
Japan
Divisional (DIV) 2009-148918
Filed on 2009-06-23
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/094,425
Filed on 1998-07-28
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US1999/017036
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 7,932,074
Filed on 2001-01-04
Status: Expired

# data[].attributes.field_patent_htmls[]
Australia
National Stage 53221/99
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Brazil
National Stage PI9912485-8
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Canada
National Stage 2336875
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
China
National Stage 99810311.X
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
India
National Stage IN/PCT/2001/0106/CHE
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2000-562050
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
South Korea
National Stage 10-2001-7001236
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Germany
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
France
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
United Kingdom
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Ireland
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
Italy
European patent (EP) 99938819.2
Filed on 1999-07-27
Status: Expired

# data[].attributes.field_patent_htmls[]
China
Divisional (DIV) 200810090397.2
Filed on 2008-04-11
Status: Expired

# data[].attributes.field_patent_htmls[]
Japan
Divisional (DIV) 2009-148918
Filed on 2009-06-23
Status: Abandoned

# data[].attributes.title
Human antibodies with anti-lymphocyte specificities and lytic activity

# data[].attributes.body.value
Antibody therapies that target human B cells are a promising way to treat diseases like B-cell cancers and autoimmune conditions like lupus and multiple sclerosis. Traditionally, these antibodies are made in animals and modified to resemble human antibodies to reduce immune rejection. Researchers in the Laboratory of Immunoregulation (LIR) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach of using blood plasma from a patient with the rare immune disorder idiopathic CD4 lymphocytopenia (ICL) to find naturally occurring human antibodies.

By using advanced genetic sequencing, the researchers discovered and reproduced several new antibodies that could effectively attack and kill B-cell tumors, normal B cells, and T cells, demonstrating potential for eliminating cancerous or disease-causing immune cells. One potent antibody, NIH58.9, killed B cells at low concentrations of 0.01 nanomolar. These new antibodies may be used as treatments, combined with other therapies, or engineered into special formats like bispecific antibodies or antibody-drug conjugates.

# data[].attributes.body.processed
Antibody therapies that target human B cells are a promising way to treat diseases like B-cell cancers and autoimmune conditions like lupus and multiple sclerosis. Traditionally, these antibodies are made in animals and modified to resemble human antibodies to reduce immune rejection. Researchers in the Laboratory of Immunoregulation (LIR) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach of using blood plasma from a patient with the rare immune disorder idiopathic CD4 lymphocytopenia (ICL) to find naturally occurring human antibodies.

By using advanced genetic sequencing, the researchers discovered and reproduced several new antibodies that could effectively attack and kill B-cell tumors, normal B cells, and T cells, demonstrating potential for eliminating cancerous or disease-causing immune cells. One potent antibody, NIH58.9, killed B cells at low concentrations of 0.01 nanomolar. These new antibodies may be used as treatments, combined with other therapies, or engineered into special formats like bispecific antibodies or antibody-drug conjugates.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Benjamin Hurley at 240-276-5489, or benjamin.hurley@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Benjamin Hurley at 240-276-5489, or benjamin.hurley@nih.gov.

# data[].attributes.field_commercial_applications.value
Development of monoclonal antibody therapies, bispecific antibodies, and antibody-targeted drugs for use in organ transplantation, B-cell lymphomas, and autoimmune conditions

# data[].attributes.field_commercial_applications.processed
Development of monoclonal antibody therapies, bispecific antibodies, and antibody-targeted drugs for use in organ transplantation, B-cell lymphomas, and autoimmune conditions

# data[].attributes.field_competitive_advantages.value
First fully human IgM antibody that binds to and kills B cells

Fully human monoclonal antibodies eliminating humanization steps associated with antibodies derived from animal models and lowering risk of anti-drug antibody response

B-cell death observed at concentrations as low as 0.01Nm

Versatile antibody that may be used directly, engineered as IgG1 antibody, and possibly developed into bispecifics or antibody-drug conjugates

# data[].attributes.field_competitive_advantages.processed
First fully human IgM antibody that binds to and kills B cells

Fully human monoclonal antibodies eliminating humanization steps associated with antibodies derived from animal models and lowering risk of anti-drug antibody response

B-cell death observed at concentrations as low as 0.01Nm

Versatile antibody that may be used directly, engineered as IgG1 antibody, and possibly developed into bispecifics or antibody-drug conjugates

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/787,190
Filed on 2025-04-11
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/787,190
Filed on 2025-04-11
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2026/022767
Filed on 2026-04-08
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2026/022767
Filed on 2026-04-08
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/787,190
Filed on 2025-04-11
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2026/022767
Filed on 2026-04-08
Status: Pending

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE

# data[].attributes.field_patent_titles[]
MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE

# data[].attributes.field_technology_names[]
Human antibodies with anti-lymphocyte specificities and lytic activity linked to ICL.

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR

# data[].attributes.title
Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy

# data[].attributes.body.value
T cell immunotherapy is used in the treatment of various pathologies – including cancers and infections. Current therapies employ chimeric antigen receptors (CARs) consisting of the intracellular fragment of CD3-zeta as the signaling domain with varied combinations of co-stimulatory, transmembrane, spacer/hinge, and extracellular targeting domains. While effective in treating hematological malignancies, CAR T cells need to be activated through T cell receptor (TCR) activation. Such activation is subject to various regulatory and inhibitory mechanisms that can limit their full therapeutic potential. Moreover, CAR T cells are less effective in the treatment of solid tumors due to exhaustion. There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have found that after T cell receptor (TCR) activation, the linker for activation of T cells (LAT) forms a distinct signaling complex and its formation is sufficient to cause full T-cell activation independent of the TCR complex. As activation of the TCR complex is highly regulated by a number of competing kinases and phosphatases, the downstream LAT molecule offers several advantages over CD3-zeta as the signaling domain in CARs.

Researchers at the NCI have developed chimeric adaptor proteins (CAPs) consisting of an extracellular targeting domain, transmembrane domain, intracellular LAT domain, and the kinase domain of ZAP70. The inventors have observed that the formation of these complexes is sufficient to cause full T-cell activation independent of TCR activation. It is expected that the circumvention of the regulatory mechanisms targeting upstream TCR activation will increase the potency of T-cell signaling and the sensitivity of immunotherapy. Furthermore, T cells prepared with these recombinant molecules may be more resistant to exhaustion by molecules targeting TCR activation, and tunable, as the activity of the kinase domain can be altered with small molecules.

The Laboratory of Cellular and Molecular Biology, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize CAPs for the treatment of solid tumors and hematological malignancies.

Competitive Advantages:

Potential for demonstrable efficacy against solid cancers previously refractory to cellular immunotherapy via:

Signaling through LAT allows circumvention of regulatory and inhibitory mechanisms involved in TCR activation

Directly triggering the downstream signaling cascade could cause more potent activation of T cells

LAT-based CAP-expressing T cells may be more resistant to PD-1-mediated T-cell exhaustion

Signaling from CAPs consisting of LAT and ZAP70 kinase domain may be tunable

Commercial Applications:

Treatment of hematological malignancies and solid tumors

Therapeutic use as a combination therapy with immune checkpoint inhibitors and/or chemotherapy

# data[].attributes.body.processed
T cell immunotherapy is used in the treatment of various pathologies – including cancers and infections. Current therapies employ chimeric antigen receptors (CARs) consisting of the intracellular fragment of CD3-zeta as the signaling domain with varied combinations of co-stimulatory, transmembrane, spacer/hinge, and extracellular targeting domains. While effective in treating hematological malignancies, CAR T cells need to be activated through T cell receptor (TCR) activation. Such activation is subject to various regulatory and inhibitory mechanisms that can limit their full therapeutic potential. Moreover, CAR T cells are less effective in the treatment of solid tumors due to exhaustion. There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have found that after T cell receptor (TCR) activation, the linker for activation of T cells (LAT) forms a distinct signaling complex and its formation is sufficient to cause full T-cell activation independent of the TCR complex. As activation of the TCR complex is highly regulated by a number of competing kinases and phosphatases, the downstream LAT molecule offers several advantages over CD3-zeta as the signaling domain in CARs.

Researchers at the NCI have developed chimeric adaptor proteins (CAPs) consisting of an extracellular targeting domain, transmembrane domain, intracellular LAT domain, and the kinase domain of ZAP70. The inventors have observed that the formation of these complexes is sufficient to cause full T-cell activation independent of TCR activation. It is expected that the circumvention of the regulatory mechanisms targeting upstream TCR activation will increase the potency of T-cell signaling and the sensitivity of immunotherapy. Furthermore, T cells prepared with these recombinant molecules may be more resistant to exhaustion by molecules targeting TCR activation, and tunable, as the activity of the kinase domain can be altered with small molecules.

The Laboratory of Cellular and Molecular Biology, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize CAPs for the treatment of solid tumors and hematological malignancies.

Competitive Advantages:

Potential for demonstrable efficacy against solid cancers previously refractory to cellular immunotherapy via:

Signaling through LAT allows circumvention of regulatory and inhibitory mechanisms involved in TCR activation

Directly triggering the downstream signaling cascade could cause more potent activation of T cells

LAT-based CAP-expressing T cells may be more resistant to PD-1-mediated T-cell exhaustion

Signaling from CAPs consisting of LAT and ZAP70 kinase domain may be tunable

Commercial Applications:

Treatment of hematological malignancies and solid tumors

Therapeutic use as a combination therapy with immune checkpoint inhibitors and/or chemotherapy

# data[].attributes.field_licensingcontact_hrefs[]
suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts[].value
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Gulay French, Suna
suna.gulay@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2020/022752
Filed on 2020-03-13
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2020/022752
Filed on 2020-03-13
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/819,386
Filed on 2019-03-15
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/819,386
Filed on 2019-03-15
Status: Abandoned

# data[].attributes.field_patents[].value
European Patent
National Stage 20718061.3
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 20718061.3
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].value
China
National Stage 202080021582.5
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].processed
China
National Stage 202080021582.5
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].value
Hong Kong
European patent (EP) 62022051308.4
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].processed
Hong Kong
European patent (EP) 62022051308.4
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patents[].value
US
Continuation in Part (CIP) 17/475,810
Filed on 2021-09-15
Status: Pending

# data[].attributes.field_patents[].processed
US
Continuation in Part (CIP) 17/475,810
Filed on 2021-09-15
Status: Pending

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/076358
Filed on 2022-09-13
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/076358
Filed on 2022-09-13
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2020/022752
Filed on 2020-03-13
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/819,386
Filed on 2019-03-15
Status: Abandoned

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 20718061.3
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patent_htmls[]
China
National Stage 202080021582.5
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patent_htmls[]
Hong Kong
European patent (EP) 62022051308.4
Filed on 2020-03-13
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Continuation in Part (CIP) 17/475,810
Filed on 2021-09-15
Status: Pending

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/076358
Filed on 2022-09-13
Status: Expired

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
RECOMBINANT MOLECULES CONTAINING LINKER FOR ACTIVATION OF T CELLS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS  AND THEIR USE IN IMMUNOTHERAPY

# data[].attributes.field_patent_titles[]
Chimeric adaptor and kinase signaling proteins and their use in immunotherapy

# data[].attributes.field_publications[].value
Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps

# data[].attributes.field_publications[].processed
Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps

# data[].attributes.field_publications[].value
Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation

# data[].attributes.field_publications[].processed
Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation

# data[].attributes.field_publications[].value
Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728)

# data[].attributes.field_publications[].processed
Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728)

# data[].attributes.field_related_inventions[].processed
E-159-2009

# data[].attributes.field_technology_names[]
Recombinant Molecule Containing LAT For Use In T Cell Immunotherapy

# data[].attributes.field_technology_names[]
Chimeric Adaptor Proteins (CAPs) For Improved T-Cell Immunotherapy

# data[].attributes.title
Levonorgestrel Butanoate Formulation and Methods Relating Thereto

# data[].attributes.body.value
Summary:

The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of an injectable contraceptive for women with a pharmaceutical formulation containing levonorgestrel butanoate (LB), a steroidal progestin.

Description of Technology:

This invention is a potential subcutaneous or intramuscular progestin-only, injectable contraceptive for women. Forty-five percent (45%) of pregnancies in the United States are unintended. In this group, one-third of reproductive age women are obese – increasing the risk of diabetes, hypertension and venous thromboembolism (VTE). All these are conditions for which most hormonal methods are contraindicated. Thus, additional safe and effective injectable contraceptive options are needed. A subcutaneous formulation may be self-injected without the need of a skilled care provider or medical office visit. Levonorgestrel butanoate (LB) serves as a pro-drug to deliver Levonorgestrel (LNG) to serum after hydrolysis of the ester. It addresses the demand for estrogen-free contraception with no increased risk of VTE. The lack of increased risk is a benefit for all women, especially those obese.

Injectables have lower failure rates than combined hormonal birth control pills or patches or progestin-only pills (POP). Also, POPs require strict adherence to a daily administration schedule. Currently, the only injectable contraceptive on the U.S. market is depomedroxyprogesterone acetate (DMPA). While popular, DMPA contraceptive with certain risks. DMPA may cause weight gain, moodiness, and a decrease in bone mineral density leading to a higher risk of bone fracture.

Levonorgestrel butanoate (LB) is a butyl prodrug of levonorgestrel, a widely-used steroidal progestin. It was in development as a long-acting injectable contraceptive since the 1980s by the World Health Organization (WHO) in collaboration with institutions around the world, including NICHD. However, conventional LB formulations, including the WHO formulation, exhibit undesirable stability issues reducing contraceptive activity and the ability to large-scale manufacture.

NICHD developed an injectable pharmaceutical formulation of LB with a potential for self-administration. The formulation promotes increased stability through a longer lasting and more concentrated dosage than previous LB formulations. This invention also involves a unique manufacturing process requiring only one vendor for more efficient production. NICHD is testing this formulation in an ongoing Phase I subcutaneous study. Results so far indicate promise as a long-lasting, reversible, injectable female contraceptive. Further, there is a competitive advantage as patients in the Phase I study thus far did not report some side effects associated with other contraceptive agents such as DMPA; e.g., weight gain or mood swings.

Potential Commercial Applications:

Injectable contraceptive use by humans

Use in the treatment of progestin-related diseases

Competitive Advantages:

Safer for women with high-risk conditions

Self-subcutaneous and reversible injectable

Long-lasting contraceptive effects

Increased stability relative to previous formulations

Amenable to large-scale manufacture relative to previous formulations

Estrogen free contraceptive

Progestin only self-injectable contraceptive

# data[].attributes.body.processed
Summary:

The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of an injectable contraceptive for women with a pharmaceutical formulation containing levonorgestrel butanoate (LB), a steroidal progestin.

Description of Technology:

This invention is a potential subcutaneous or intramuscular progestin-only, injectable contraceptive for women. Forty-five percent (45%) of pregnancies in the United States are unintended. In this group, one-third of reproductive age women are obese – increasing the risk of diabetes, hypertension and venous thromboembolism (VTE). All these are conditions for which most hormonal methods are contraindicated. Thus, additional safe and effective injectable contraceptive options are needed. A subcutaneous formulation may be self-injected without the need of a skilled care provider or medical office visit. Levonorgestrel butanoate (LB) serves as a pro-drug to deliver Levonorgestrel (LNG) to serum after hydrolysis of the ester. It addresses the demand for estrogen-free contraception with no increased risk of VTE. The lack of increased risk is a benefit for all women, especially those obese.

Injectables have lower failure rates than combined hormonal birth control pills or patches or progestin-only pills (POP). Also, POPs require strict adherence to a daily administration schedule. Currently, the only injectable contraceptive on the U.S. market is depomedroxyprogesterone acetate (DMPA). While popular, DMPA contraceptive with certain risks. DMPA may cause weight gain, moodiness, and a decrease in bone mineral density leading to a higher risk of bone fracture.

Levonorgestrel butanoate (LB) is a butyl prodrug of levonorgestrel, a widely-used steroidal progestin. It was in development as a long-acting injectable contraceptive since the 1980s by the World Health Organization (WHO) in collaboration with institutions around the world, including NICHD. However, conventional LB formulations, including the WHO formulation, exhibit undesirable stability issues reducing contraceptive activity and the ability to large-scale manufacture.

NICHD developed an injectable pharmaceutical formulation of LB with a potential for self-administration. The formulation promotes increased stability through a longer lasting and more concentrated dosage than previous LB formulations. This invention also involves a unique manufacturing process requiring only one vendor for more efficient production. NICHD is testing this formulation in an ongoing Phase I subcutaneous study. Results so far indicate promise as a long-lasting, reversible, injectable female contraceptive. Further, there is a competitive advantage as patients in the Phase I study thus far did not report some side effects associated with other contraceptive agents such as DMPA; e.g., weight gain or mood swings.

Potential Commercial Applications:

Injectable contraceptive use by humans

Use in the treatment of progestin-related diseases

Competitive Advantages:

Safer for women with high-risk conditions

Self-subcutaneous and reversible injectable

Long-lasting contraceptive effects

Increased stability relative to previous formulations

Amenable to large-scale manufacture relative to previous formulations

Estrogen free contraceptive

Progestin only self-injectable contraceptive

# data[].attributes.field_keywords[]
National Institute of Child Health and Human Development

# data[].attributes.field_licensingcontact_htmls[]
Gunas, Heather
gunash@mail.nih.gov

# data[].attributes.field_licensing_contacts[].value
Gunas, Heather
gunash@mail.nih.gov

# data[].attributes.field_licensing_contacts[].processed
Gunas, Heather
gunash@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/289,965
Filed on 2021-12-15
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/289,965
Filed on 2021-12-15
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/052704
Filed on 2022-12-13
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/052704
Filed on 2022-12-13
Status: Expired

# data[].attributes.field_patents[].value
India
National Stage 202417045561
Filed on 2024-06-13
Status: Pending

# data[].attributes.field_patents[].processed
India
National Stage 202417045561
Filed on 2024-06-13
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/289,965
Filed on 2021-12-15
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/052704
Filed on 2022-12-13
Status: Expired

# data[].attributes.field_patent_htmls[]
India
National Stage 202417045561
Filed on 2024-06-13
Status: Pending

# data[].attributes.field_patent_titles[]
LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO

# data[].attributes.field_patent_titles[]
LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO

# data[].attributes.field_patent_titles[]
LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO

# data[].attributes.field_technology_names[]
Levonorgestrel Prodrug Formulation And Methods Relating Thereto

# data[].attributes.title
Novel malaria vaccine candidates comprising engineered nanoparticles

# data[].attributes.body.value
Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5’-phosphate (PLP) synthase protein to form a nanoparticle displaying 48 copies of up to 4 different proteins. The second platform uses the chaperone 60 (Cpn60), which can display 28 copies of up to 2 different proteins. The third platform uses a caseinolytic protease (Clp) which can display 28 copies of up to two different proteins.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5’-phosphate (PLP) synthase protein to form a nanoparticle displaying 48 copies of up to 4 different proteins. The second platform uses the chaperone 60 (Cpn60), which can display 28 copies of up to 2 different proteins. The third platform uses a caseinolytic protease (Clp) which can display 28 copies of up to two different proteins.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-565-2632, or chris.kornak@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-565-2632, or chris.kornak@nih.gov.

# data[].attributes.field_commercial_applications.value
Malaria vaccinology

# data[].attributes.field_commercial_applications.processed
Malaria vaccinology

# data[].attributes.field_competitive_advantages.value
Pre-clinical data indicates that nanoparticles displaying the malaria circumsporozoite protein (CSP) confer 100% sterilizing immunity in mice.

# data[].attributes.field_competitive_advantages.processed
Pre-clinical data indicates that nanoparticles displaying the malaria circumsporozoite protein (CSP) confer 100% sterilizing immunity in mice.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/695,288
Filed on 2024-09-16
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/695,288
Filed on 2024-09-16
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/046419
Filed on 2025-09-15
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/046419
Filed on 2025-09-15
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/695,288
Filed on 2024-09-16
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/046419
Filed on 2025-09-15
Status: Pending

# data[].attributes.field_patent_titles[]
MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF

# data[].attributes.field_patent_titles[]
MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF

# data[].attributes.field_publications[].value
Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y)

# data[].attributes.field_publications[].processed
Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y)

# data[].attributes.field_technology_names[]
Novel malaria vaccine candidates comprising engineered nanoparticles

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, NIH - NIAID

# data[].attributes.title
A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions

# data[].attributes.body.value
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease.

The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:

The inventors designed fusion protein sequences incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with additional Plasmodium 6-cys domains downstream.

The artificial immunogens retained structured transmission blocking epitopes.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease.

The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:

The inventors designed fusion protein sequences incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with additional Plasmodium 6-cys domains downstream.

The artificial immunogens retained structured transmission blocking epitopes.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak 240-627-3705 or chris.kornak@nih.gov, and reference E-086-2023.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak 240-627-3705 or chris.kornak@nih.gov, and reference E-086-2023.

# data[].attributes.field_commercial_applications.value
This technology could be used alone or in combination with existing malaria vaccines.

# data[].attributes.field_commercial_applications.processed
This technology could be used alone or in combination with existing malaria vaccines.

# data[].attributes.field_competitive_advantages.value
The immunogens were used in small animal vaccination studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3 fusions prompted greater functional serum activity compared to Pfs230D1 alone.

Pfs230D1 or its ortholog Pvs230D1 enabled expression of other downstream domains of Pvs230 or Pv48/45D3 another malaria species that causes human disease.

# data[].attributes.field_competitive_advantages.processed
The immunogens were used in small animal vaccination studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3 fusions prompted greater functional serum activity compared to Pfs230D1 alone.

Pfs230D1 or its ortholog Pvs230D1 enabled expression of other downstream domains of Pvs230 or Pv48/45D3 another malaria species that causes human disease.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/617,717
Filed on 2024-01-04
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/617,717
Filed on 2024-01-04
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/010325
Filed on 2025-01-03
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/010325
Filed on 2025-01-03
Status: Pending

# data[].attributes.field_patents[].value
India
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].processed
India
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].value
US
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].processed
US
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].value
European Patent
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patents[].processed
European Patent
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/617,717
Filed on 2024-01-04
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/010325
Filed on 2025-01-03
Status: Pending

# data[].attributes.field_patent_htmls[]
India
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_htmls[]
US
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_htmls[]
European Patent
National Stage None
Filed on None
Status: In Preparation

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_patent_titles[]
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE

# data[].attributes.field_technology_names[]
A Novel Strategy To Produce 6-cys Proteins Based On Pfs230D1 Domain Fusions

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.title
Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization

# data[].attributes.body.value
This technology focuses on the creation of single-component AMA1-RON2 (Apical membrane antigen 1-rhoptry neck protein 2) vaccine candidates. These candidates are based on a novel composition of matter designed to elicit a more effective immune response against the malaria parasite Plasmodium falciparum. The standout aspect of this technology is the Structure-Based Design 1 (SBD1) immunogen, engineered through a structure-based design that significantly enhances its ability to produce potent, strain-transcending neutralizing antibodies. This approach not only surpasses the efficacy of traditional AMA1-RON2 complexes and other insertion fusion designs but also boasts higher thermal stability, indicating better preservation and longevity of the vaccine. The technology’s increased stability and efficiency in production present an opportunity to lower vaccine manufacturing costs and simplify logistics, especially in regions where malaria is endemic. Additionally, the adaptability of these immunogens for integration with nanoparticle platforms could further amplify their immunogenicity, paving the way for more robust and lasting protection against malaria. This innovation can potentially transform malaria prevention and control, offering a more effective, stable, and cost-efficient solution to a disease that continues to impact millions worldwide.

# data[].attributes.body.processed
This technology focuses on the creation of single-component AMA1-RON2 (Apical membrane antigen 1-rhoptry neck protein 2) vaccine candidates. These candidates are based on a novel composition of matter designed to elicit a more effective immune response against the malaria parasite Plasmodium falciparum. The standout aspect of this technology is the Structure-Based Design 1 (SBD1) immunogen, engineered through a structure-based design that significantly enhances its ability to produce potent, strain-transcending neutralizing antibodies. This approach not only surpasses the efficacy of traditional AMA1-RON2 complexes and other insertion fusion designs but also boasts higher thermal stability, indicating better preservation and longevity of the vaccine. The technology’s increased stability and efficiency in production present an opportunity to lower vaccine manufacturing costs and simplify logistics, especially in regions where malaria is endemic. Additionally, the adaptability of these immunogens for integration with nanoparticle platforms could further amplify their immunogenicity, paving the way for more robust and lasting protection against malaria. This innovation can potentially transform malaria prevention and control, offering a more effective, stable, and cost-efficient solution to a disease that continues to impact millions worldwide.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_commercial_applications.value
Stable single-component AMA1-RON2 immunogens hold promise for improving malaria prevention and control efforts in endemic regions around the world.

# data[].attributes.field_commercial_applications.processed
Stable single-component AMA1-RON2 immunogens hold promise for improving malaria prevention and control efforts in endemic regions around the world.

# data[].attributes.field_competitive_advantages.value
No blood-stage malaria vaccine has been approved. This technology offers a competitive edge over other vaccine candidates in development through its easily manufactured single-component AMA1-RON2 design that elicits a potent broadly neutralizing response that is better than competing candidates

# data[].attributes.field_competitive_advantages.processed
No blood-stage malaria vaccine has been approved. This technology offers a competitive edge over other vaccine candidates in development through its easily manufactured single-component AMA1-RON2 design that elicits a potent broadly neutralizing response that is better than competing candidates

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/524,522
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/524,522
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2024/035244
Filed on 2024-06-24
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2024/035244
Filed on 2024-06-24
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/524,522
Filed on 2023-06-30
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2024/035244
Filed on 2024-06-24
Status: Expired

# data[].attributes.field_patent_titles[]
NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS

# data[].attributes.field_patent_titles[]
NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS

# data[].attributes.field_publications[].value
Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023

# data[].attributes.field_publications[].processed
Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023

# data[].attributes.field_technology_names[]
Novel malaria vaccine candidates comprising a stabilized designs of AMA1 and RON2 antigens

# data[].attributes.field_technology_owners[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.title
Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies

# data[].attributes.body.value
This technology encompasses the development of highly advanced malaria vaccine candidates and human monoclonal antibodies, both centered on targeting the Merozoite Surface Protein 1 (MSP1) of the Plasmodium falciparum malaria parasite. The innovation lies in utilizing a novel computational design and in vitro screening process, which has created MSP1 vaccine candidates that are significantly more immunogenic, stable, and cost-effective than existing alternatives. These vaccines focus on the 19 kDa carboxy-terminus fragment of MSP1. They contain engineered amino acid changes and are displayed on self-assembling nanoparticles to elicit a more potent immune response, potentially offering more robust and durable protection against malaria. Additionally, the technology includes the production of enhanced human monoclonal antibodies with improved affinity for the same fragment of MSP1, designed to overcome the parasite's immune evasion tactics. These advancements hold immense promise for significantly improving malaria prevention and treatment. They could lead to the development of more effective vaccines and therapeutic antibodies, providing a critical solution to a significant global health challenge.

# data[].attributes.body.processed
This technology encompasses the development of highly advanced malaria vaccine candidates and human monoclonal antibodies, both centered on targeting the Merozoite Surface Protein 1 (MSP1) of the Plasmodium falciparum malaria parasite. The innovation lies in utilizing a novel computational design and in vitro screening process, which has created MSP1 vaccine candidates that are significantly more immunogenic, stable, and cost-effective than existing alternatives. These vaccines focus on the 19 kDa carboxy-terminus fragment of MSP1. They contain engineered amino acid changes and are displayed on self-assembling nanoparticles to elicit a more potent immune response, potentially offering more robust and durable protection against malaria. Additionally, the technology includes the production of enhanced human monoclonal antibodies with improved affinity for the same fragment of MSP1, designed to overcome the parasite's immune evasion tactics. These advancements hold immense promise for significantly improving malaria prevention and treatment. They could lead to the development of more effective vaccines and therapeutic antibodies, providing a critical solution to a significant global health challenge.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_commercial_applications.value
This MSP1-focused technology has the potential to transform malaria treatment and prevention worldwide, offering more effective vaccines and therapeutic antibodies for use in clinical settings, public health programs, and potentially in regions with high malaria prevalence.

# data[].attributes.field_commercial_applications.processed
This MSP1-focused technology has the potential to transform malaria treatment and prevention worldwide, offering more effective vaccines and therapeutic antibodies for use in clinical settings, public health programs, and potentially in regions with high malaria prevalence.

# data[].attributes.field_competitive_advantages.value
This technology offers highly immunogenic and stable MSP1-based vaccine candidates and monoclonal antibodies, with superior efficacy, cost-effectiveness, and ease of production compared to current alternatives.

# data[].attributes.field_competitive_advantages.processed
This technology offers highly immunogenic and stable MSP1-based vaccine candidates and monoclonal antibodies, with superior efficacy, cost-effectiveness, and ease of production compared to current alternatives.

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/369,909
Filed on 2022-07-29
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/369,909
Filed on 2022-07-29
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2023/070926
Filed on 2023-07-25
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2023/070926
Filed on 2023-07-25
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/369,909
Filed on 2022-07-29
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2023/070926
Filed on 2023-07-25
Status: Expired

# data[].attributes.field_patent_titles[]
METHOD OF IMMUNOFOCUSING AN IMMUNE RESPONSE

# data[].attributes.field_patent_titles[]
METHOD OF IMMMUNOFOCUSING AN IMMUNE RESPONSE

# data[].attributes.field_publications[].value
Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3

# data[].attributes.field_publications[].processed
Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3

# data[].attributes.field_technology_names[]
Novel Compositions Of Matter Comprising Stabilized MSP1 Malaria Antigens And High Affinity Anti-MSP1 Human Monoclonal Antibodies And Their Use

# data[].attributes.title
Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology

# data[].attributes.body.value
The technology includes modifying the Plasmodium falciparum Pfs48/45 Domain III protein sequence to enhance its stability and efficacy to aid in malaria vaccine development. This approach successfully overcomes previous production challenges by increasing the thermostability of the antigen and eliminating the need for additional modifications that could impair vaccine effectiveness. Crucially, the technology maintains the essential neutralizing epitope of Pfs48/45, ensuring its effectiveness in preventing malaria transmission as a transmission-blocking vaccine. Developed using the SPEEDesign program, these novel protein variants show increased stability and a more robust transmission blocking response than wild-type proteins. The potential applications of this technology are providing a more stable and effective vaccine, potentially reducing the incidence of malaria and leading to improved health outcomes.

# data[].attributes.body.processed
The technology includes modifying the Plasmodium falciparum Pfs48/45 Domain III protein sequence to enhance its stability and efficacy to aid in malaria vaccine development. This approach successfully overcomes previous production challenges by increasing the thermostability of the antigen and eliminating the need for additional modifications that could impair vaccine effectiveness. Crucially, the technology maintains the essential neutralizing epitope of Pfs48/45, ensuring its effectiveness in preventing malaria transmission as a transmission-blocking vaccine. Developed using the SPEEDesign program, these novel protein variants show increased stability and a more robust transmission blocking response than wild-type proteins. The potential applications of this technology are providing a more stable and effective vaccine, potentially reducing the incidence of malaria and leading to improved health outcomes.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov.

# data[].attributes.field_commercial_applications.value
This malaria vaccine technology offers competitive advantages by providing increased thermostability and enhanced immune response without the need for efficacy-reducing modifications, potentially revolutionizing malaria prevention with more effective and stable vaccine options.

# data[].attributes.field_commercial_applications.processed
This malaria vaccine technology offers competitive advantages by providing increased thermostability and enhanced immune response without the need for efficacy-reducing modifications, potentially revolutionizing malaria prevention with more effective and stable vaccine options.

# data[].attributes.field_competitive_advantages.value
The development of more effective and stable malaria vaccines offers improved prevention strategies in regions affected by this disease and significantly contributing to global health initiatives.

# data[].attributes.field_competitive_advantages.processed
The development of more effective and stable malaria vaccines offers improved prevention strategies in regions affected by this disease and significantly contributing to global health initiatives.

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_inventor_companies[]
National Institute of Allergy and Infectious Diseases (NIAID/NIH)

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/476,897
Filed on 2022-12-22
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/476,897
Filed on 2022-12-22
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2023/085849
Filed on 2023-12-22
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2023/085849
Filed on 2023-12-22
Status: Expired

# data[].attributes.field_patents[].value
India
National Stage 202517060138
Filed on 2025-06-24
Status: Pending

# data[].attributes.field_patents[].processed
India
National Stage 202517060138
Filed on 2025-06-24
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 19/142,034
Filed on 2025-06-20
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 19/142,034
Filed on 2025-06-20
Status: Pending

# data[].attributes.field_patents[].value
European Patent
National Stage 23848442.2
Filed on 2025-07-04
Status: Pending

# data[].attributes.field_patents[].processed
European Patent
National Stage 23848442.2
Filed on 2025-07-04
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/476,897
Filed on 2022-12-22
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2023/085849
Filed on 2023-12-22
Status: Expired

# data[].attributes.field_patent_htmls[]
India
National Stage 202517060138
Filed on 2025-06-24
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 19/142,034
Filed on 2025-06-20
Status: Pending

# data[].attributes.field_patent_htmls[]
European Patent
National Stage 23848442.2
Filed on 2025-07-04
Status: Pending

# data[].attributes.field_patent_titles[]
Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use

# data[].attributes.field_patent_titles[]
STABILIZED PFS48/45 PROTEINS AND USES THEREOF

# data[].attributes.field_patent_titles[]
STABILIZED PFS48/45 PROTEINS AND USES THEREOF

# data[].attributes.field_patent_titles[]
STABILIZED PFS48/45 PROTEINS AND USES THEREOF

# data[].attributes.field_patent_titles[]
STABILIZED PFS48/45 PROTEINS AND USES THEREOF

# data[].attributes.field_technology_names[]
Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use

# data[].attributes.title
Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use

# data[].attributes.body.value
Using a computational design methodology, SARS-CoV-2 spike proteins containing engineered amino acid changes to the receptor binding domain (RBD) were designed. These engineered spike proteins improved the immune response upon immunization of animals. An engineered RBD was also expressed at greater yield, had increased temperature stability, and improved the immune response upon immunization of animals. Specifically, the disclosed RBD designs can be produced approximately 7 times more efficiently than the native sequence, facilitating vaccine manufacturing on a global scale. The disclosed designs also have up to 10 °C higher thermal stability than the native sequence, suggesting enhanced stability during storage and when in the body. Finally, immunization of animals with the disclosed antigens produces up to 10-fold higher levels of blocking antibodies than the native sequence and 30-fold higher levels of pseudoviral neutralizing antibodies. An additional RBD protein has been engineered to eliminate the need for glycosylation, facilitating production and single-component nanoparticle display of the antigen. The engineered receptor binding domain (RBD) and spike protein antigens produce significant improvements in pre-clinical animal models and may be used to develop improved coronavirus vaccines.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.body.processed
Using a computational design methodology, SARS-CoV-2 spike proteins containing engineered amino acid changes to the receptor binding domain (RBD) were designed. These engineered spike proteins improved the immune response upon immunization of animals. An engineered RBD was also expressed at greater yield, had increased temperature stability, and improved the immune response upon immunization of animals. Specifically, the disclosed RBD designs can be produced approximately 7 times more efficiently than the native sequence, facilitating vaccine manufacturing on a global scale. The disclosed designs also have up to 10 °C higher thermal stability than the native sequence, suggesting enhanced stability during storage and when in the body. Finally, immunization of animals with the disclosed antigens produces up to 10-fold higher levels of blocking antibodies than the native sequence and 30-fold higher levels of pseudoviral neutralizing antibodies. An additional RBD protein has been engineered to eliminate the need for glycosylation, facilitating production and single-component nanoparticle display of the antigen. The engineered receptor binding domain (RBD) and spike protein antigens produce significant improvements in pre-clinical animal models and may be used to develop improved coronavirus vaccines.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; peter.tung@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; peter.tung@nih.gov.

# data[].attributes.field_commercial_applications.value
Novel SARS-CoV-2 vaccine.

Improved SARS-CoV-2 diagnostics using stabilized antigens.

Method of designing vaccine candidates or stabilized antigens by computational. optimization of amino acid identity, followed by additional sequence comparison and selection (Stabilizer for Protein Expression and Epitope Design (SPEEDesign)).

# data[].attributes.field_commercial_applications.processed
Novel SARS-CoV-2 vaccine.

Improved SARS-CoV-2 diagnostics using stabilized antigens.

Method of designing vaccine candidates or stabilized antigens by computational. optimization of amino acid identity, followed by additional sequence comparison and selection (Stabilizer for Protein Expression and Epitope Design (SPEEDesign)).

# data[].attributes.field_competitive_advantages.value
Novel SARS-CoV-2 spike vaccine with improved breadth and duration of protection.

Novel RBD monomer and nanoparticle designs that are more immunogenic and stable than the naturally occurring RBD sequence.

Computational method of designing vaccine antigens.

# data[].attributes.field_competitive_advantages.processed
Novel SARS-CoV-2 spike vaccine with improved breadth and duration of protection.

Novel RBD monomer and nanoparticle designs that are more immunogenic and stable than the naturally occurring RBD sequence.

Computational method of designing vaccine antigens.

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use.

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2022/070744
Filed on 2022-02-18
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2022/070744
Filed on 2022-02-18
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/200,194
Filed on 2021-02-19
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/200,194
Filed on 2021-02-19
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2022/070744
Filed on 2022-02-18
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/200,194
Filed on 2021-02-19
Status: Abandoned

# data[].attributes.field_patent_titles[]
COMPOSITIONS OF MATTER COMPRISING STABILIZED CORONAVIRUS ANTIGENS AND THEIR USE

# data[].attributes.field_patent_titles[]
Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use

# data[].attributes.field_publications[].value
Dickey TH, et al.

# data[].attributes.field_publications[].processed
Dickey TH, et al.

# data[].attributes.field_technology_names[]
Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use

# data[].attributes.title
Novel VAR2CSA Immunogens and Methods of Use Thereof

# data[].attributes.body.value
The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen polypeptides comprise all or portions of the chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified by a structural study of VAR2CSA conducted by the inventors, that possess great sequence conservation among P. falciparum strains when compared to competing clinical vaccine candidates PRIMVAC and PAMVAC. Also provided are methods of using the immunogen polypeptides for vaccination and treatment of disease.

# data[].attributes.body.processed
The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen polypeptides comprise all or portions of the chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified by a structural study of VAR2CSA conducted by the inventors, that possess great sequence conservation among P. falciparum strains when compared to competing clinical vaccine candidates PRIMVAC and PAMVAC. Also provided are methods of using the immunogen polypeptides for vaccination and treatment of disease.

# data[].attributes.field_collaboration_description.value
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; Peter Tung@nih.gov.

# data[].attributes.field_collaboration_description.processed
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; Peter Tung@nih.gov.

# data[].attributes.field_commercial_applications.value
The VAR2CSA immunogens bind to oncofetal CSA, a putative therapeutic target for multiple cancers, including NSCLC, breast, bladder and 40-50% of all pediatric solid tumors. Oncofetal CSA is only expressed solely in the placenta, except in several cancerous tissues, making it an ideal target for targeted therapeutics such as immunogens that are cross linked to cytotoxic agents.

Placental malaria vaccine

CSA-binding proteins for cancer therapeutics

# data[].attributes.field_commercial_applications.processed
The VAR2CSA immunogens bind to oncofetal CSA, a putative therapeutic target for multiple cancers, including NSCLC, breast, bladder and 40-50% of all pediatric solid tumors. Oncofetal CSA is only expressed solely in the placenta, except in several cancerous tissues, making it an ideal target for targeted therapeutics such as immunogens that are cross linked to cytotoxic agents.

Placental malaria vaccine

CSA-binding proteins for cancer therapeutics

# data[].attributes.field_competitive_advantages.value
Strain-transcending immunogens for vaccination

Improved immunogen production through expression of key protein regions

# data[].attributes.field_competitive_advantages.processed
Strain-transcending immunogens for vaccination

Improved immunogen production through expression of key protein regions

# data[].attributes.field_licensingcontact_hrefs[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof.

# data[].attributes.field_licensingcontact_htmls[]
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].value
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Hurley, Benjamin
benjamin.hurley@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/115,729
Filed on 2020-11-19
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/115,729
Filed on 2020-11-19
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2021/059941
Filed on 2021-11-18
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2021/059941
Filed on 2021-11-18
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/115,729
Filed on 2020-11-19
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2021/059941
Filed on 2021-11-18
Status: Expired

# data[].attributes.field_patent_titles[]
NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF

# data[].attributes.field_patent_titles[]
NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF

# data[].attributes.field_technology_names[]
New Composition Of Matter Comprising Immunogens That Will Protect Against Placental Malaria, And Proteins That Can Be Used For Cancer Diagnostics And Therapeutics

# data[].attributes.title
Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy

# data[].attributes.body.value
Summary:

Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.

Description of Technology:

ACT offers hope for patients with refractory or metastatic cancers, but effectiveness is frequently undermined by the immunosuppressive tumor microenvironment and T-cell dysfunction. Interleukin-12 (IL-12), a powerful cytokine with strong anti-tumor properties, has long been recognized for its potential to invigorate T-cell responses within tumors. However, systemic administration of IL-12 results in severe toxicity. Further, prior gene therapy strategies failed to provide sufficient control over IL-12 expression. These two factors compromise safety and therapeutic performance.

This invention introduces a Nuclear Factor of Activated T cells (NFAT)-inducible, drug-regulatable, membrane-bound IL-12 (DRIM-IL-12) system that delivers spatiotemporally controlled cytokine expression within the engineered T cell therapy product. This platform ensures IL-12 is expressed only upon T-cell activation. Concurrently, the degron (D) sequence confers lenalidomide-dependent proteasome-mediated degradation–serving as a drug-controlled safety switch to limit systemic toxicity. A transmembrane (TM) domain anchors IL-12 in the plasma membrane, preventing unintended secretion and promoting localized immune modulation. When paired with tumor-specific TCRs or CARs (e.g., anti-mutant p53 or KRAS TCRs, or CD19 CAR), this platform enhances tumor cell killing and long-term survival in preclinical models. In a mouse model, DRIM-IL-12 demonstrated substantially improved safety compared to the previous generation of NFAT-inducible IL-12. The inventors also demonstrate that DRIM-IL-12 expression can be dialed down or fine-tuned to prevent T-cell exhaustion or differentiation, which can occur with uncontrolled IL-12 expression.

The NCI invites industry partners and translational researchers to collaborate or license this technology for the next generation of safer, more effective ACT-based immunotherapies.

Potential Commercial Applications:

Solid tumors expressing p53 or KRAS mutations

Hematologic malignancies

Melanoma

Competitive Advantages:

Versatile platform for inducible cytokine regulation

Superior survival in mouse models compared with TCR-only T-cells

Enhanced tumor cell killing and long-term survival in murine models

Decreased IL-12–associated toxicity

Maintenance of higher IL-12 expression

Improved sensitivity to lenalidomide-mediated degradation

# data[].attributes.body.processed
Summary:

Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.

Description of Technology:

ACT offers hope for patients with refractory or metastatic cancers, but effectiveness is frequently undermined by the immunosuppressive tumor microenvironment and T-cell dysfunction. Interleukin-12 (IL-12), a powerful cytokine with strong anti-tumor properties, has long been recognized for its potential to invigorate T-cell responses within tumors. However, systemic administration of IL-12 results in severe toxicity. Further, prior gene therapy strategies failed to provide sufficient control over IL-12 expression. These two factors compromise safety and therapeutic performance.

This invention introduces a Nuclear Factor of Activated T cells (NFAT)-inducible, drug-regulatable, membrane-bound IL-12 (DRIM-IL-12) system that delivers spatiotemporally controlled cytokine expression within the engineered T cell therapy product. This platform ensures IL-12 is expressed only upon T-cell activation. Concurrently, the degron (D) sequence confers lenalidomide-dependent proteasome-mediated degradation–serving as a drug-controlled safety switch to limit systemic toxicity. A transmembrane (TM) domain anchors IL-12 in the plasma membrane, preventing unintended secretion and promoting localized immune modulation. When paired with tumor-specific TCRs or CARs (e.g., anti-mutant p53 or KRAS TCRs, or CD19 CAR), this platform enhances tumor cell killing and long-term survival in preclinical models. In a mouse model, DRIM-IL-12 demonstrated substantially improved safety compared to the previous generation of NFAT-inducible IL-12. The inventors also demonstrate that DRIM-IL-12 expression can be dialed down or fine-tuned to prevent T-cell exhaustion or differentiation, which can occur with uncontrolled IL-12 expression.

The NCI invites industry partners and translational researchers to collaborate or license this technology for the next generation of safer, more effective ACT-based immunotherapies.

Potential Commercial Applications:

Solid tumors expressing p53 or KRAS mutations

Hematologic malignancies

Melanoma

Competitive Advantages:

Versatile platform for inducible cytokine regulation

Superior survival in mouse models compared with TCR-only T-cells

Enhanced tumor cell killing and long-term survival in murine models

Decreased IL-12–associated toxicity

Maintenance of higher IL-12 expression

Improved sensitivity to lenalidomide-mediated degradation

# data[].attributes.field_collaboration_description.value
Researchers at the NCI seek licensing and/or co-development research collaborations for developing a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs).

# data[].attributes.field_collaboration_description.processed
Researchers at the NCI seek licensing and/or co-development research collaborations for developing a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs).

# data[].attributes.field_licensingcontact_hrefs[]
burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_licensingcontact_htmls[]
Burke, Andrew
burkear@nih.gov

# data[].attributes.field_licensing_contacts[].value
Burke, Andrew
burkear@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Burke, Andrew
burkear@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov

# data[].attributes.field_patents[].value
US
Provisional (PRV) 63/652,871
Filed on 2024-05-29
Status: Expired

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 63/652,871
Filed on 2024-05-29
Status: Expired

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2025/031121
Filed on 2025-05-28
Status: Pending

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2025/031121
Filed on 2025-05-28
Status: Pending

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 63/652,871
Filed on 2024-05-29
Status: Expired

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2025/031121
Filed on 2025-05-28
Status: Pending

# data[].attributes.field_publications[].value
Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344

# data[].attributes.field_publications[].processed
Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344

# data[].attributes.field_technology_names[]
Drug-regulatable, inducible expression of membrane-bound interleukin 12 for use in adoptive cell therapy.

# data[].attributes.field_technology_owners[]
National Cancer Institute (NCI), Surgery Branch

# data[].attributes.title
Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces

# data[].attributes.body.value
Exposure to lead (Pb) has long posed serious health risks. Ingestion of lead from skin exposure can adversely impact every organ in the body; the kidneys, blood, nervous, and reproductive systems are most affected. Washing skin with soap and water is not sufficient to remove lead residues. To prevent adverse impacts from Pb exposure, exposed individuals need cleaning methods that will effectively remove Pb ions from the skin to less than the limit of identification (i.e., 10 µg or less).

Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to remove metals such as lead from surfaces, including skin. This method includes applying a cationic surfactant (ISML (isostearamidopropyl morpholine lactate), a compound that lowers surface tension) and a weak acid (such as citric acid) to a surface and wiping the surface with a three-dimensionally textured absorbent support. The cationic surfactant and weak acid are in liquid form or are dissolved in a suitable solvent, such as water. This wetting agent can be applied directly to the surface and wiped away or can be contained within the absorbent support. Research has shown that this method does not damage or irritate the skin.
This technology can be used in conjunction with another CDC NIOSH invention, a handwipe disclosing method (HHS Reference No. E-336-2013) which uses colorimetric chemistry (a color change occurs) to detect lead sampled from surfaces. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin or other surfaces contaminated with lead.

# data[].attributes.body.processed
Exposure to lead (Pb) has long posed serious health risks. Ingestion of lead from skin exposure can adversely impact every organ in the body; the kidneys, blood, nervous, and reproductive systems are most affected. Washing skin with soap and water is not sufficient to remove lead residues. To prevent adverse impacts from Pb exposure, exposed individuals need cleaning methods that will effectively remove Pb ions from the skin to less than the limit of identification (i.e., 10 µg or less).

Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to remove metals such as lead from surfaces, including skin. This method includes applying a cationic surfactant (ISML (isostearamidopropyl morpholine lactate), a compound that lowers surface tension) and a weak acid (such as citric acid) to a surface and wiping the surface with a three-dimensionally textured absorbent support. The cationic surfactant and weak acid are in liquid form or are dissolved in a suitable solvent, such as water. This wetting agent can be applied directly to the surface and wiped away or can be contained within the absorbent support. Research has shown that this method does not damage or irritate the skin.

This technology can be used in conjunction with another CDC NIOSH invention, a handwipe disclosing method (HHS Reference No. E-336-2013) which uses colorimetric chemistry (a color change occurs) to detect lead sampled from surfaces. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin or other surfaces contaminated with lead.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.
For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.
For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_commercial_applications.value
Cleansing the hands of workers who have occupational exposure to lead (e.g., auto repairers, battery manufacturers, pipe fitters, recyclers of metal and batteries, etc.) prior to eating, smoking, or leaving their work for the day

Cleansing the hands of police, other law enforcement officers (e.g., immigration, customs, or Secret Service) or recreational firearms users after using firearms

Cleansing the hands of lead abatement workers or those renovating old homes with lead-based paint

Removing lead from any contaminated surface other than skin such as floors, walls, windowsills, clothing, laundry, shoes, equipment surfaces, and furniture surfaces that may pose an exposure risk

Kit for detecting and removing lead from surfaces (when combined with the handwipe disclosing method to detect the presence of lead sampled from surfaces (HHS Reference No. E-336-2013))

May be used to solubilize and remove a variety of metals such as cadmium, tin, barium, arsenic, chromium, copper, mercury, silver, zinc, strontium, thallium, germanium, or zirconium, or a combination thereof

# data[].attributes.field_commercial_applications.processed
Cleansing the hands of workers who have occupational exposure to lead (e.g., auto repairers, battery manufacturers, pipe fitters, recyclers of metal and batteries, etc.) prior to eating, smoking, or leaving their work for the day

Cleansing the hands of police, other law enforcement officers (e.g., immigration, customs, or Secret Service) or recreational firearms users after using firearms

Cleansing the hands of lead abatement workers or those renovating old homes with lead-based paint

Removing lead from any contaminated surface other than skin such as floors, walls, windowsills, clothing, laundry, shoes, equipment surfaces, and furniture surfaces that may pose an exposure risk

Kit for detecting and removing lead from surfaces (when combined with the handwipe disclosing method to detect the presence of lead sampled from surfaces (HHS Reference No. E-336-2013))

May be used to solubilize and remove a variety of metals such as cadmium, tin, barium, arsenic, chromium, copper, mercury, silver, zinc, strontium, thallium, germanium, or zirconium, or a combination thereof

# data[].attributes.field_competitive_advantages.value
Safe for use on skin

Quick and easy to use

Portable and convenient to use wherever lead is present

Effectively removes Pb ions from the skin to less than the limit of identification

Can be used to complement other lead detection methods

Uses physical (wiping) and chemical means to decontaminate surfaces from lead and other metals mentioned above

# data[].attributes.field_competitive_advantages.processed
Safe for use on skin

Quick and easy to use

Portable and convenient to use wherever lead is present

Effectively removes Pb ions from the skin to less than the limit of identification

Can be used to complement other lead detection methods

Uses physical (wiping) and chemical means to decontaminate surfaces from lead and other metals mentioned above

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces.

# data[].attributes.field_patents[].value
US Patent 7,604,997
Filed on 2005-01-18
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 7,604,997
Filed on 2005-01-18
Status: Issued

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2006/001515
Filed on 2006-01-17
Status: Abandoned

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2006/001515
Filed on 2006-01-17
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,604,997
Filed on 2005-01-18
Status: Issued

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2006/001515
Filed on 2006-01-17
Status: Abandoned

# data[].attributes.field_patent_titles[]
WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES

# data[].attributes.field_patent_titles[]
WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES

# data[].attributes.field_publications[].value
Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9)

# data[].attributes.field_publications[].processed
Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9)

# data[].attributes.field_publications[].value
Esswein EJ, et al.

# data[].attributes.field_publications[].processed
Esswein EJ, et al.

# data[].attributes.field_publications[].value
NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way

# data[].attributes.field_publications[].processed
NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way

# data[].attributes.field_publications[].value
NIOSH. (2018). Workplace Safety and Health Topics

# data[].attributes.field_publications[].processed
NIOSH. (2018). Workplace Safety and Health Topics

# data[].attributes.field_related_inventions[].processed
E-336-2013-0

# data[].attributes.field_technology_names[]
WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Handwipe Disclosing Method for Detecting the Presence of Lead

# data[].attributes.body.value
Lead (Pb) exposure can cause serious health concerns including abdominal pain, headaches, loss of appetite, memory loss, weakness, and other symptoms. Lead residues on human skin, especially on the hands of workers can be a significant health risk since such residues may be ingested during normal activities (e.g. eating, drinking, and smoking). A key component to reducing lead exposure is being able to identify areas of lead contamination.

US Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to detect lead on surfaces, including skin, using a handwipe system and a chemical test to effect a color change if lead is present. A handwipe is used to collect any lead contamination on the surface. Then the lead is solubilized with an aqueous acid solution and treated with rhodizonate or sulfide anions. When lead is detected, the color changes from pink to red (when rhodizonate anions are used) or from brown to black (where sulfide anions are used).

This invention can be used to test surfaces including human skin, floors, walls, windowsills, etc. It can be used to inform employers and workers on potential lead contamination, as well as evaluate lead removal efforts. This technology can also be used in conjunction with another CDC NIOSH invention involving wipes and methods for removal of lead. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin and other surfaces contaminated with lead.

# data[].attributes.body.processed
Lead (Pb) exposure can cause serious health concerns including abdominal pain, headaches, loss of appetite, memory loss, weakness, and other symptoms. Lead residues on human skin, especially on the hands of workers can be a significant health risk since such residues may be ingested during normal activities (e.g. eating, drinking, and smoking). A key component to reducing lead exposure is being able to identify areas of lead contamination.

US Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to detect lead on surfaces, including skin, using a handwipe system and a chemical test to effect a color change if lead is present. A handwipe is used to collect any lead contamination on the surface. Then the lead is solubilized with an aqueous acid solution and treated with rhodizonate or sulfide anions. When lead is detected, the color changes from pink to red (when rhodizonate anions are used) or from brown to black (where sulfide anions are used).

This invention can be used to test surfaces including human skin, floors, walls, windowsills, etc. It can be used to inform employers and workers on potential lead contamination, as well as evaluate lead removal efforts. This technology can also be used in conjunction with another CDC NIOSH invention involving wipes and methods for removal of lead. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin and other surfaces contaminated with lead.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize the Handwipe Disclosing Method for Detecting the Presence of Lead. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize the Handwipe Disclosing Method for Detecting the Presence of Lead. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_commercial_applications.value
Testing potentially contaminated surfaces such as skin, floors, walls, windowsills, etc., for lead

Informing employers and workers on potential lead contamination and exposure

Educating potentially exposed individuals about their lead exposure and effectiveness of lead removal methods

Evaluating effectiveness of lead removal from surfaces in workplaces, homes, hospitals, and schools
Confirming hand/skin/shoe/clothing washing effectiveness of lead removal for military, law enforcement, and target range personnel

Part of a kit for detecting and removing lead from a surface (when combined with CDC NIOSH’s wipes and methods for removing lead and other metal contamination from surfaces technology (HHS Reference Number E-221-2013-0))

# data[].attributes.field_commercial_applications.processed
Testing potentially contaminated surfaces such as skin, floors, walls, windowsills, etc., for lead

Informing employers and workers on potential lead contamination and exposure

Educating potentially exposed individuals about their lead exposure and effectiveness of lead removal methods

Evaluating effectiveness of lead removal from surfaces in workplaces, homes, hospitals, and schools

Confirming hand/skin/shoe/clothing washing effectiveness of lead removal for military, law enforcement, and target range personnel

Part of a kit for detecting and removing lead from a surface (when combined with CDC NIOSH’s wipes and methods for removing lead and other metal contamination from surfaces technology (HHS Reference Number E-221-2013-0))

# data[].attributes.field_competitive_advantages.value
Safe for use on skin

Quick and easy to use
-
Portable and can be used during field evaluations

Can be used wherever lead is present

Simple color change readout indicates the presence of lead on a surface

Lead concentration can be inferred by degree of color shift

Can be used to guide and evaluate lead removal methods

# data[].attributes.field_competitive_advantages.processed
Safe for use on skin

Quick and easy to use
-
Portable and can be used during field evaluations

Can be used wherever lead is present

Simple color change readout indicates the presence of lead on a surface

Lead concentration can be inferred by degree of color shift

Can be used to guide and evaluate lead removal methods

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead .

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead .

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/049,352
Filed on 1997-06-11
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/049,352
Filed on 1997-06-11
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US1998/011776
Filed on 1998-06-08
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US1998/011776
Filed on 1998-06-08
Status: Expired

# data[].attributes.field_patents[].value
US Patent 6,248,593
Filed on 1999-12-09
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 6,248,593
Filed on 1999-12-09
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/049,352
Filed on 1997-06-11
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US1998/011776
Filed on 1998-06-08
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 6,248,593
Filed on 1999-12-09
Status: Expired

# data[].attributes.field_patent_titles[]
HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD

# data[].attributes.field_patent_titles[]
HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD

# data[].attributes.field_patent_titles[]
HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD

# data[].attributes.field_publications[].value
Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28.

# data[].attributes.field_publications[].processed
Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28.

# data[].attributes.field_publications[].value
Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4).

# data[].attributes.field_publications[].processed
Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4).

# data[].attributes.field_publications[].value
Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9).

# data[].attributes.field_publications[].processed
Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9).

# data[].attributes.field_publications[].value
Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5).

# data[].attributes.field_publications[].processed
Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5).

# data[].attributes.field_publications[].value
NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way!

# data[].attributes.field_publications[].processed
NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way!

# data[].attributes.field_publications[].value
NIOSH. (2018). Workplace Safety and Health Topics: Lead.

# data[].attributes.field_publications[].processed
NIOSH. (2018). Workplace Safety and Health Topics: Lead.

# data[].attributes.field_publications[].value
NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH.

# data[].attributes.field_publications[].processed
NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH.

# data[].attributes.field_related_inventions[].processed
E-221-2013-0

# data[].attributes.field_technology_names[]
HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring

# data[].attributes.body.value
Exposures to hazardous airborne particles can pose a significant health risk to those routinely exposed in ambient air and industrial work environments. Measuring chemical composition and concentration of aerosol particles is important to preventing worker exposures and protecting health. Current, widely used methods to measure aerosol chemicals in the workplace involve particle collection on filters over several hours, followed by laboratory analysis which requires considerable time and resources, cannot capture transient exposures, and provide results several days after the exposure has occurred.

CDC National Institute for Occupational Safety and Health (NIOSH) researchers have developed new methods to collect and analyze aerosol particles from an air sample. These direct-reading methods allow aerosol chemical analysis with high selectivity in near real-time in a portable or hand-held instrument. The methods allow collection of aerosols at high flow rates, 5-15 times higher than those in current commercial instruments, and involves concentration of the aerosol as a spot sample, followed by chemical analysis using laser spectroscopy techniques such as reflectance, Raman, absorption, fluorescence, and also through pulsed spark emission spectroscopy. The methods can be extended to detection of bioaerosols. The technology allows development of wearable, portable, or handheld instruments for continuous automated quantification of particulate chemical concentrations and bioaerosol analysis for environmental and occupational air quality monitoring applications.

# data[].attributes.body.processed
Exposures to hazardous airborne particles can pose a significant health risk to those routinely exposed in ambient air and industrial work environments. Measuring chemical composition and concentration of aerosol particles is important to preventing worker exposures and protecting health. Current, widely used methods to measure aerosol chemicals in the workplace involve particle collection on filters over several hours, followed by laboratory analysis which requires considerable time and resources, cannot capture transient exposures, and provide results several days after the exposure has occurred.

CDC National Institute for Occupational Safety and Health (NIOSH) researchers have developed new methods to collect and analyze aerosol particles from an air sample. These direct-reading methods allow aerosol chemical analysis with high selectivity in near real-time in a portable or hand-held instrument. The methods allow collection of aerosols at high flow rates, 5-15 times higher than those in current commercial instruments, and involves concentration of the aerosol as a spot sample, followed by chemical analysis using laser spectroscopy techniques such as reflectance, Raman, absorption, fluorescence, and also through pulsed spark emission spectroscopy. The methods can be extended to detection of bioaerosols. The technology allows development of wearable, portable, or handheld instruments for continuous automated quantification of particulate chemical concentrations and bioaerosol analysis for environmental and occupational air quality monitoring applications.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.  For collaboration opportunities, please contact CDC Technology Transfer Office at tto@cdc.gov or 404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.  For collaboration opportunities, please contact CDC Technology Transfer Office at tto@cdc.gov or 404-639-1330.

# data[].attributes.field_commercial_applications.value
Collecting and analyzing aerosol particles for the prevention and testing of hazardous exposures

Air pollution studies and particulate matter monitoring

Environmental and occupational personal exposure monitoring

Evaluation of engineering controls

Occupational safety and health

Monitoring/public health surveillance

# data[].attributes.field_commercial_applications.processed
Collecting and analyzing aerosol particles for the prevention and testing of hazardous exposures

Air pollution studies and particulate matter monitoring

Environmental and occupational personal exposure monitoring

Evaluation of engineering controls

Occupational safety and health

Monitoring/public health surveillance

# data[].attributes.field_competitive_advantages.value
Near real-time and continuous automatic measurement of aerosol and bioaerosol

Tandem spectroscopy: allows simultaneous elemental (i.e., atomic emission spectroscopy) and molecular (e.g., Raman and near infrared spectroscopy) analysis of aerosol samples with high selectivity

High sample throughput collection

- Allows space-saving and miniature designs for easy integration into portable instruments

Eliminates the need for carrying heavy equipment in the field or waiting for laboratory analysis results

# data[].attributes.field_competitive_advantages.processed
Near real-time and continuous automatic measurement of aerosol and bioaerosol

Tandem spectroscopy: allows simultaneous elemental (i.e., atomic emission spectroscopy) and molecular (e.g., Raman and near infrared spectroscopy) analysis of aerosol samples with high selectivity

High sample throughput collection

- Allows space-saving and miniature designs for easy integration into portable instruments

Eliminates the need for carrying heavy equipment in the field or waiting for laboratory analysis results

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring.

# data[].attributes.field_patents[].value
Japan
National Stage 2024-544936
Filed on 2024-07-29
Status: Pending

# data[].attributes.field_patents[].processed
Japan
National Stage 2024-544936
Filed on 2024-07-29
Status: Pending

# data[].attributes.field_patents[].value
US
National Stage 18/832,139
Filed on 2024-07-23
Status: Pending

# data[].attributes.field_patents[].processed
US
National Stage 18/832,139
Filed on 2024-07-23
Status: Pending

# data[].attributes.field_patent_htmls[]
Japan
National Stage 2024-544936
Filed on 2024-07-29
Status: Pending

# data[].attributes.field_patent_htmls[]
US
National Stage 18/832,139
Filed on 2024-07-23
Status: Pending

# data[].attributes.field_patent_titles[]
METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES

# data[].attributes.field_patent_titles[]
METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES

# data[].attributes.field_related_inventions[].processed
E-291-2016-0

# data[].attributes.field_related_inventions[].processed
E-205-2013-0

# data[].attributes.field_related_inventions[].processed
E-163-2013-0

# data[].attributes.field_related_inventions[].processed
E-026-2014-0

# data[].attributes.field_related_inventions[].processed
E-146-2013-0

# data[].attributes.field_technology_names[]
Methods For High Sample Throughput Collection And Trace Chemical Analysis Of Aerosols Using Laser And Optical Spectroscopies

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs

# data[].attributes.body.value
Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory. CDC researchers developed a real-time detection kit that can be used in the workplace to test for anti-neoplastic drug contamination. The direct reading anti-neoplastic drug detector based on lateral flow immunoassay (LFIA) technology has been developed for the assessment of drug residues on surfaces. These detectors are incorporated into kits that allow workers to sample surfaces to assess drug contamination in near real-time. Detection kits for three anti-neoplastic drugs (5-Fluorouracil, Paclitaxel, and Doxorubicin) have been developed and kits for several other anti-neoplastic agents may be possible based on this technology.

# data[].attributes.body.processed
Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory. CDC researchers developed a real-time detection kit that can be used in the workplace to test for anti-neoplastic drug contamination. The direct reading anti-neoplastic drug detector based on lateral flow immunoassay (LFIA) technology has been developed for the assessment of drug residues on surfaces. These detectors are incorporated into kits that allow workers to sample surfaces to assess drug contamination in near real-time. Detection kits for three anti-neoplastic drugs (5-Fluorouracil, Paclitaxel, and Doxorubicin) have been developed and kits for several other anti-neoplastic agents may be possible based on this technology.

# data[].attributes.field_collaboration_description.value
The CDC/NIOSH is seeking statements of capability or interest from parties interested in collaborative reasearch to further develop, evaluate, or commercialize Detection Kits for Surface Contamination by Anti-Neoplastic Drugs. For collaboration opportunities, please contact Kathleen Goedel at keg2@cdc.gov or 1-513-533-8686.

# data[].attributes.field_collaboration_description.processed
The CDC/NIOSH is seeking statements of capability or interest from parties interested in collaborative reasearch to further develop, evaluate, or commercialize Detection Kits for Surface Contamination by Anti-Neoplastic Drugs. For collaboration opportunities, please contact Kathleen Goedel at keg2@cdc.gov or 1-513-533-8686.

# data[].attributes.field_commercial_applications.value
Environmental sampling / detection kit for surface contamination by anti-neoplastic (anti-cancer) drugs in hospitals and pharmacies

Kits can be used to assess decontamination procedures

Kits can be used to assess protective equipment and closed system drug-transfer devices

Kits can aid in the development of work practices to lower healthcare worker exposure to anti-neoplastic drugs from contaminated surfaces

# data[].attributes.field_commercial_applications.processed
Environmental sampling / detection kit for surface contamination by anti-neoplastic (anti-cancer) drugs in hospitals and pharmacies

Kits can be used to assess decontamination procedures

Kits can be used to assess protective equipment and closed system drug-transfer devices

Kits can aid in the development of work practices to lower healthcare worker exposure to anti-neoplastic drugs from contaminated surfaces

# data[].attributes.field_competitive_advantages.value
Near real-time results

Can be used in various locations, on surfaces, and on protective equipment

Simple to use

Final kit configuration to incorporate laboratory and field studies for maximum benefit to healthcare workers

# data[].attributes.field_competitive_advantages.processed
Near real-time results

Can be used in various locations, on surfaces, and on protective equipment

Simple to use

Final kit configuration to incorporate laboratory and field studies for maximum benefit to healthcare workers

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/672,059
Filed on 2012-07-16
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/672,059
Filed on 2012-07-16
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2013/050688
Filed on 2013-07-16
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2013/050688
Filed on 2013-07-16
Status: Expired

# data[].attributes.field_patents[].value
US Patent 10,782,308
Filed on 2013-07-16
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 10,782,308
Filed on 2013-07-16
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/672,059
Filed on 2012-07-16
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2013/050688
Filed on 2013-07-16
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 10,782,308
Filed on 2013-07-16
Status: Issued

# data[].attributes.field_patent_titles[]
Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs

# data[].attributes.field_patent_titles[]
Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs

# data[].attributes.field_patent_titles[]
Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs

# data[].attributes.field_publications[].value
Smith JP

# data[].attributes.field_publications[].processed
Smith JP

# data[].attributes.field_publications[].value
Smith JP

# data[].attributes.field_publications[].processed
Smith JP

# data[].attributes.field_publications[].value
Smith JP

# data[].attributes.field_publications[].processed
Smith JP

# data[].attributes.field_technology_names[]
Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring

# data[].attributes.body.value
Airborne particles can have great impact on air quality, weather, and human health. In particular, long-term inhalation of toxic particulate matter in workplaces could pose a significant health risk. NIOSH scientists have developed a new, low-cost approach based on application of atmospheric radio frequency glow discharge (rf-GD) optical emission spectroscopy for near real-time measurement of elemental concentration in aerosols. The method involves collection of aerosol particles on an electrode tip in a coaxial microelectrode system, followed by excitation of the particles using rf-GD. NIOSH scientists identified far less expensive excitation sources for the rf-GD than traditional spark and laser-based excitation sources. Additionally, these excitation sources are compact and can be miniaturized for development of sensors for personal air sampling. The scientists developed a laboratory instrument, calibrated it for various elements including carbon, cadmium, manganese, and sodium, and established analytical detection limits for these elements. They demonstrated that these limits are well below most occupational exposure limits, allowing sensitive near real-time detection. This technology provides an excellent resource for air quality monitoring and the development of low-cost, hand-held sensors for aerosol measurement.

# data[].attributes.body.processed
Airborne particles can have great impact on air quality, weather, and human health. In particular, long-term inhalation of toxic particulate matter in workplaces could pose a significant health risk. NIOSH scientists have developed a new, low-cost approach based on application of atmospheric radio frequency glow discharge (rf-GD) optical emission spectroscopy for near real-time measurement of elemental concentration in aerosols. The method involves collection of aerosol particles on an electrode tip in a coaxial microelectrode system, followed by excitation of the particles using rf-GD. NIOSH scientists identified far less expensive excitation sources for the rf-GD than traditional spark and laser-based excitation sources. Additionally, these excitation sources are compact and can be miniaturized for development of sensors for personal air sampling. The scientists developed a laboratory instrument, calibrated it for various elements including carbon, cadmium, manganese, and sodium, and established analytical detection limits for these elements. They demonstrated that these limits are well below most occupational exposure limits, allowing sensitive near real-time detection. This technology provides an excellent resource for air quality monitoring and the development of low-cost, hand-held sensors for aerosol measurement.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov.

# data[].attributes.field_commercial_applications.value
Air pollution studies and particulate matter monitoring

Environmental and occupational personal exposure monitoring

Evaluation of engineering controls

# data[].attributes.field_commercial_applications.processed
Air pollution studies and particulate matter monitoring

Environmental and occupational personal exposure monitoring

Evaluation of engineering controls

# data[].attributes.field_competitive_advantages.value
Currently, there are no real-time hand-held instruments (commercial or otherwise) for measuring elemental concentration of airborne particles (metals and nonmetals) in environmental and occupational settings

Enables elemental analysis of aerosols in near real-time

Uses low-cost and miniature-sized (approximately 3 x 1 x .05 inch) excitation sources

# data[].attributes.field_competitive_advantages.processed
Currently, there are no real-time hand-held instruments (commercial or otherwise) for measuring elemental concentration of airborne particles (metals and nonmetals) in environmental and occupational settings

Enables elemental analysis of aerosols in near real-time

Uses low-cost and miniature-sized (approximately 3 x 1 x .05 inch) excitation sources

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/484,300
Filed on 2017-04-11
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/484,300
Filed on 2017-04-11
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2018/027105
Filed on 2018-04-11
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2018/027105
Filed on 2018-04-11
Status: Expired

# data[].attributes.field_patents[].value
US
National Stage 16/500,925
Filed on 2019-10-04
Status: Abandoned

# data[].attributes.field_patents[].processed
US
National Stage 16/500,925
Filed on 2019-10-04
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/484,300
Filed on 2017-04-11
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2018/027105
Filed on 2018-04-11
Status: Expired

# data[].attributes.field_patent_htmls[]
US
National Stage 16/500,925
Filed on 2019-10-04
Status: Abandoned

# data[].attributes.field_patent_titles[]
Elemental Analysis of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY

# data[].attributes.field_patent_titles[]
SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY

# data[].attributes.field_publications[].value
Zheng L, et al.

# data[].attributes.field_publications[].processed
Zheng L, et al.

# data[].attributes.field_related_inventions[].processed
E-205-2013-0

# data[].attributes.field_related_inventions[].processed
E-163-2013-0

# data[].attributes.field_technology_names[]
Elemental Analysis Of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters

# data[].attributes.body.value
A respirator protects the wearer from inhaling dangerous substances, such as chemicals and infectious particles. CDC developed devices and methods to detect and remove chemicals such as hydrogen cyanide, cyanogen, hydrogen sulfide, nitrite, and nitric oxide from the air for those wearing respirators. Cobinamide (a Vitamin B12 analog with a high affinity to cyanide) molecules are immobilized within a silica matrix that allows for the infiltration and containment of gaseous chemicals. Since the chemical(s) bind to the cobinamide, such material is embedded into respirator canisters to help facilitate the removal of toxic molecules from the air.

The chemical(s) binding to the cobinamide also result in a color change that can be analyzed qualitatively or quantitatively. The cobinamide-loaded silica matrix can be incorporated into a respirator canister (such as a canister designed to protect workers against chemical, biological, radiological and nuclear weapons (CBRN)) to act as an end-of-service-life indicator (ESLI) alerting when to change equipment. Different absorbance of the cobinamide/silica composite within the respirator canister can be monitored, and the device can be configured to trigger a visual and/or audible alarm once a particular concentration of the chemical(s) meets a certain threshold, indicating that the canister needs to be replaced. Current ESLI technology only depends on the user to monitor a color change via a colorimetric indicator, viewed through a clear box on the outside of the gas mask canister. This is an issue for color-blind persons, those in low-light settings, and users if they are preoccupied and unable to continuously monitor the indicator. The CDC/NIOSH technology can be configured for both a visual and/or audible alarm.

# data[].attributes.body.processed
A respirator protects the wearer from inhaling dangerous substances, such as chemicals and infectious particles. CDC developed devices and methods to detect and remove chemicals such as hydrogen cyanide, cyanogen, hydrogen sulfide, nitrite, and nitric oxide from the air for those wearing respirators. Cobinamide (a Vitamin B12 analog with a high affinity to cyanide) molecules are immobilized within a silica matrix that allows for the infiltration and containment of gaseous chemicals. Since the chemical(s) bind to the cobinamide, such material is embedded into respirator canisters to help facilitate the removal of toxic molecules from the air.

The chemical(s) binding to the cobinamide also result in a color change that can be analyzed qualitatively or quantitatively. The cobinamide-loaded silica matrix can be incorporated into a respirator canister (such as a canister designed to protect workers against chemical, biological, radiological and nuclear weapons (CBRN)) to act as an end-of-service-life indicator (ESLI) alerting when to change equipment. Different absorbance of the cobinamide/silica composite within the respirator canister can be monitored, and the device can be configured to trigger a visual and/or audible alarm once a particular concentration of the chemical(s) meets a certain threshold, indicating that the canister needs to be replaced. Current ESLI technology only depends on the user to monitor a color change via a colorimetric indicator, viewed through a clear box on the outside of the gas mask canister. This is an issue for color-blind persons, those in low-light settings, and users if they are preoccupied and unable to continuously monitor the indicator. The CDC/NIOSH technology can be configured for both a visual and/or audible alarm.

# data[].attributes.field_collaboration_description.value
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica- based Materials for Respirator Canisters. For collaboration opportunities, please contact CDC TTO at tto@cdc.govor 1-404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica- based Materials for Respirator Canisters. For collaboration opportunities, please contact CDC TTO at tto@cdc.govor 1-404-639-1330.

# data[].attributes.field_commercial_applications.value
Detection and removal of chemical, biological, radiological, and nuclear (CBRN) agents for military and emergency response workers such as police, EMTs and fire fighters

Detection of nitric oxide for miners exposed from the use of explosives for blasting and diesel engine emissions

Occupational safety for manufacturing, agriculture, chemicals/pesticides, construction, roofing, painting, etc.

# data[].attributes.field_commercial_applications.processed
Detection and removal of chemical, biological, radiological, and nuclear (CBRN) agents for military and emergency response workers such as police, EMTs and fire fighters

Detection of nitric oxide for miners exposed from the use of explosives for blasting and diesel engine emissions

Occupational safety for manufacturing, agriculture, chemicals/pesticides, construction, roofing, painting, etc.

# data[].attributes.field_competitive_advantages.value
Technology senses and removes particles

Ability to monitor several ligands (molecules that bind with others) at once

An "active" vs. "passive" ESLI that will alert user to thresholds of CBRN agents important for replacing respirator canisters

To the inventor’s knowledge, there is no known commercially-available ESLI for hydrogen cyanide gas, a significant risk with fires and chemical explosions

Not based on electrochemical technology

Apparatus is added to gas canisters

Light weight and inexpensive

Uses a light source and mini spectrometer

Uses color and/or audible detection

# data[].attributes.field_competitive_advantages.processed
Technology senses and removes particles

Ability to monitor several ligands (molecules that bind with others) at once

An "active" vs. "passive" ESLI that will alert user to thresholds of CBRN agents important for replacing respirator canisters

To the inventor’s knowledge, there is no known commercially-available ESLI for hydrogen cyanide gas, a significant risk with fires and chemical explosions

Not based on electrochemical technology

Apparatus is added to gas canisters

Light weight and inexpensive

Uses a light source and mini spectrometer

Uses color and/or audible detection

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/016,565
Filed on 2014-06-24
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/016,565
Filed on 2014-06-24
Status: Abandoned

# data[].attributes.field_patents[].value
US
Ordinary Patent (ORD) 14/748,163
Filed on 2015-06-23
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Ordinary Patent (ORD) 14/748,163
Filed on 2015-06-23
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/016,565
Filed on 2014-06-24
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US
Ordinary Patent (ORD) 14/748,163
Filed on 2015-06-23
Status: Abandoned

# data[].attributes.field_patent_titles[]
Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters

# data[].attributes.field_patent_titles[]
Cobinamide-Based Materials For Optical Sensing And Gas Removal

# data[].attributes.field_publications[].value
Greenawald LA, et al.

# data[].attributes.field_publications[].processed
Greenawald LA, et al.

# data[].attributes.field_technology_names[]
Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC), University of California, San Diego

# data[].attributes.title
Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls

# data[].attributes.body.value
Falls are the leading cause of death in construction. In 2016, there were 370 fatal falls out of 991 construction fatalities (Bureau of Labor Statistics, Census of Fatal Occupational Injuries data). These deaths are preventable. According to the Occupational Safety and Health Administration, employers must set up the workplace to prevent employees from falling from overhead platforms, elevated work stations, or into holes in the floor and walls. For a roofing job, employers should consider all potential fall hazards, such as holes, skylights, and leading edges, then plan and select fall protection suitable for the proposed work.

CDC's National Institute for Occupational Safety and Health (NIOSH) inventors developed a protective barricade system to prevent workers from accidentally falling through holes in roofs/floors, from the edges of stairwells, balconies, or pitched roofs. The barricade system comprises several barricade brackets that are spaced apart and can be temporarily fastened to the underlying surface. Using the adjustable safety rail and roof bracket assembly creates a protective guardrail system that can be easily installed along roof edges and around openings or skylights on roofs with slopes ranging from 18 degrees (4:12) to 63 degrees (24:12). The durable construction of the assembly provides a secure walking/working surface for workers while working on steep roof surfaces. This design also includes an adjustable plank adapter, which permits the use of wider planks, resulting in an increase of up to 20% in the foot-bearing surface area, thus providing more worker stability.

# data[].attributes.body.processed
Falls are the leading cause of death in construction. In 2016, there were 370 fatal falls out of 991 construction fatalities (Bureau of Labor Statistics, Census of Fatal Occupational Injuries data). These deaths are preventable. According to the Occupational Safety and Health Administration, employers must set up the workplace to prevent employees from falling from overhead platforms, elevated work stations, or into holes in the floor and walls. For a roofing job, employers should consider all potential fall hazards, such as holes, skylights, and leading edges, then plan and select fall protection suitable for the proposed work.

CDC's National Institute for Occupational Safety and Health (NIOSH) inventors developed a protective barricade system to prevent workers from accidentally falling through holes in roofs/floors, from the edges of stairwells, balconies, or pitched roofs. The barricade system comprises several barricade brackets that are spaced apart and can be temporarily fastened to the underlying surface. Using the adjustable safety rail and roof bracket assembly creates a protective guardrail system that can be easily installed along roof edges and around openings or skylights on roofs with slopes ranging from 18 degrees (4:12) to 63 degrees (24:12). The durable construction of the assembly provides a secure walking/working surface for workers while working on steep roof surfaces. This design also includes an adjustable plank adapter, which permits the use of wider planks, resulting in an increase of up to 20% in the foot-bearing surface area, thus providing more worker stability.

# data[].attributes.field_collaboration_description.value
The CDC National Institute for Occupational Safety and Health (NIOSH) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_collaboration_description.processed
The CDC National Institute for Occupational Safety and Health (NIOSH) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.

# data[].attributes.field_commercial_applications.value
May be used widely throughout the residential and commercial construction building industry

May be used to safeguard roof workers

May be useful to do-it-yourself (DIY) home improvers

# data[].attributes.field_commercial_applications.processed
May be used widely throughout the residential and commercial construction building industry

May be used to safeguard roof workers

May be useful to do-it-yourself (DIY) home improvers

# data[].attributes.field_competitive_advantages.value
A portable, easily-installed guardrail system to protect workers from falling into holes of roofs and floors during all construction

Easily deployable around skylight fixtures to guard workers from inadvertently stepping onto or sitting down onto the skylight lens and falling through

Roof bracket can provide worker support when moving up-slope while installing roofing shingles

Safety rail and roof bracket assembly can be used together as edge guarding for both low- and steep-slope roofs to prevent workers from falling or sliding off

# data[].attributes.field_competitive_advantages.processed
A portable, easily-installed guardrail system to protect workers from falling into holes of roofs and floors during all construction

Easily deployable around skylight fixtures to guard workers from inadvertently stepping onto or sitting down onto the skylight lens and falling through

Roof bracket can provide worker support when moving up-slope while installing roofing shingles

Safety rail and roof bracket assembly can be used together as edge guarding for both low- and steep-slope roofs to prevent workers from falling or sliding off

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls.

# data[].attributes.field_patents[].value
US Patent 7,509,702
Filed on 2005-10-24
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 7,509,702
Filed on 2005-10-24
Status: Issued

# data[].attributes.field_patent_htmls[]
US Patent 7,509,702
Filed on 2005-10-24
Status: Issued

# data[].attributes.field_patent_titles[]
BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN

# data[].attributes.field_publications[].value
Bobick-TG, et al.

# data[].attributes.field_publications[].processed
Bobick-TG, et al.

# data[].attributes.field_publications[].value
Bobick T, et al.

# data[].attributes.field_publications[].processed
Bobick T, et al.

# data[].attributes.field_publications[].value
Bobick-TG, et al.

# data[].attributes.field_publications[].processed
Bobick-TG, et al.

# data[].attributes.field_publications[].value
Bobick-TG, el al.

# data[].attributes.field_publications[].processed
Bobick-TG, el al.

# data[].attributes.field_related_inventions[].processed
E-141-2013-0

# data[].attributes.field_technology_names[]
BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise

# data[].attributes.body.value
This CDC-developed technology entails a system for monitoring and assessing the risk of auditory damage from exposure to impulse noise, such as noise created by construction machinery and firearms. Noise dosimeters have been used extensively over the past two decades to document personal exposure to noise and assure workplaces comply with permissible noise exposure levels. However, due to older methods of calculating "noise dose," current noise dosimeters often inaccurately determine the risk of an impulse event. Further, current state-of-the-art noise dosimeters have a sound pressure level (SPL) dynamic measurement range of about 80-146 dB, which is adequate for some impact noise environments, but cannot accurately measure impulse noise levels above 146 dB. When a dosimeter is used to measure a noise level greater than its dynamic range, the dosimeter “clips” the noise level at the upper end of its measurement range, resulting in errant assessments of noise exposure.

The system described by this technology can be used to measure exposure to impulse noise and replace older, "clipped-range" dosimeters. Additionally, this new technology will improve the collection of empirical data for establishing association of noise levels with hearing loss.

# data[].attributes.body.processed
This CDC-developed technology entails a system for monitoring and assessing the risk of auditory damage from exposure to impulse noise, such as noise created by construction machinery and firearms. Noise dosimeters have been used extensively over the past two decades to document personal exposure to noise and assure workplaces comply with permissible noise exposure levels. However, due to older methods of calculating "noise dose," current noise dosimeters often inaccurately determine the risk of an impulse event. Further, current state-of-the-art noise dosimeters have a sound pressure level (SPL) dynamic measurement range of about 80-146 dB, which is adequate for some impact noise environments, but cannot accurately measure impulse noise levels above 146 dB. When a dosimeter is used to measure a noise level greater than its dynamic range, the dosimeter “clips” the noise level at the upper end of its measurement range, resulting in errant assessments of noise exposure.

The system described by this technology can be used to measure exposure to impulse noise and replace older, "clipped-range" dosimeters. Additionally, this new technology will improve the collection of empirical data for establishing association of noise levels with hearing loss.

# data[].attributes.field_commercial_applications.value
Assessment of potentially hazardous levels of impulse noise

Use by law enforcement officers, DOD infantry, armor and artillery personnel, and workers in the construction trades

Improving collection of empirical data to gauge risk and establish links to possible causes of hearing loss

# data[].attributes.field_commercial_applications.processed
Assessment of potentially hazardous levels of impulse noise

Use by law enforcement officers, DOD infantry, armor and artillery personnel, and workers in the construction trades

Improving collection of empirical data to gauge risk and establish links to possible causes of hearing loss

# data[].attributes.field_competitive_advantages.value
This technology will accurately quantify noise dose and measure impulse noise and avoid "clipping" artifacts associated with currently available noise dosimeters.

# data[].attributes.field_competitive_advantages.processed
This technology will accurately quantify noise dose and measure impulse noise and avoid "clipping" artifacts associated with currently available noise dosimeters.

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/487,449
Filed on 2003-07-14
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/487,449
Filed on 2003-07-14
Status: Abandoned

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2004/022499
Filed on 2004-07-13
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2004/022499
Filed on 2004-07-13
Status: Expired

# data[].attributes.field_patents[].value
US Patent 7,401,519
Filed on 2006-01-11
Status: Expired

# data[].attributes.field_patents[].processed
US Patent 7,401,519
Filed on 2006-01-11
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/487,449
Filed on 2003-07-14
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2004/022499
Filed on 2004-07-13
Status: Expired

# data[].attributes.field_patent_htmls[]
US Patent 7,401,519
Filed on 2006-01-11
Status: Expired

# data[].attributes.field_patent_titles[]
System For Monitoring Exposure To Impulse Noise

# data[].attributes.field_patent_titles[]
System For Monitoring Exposure To Impulse Noise

# data[].attributes.field_patent_titles[]
System For Monitoring Exposure To Impulse Noise

# data[].attributes.field_publications[].value
Kardous CA, et al.

# data[].attributes.field_publications[].processed
Kardous CA, et al.

# data[].attributes.field_publications[].value
Kardous CA, et al.

# data[].attributes.field_publications[].processed
Kardous CA, et al.

# data[].attributes.field_publications[].value
Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013.

# data[].attributes.field_publications[].processed
Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013.

# data[].attributes.field_publications[].value
Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85.

# data[].attributes.field_publications[].processed
Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85.

# data[].attributes.field_technology_names[]
System For Monitoring Exposure To Impulse Noise

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury

# data[].attributes.body.value
CDC researchers have developed the Portable Exposure Assessment System (PEAS), a field-based, remotely deployed tool to monitor and provide early warning of working conditions that have a high likelihood of musculoskeletal injury.  PEAS is a noninvasive, real-time, instrument-based system.  Sensor technology simultaneously measures and collects data regarding the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibrations. Wireless technology establishes communication links between the sensors and a data logger and between the data logger and a smart phone with positioning and text messaging capabilities. The data logger records the body weight, posture, and vibration data over time and transfers the data to a databank for archiving and further data analysis.  During data recording, the data logger detects the data that either exceed the lifting index limit defined by the NIOSH Lifting Equation or the human whole-body vibration exposure limit defined by the ISO-2631-1 Human Exposure to Whole-Body Vibration standard. The data logger wirelessly transmits the data segment, which contains the marked out-of-limit data, to the smart phone in real-time.  The smart phone then automatically dials a predefined number and sends an alert text message and alarm detailing the exposure/safety data, the GPS location of the occurrence, the date/time stamps, and a corresponding safety message.  Additionally, the smart phone stores the sent text message for archiving and further data analysis.

# data[].attributes.body.processed
CDC researchers have developed the Portable Exposure Assessment System (PEAS), a field-based, remotely deployed tool to monitor and provide early warning of working conditions that have a high likelihood of musculoskeletal injury.  PEAS is a noninvasive, real-time, instrument-based system.  Sensor technology simultaneously measures and collects data regarding the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibrations. Wireless technology establishes communication links between the sensors and a data logger and between the data logger and a smart phone with positioning and text messaging capabilities. The data logger records the body weight, posture, and vibration data over time and transfers the data to a databank for archiving and further data analysis.  During data recording, the data logger detects the data that either exceed the lifting index limit defined by the NIOSH Lifting Equation or the human whole-body vibration exposure limit defined by the ISO-2631-1 Human Exposure to Whole-Body Vibration standard. The data logger wirelessly transmits the data segment, which contains the marked out-of-limit data, to the smart phone in real-time.  The smart phone then automatically dials a predefined number and sends an alert text message and alarm detailing the exposure/safety data, the GPS location of the occurrence, the date/time stamps, and a corresponding safety message.  Additionally, the smart phone stores the sent text message for archiving and further data analysis.

# data[].attributes.field_commercial_applications.value
Safety officers within the environmental, safety, and health departments of public and private entities

Industrial sectors such as construction, package delivery, manufacturing, healthcare, and trucking

Workers' well-being concern groups

Insurers and workers' compensation operations

Monitoring tasks associated with high rates of personal injury and workers' compensation payments linked to repeated or continual heavy lifting

# data[].attributes.field_commercial_applications.processed
Safety officers within the environmental, safety, and health departments of public and private entities

Industrial sectors such as construction, package delivery, manufacturing, healthcare, and trucking

Workers' well-being concern groups

Insurers and workers' compensation operations

Monitoring tasks associated with high rates of personal injury and workers' compensation payments linked to repeated or continual heavy lifting

# data[].attributes.field_competitive_advantages.value
No comparable technology currently exists in the marketplace

Real-time notification, via alarm and smart-phone transmission, of injury-risk conditions that are likely to lead to musculoskeletal injury, as well as exposure to slip-, trip-, and fall-related traumatic injuries; both the worker and any monitoring station can be notified by the alarm

Portable; approximately the size of a mobile phone and uses comparable technology

# data[].attributes.field_competitive_advantages.processed
No comparable technology currently exists in the marketplace

Real-time notification, via alarm and smart-phone transmission, of injury-risk conditions that are likely to lead to musculoskeletal injury, as well as exposure to slip-, trip-, and fall-related traumatic injuries; both the worker and any monitoring station can be notified by the alarm

Portable; approximately the size of a mobile phone and uses comparable technology

# data[].attributes.field_development_status.value
Early-stage

In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
Early-stage

In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury.

# data[].attributes.field_patents[].value
US
Provisional (PRV) 61/599,525
Filed on 2012-02-16
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 61/599,525
Filed on 2012-02-16
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 8,942,662
Filed on 2013-02-15
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 8,942,662
Filed on 2013-02-15
Status: Issued

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 61/599,525
Filed on 2012-02-16
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 8,942,662
Filed on 2013-02-15
Status: Issued

# data[].attributes.field_patent_titles[]
Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries

# data[].attributes.field_patent_titles[]
SYSTEM AND METHOD TO PREDICT AND AVOID MUSCULOSKELETAL INJURIES

# data[].attributes.field_technology_names[]
Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications

# data[].attributes.body.value
This CDC-developed technology describes a novel ergonomic device that supports a portion of the worker's weight while kneeling, relieving the knee pressure and pain common to many manual labor occupations. Unfortunately, many of the devices that have been used in the past to relieve pressure on the knees are bulky, heavy, and of questionable durability.

This device relieves pressure from the knees while kneeling, is easily portable, is attachable to the body, and can be moved automatically by the user without the user having to pick up the device and manually move it to a new position. The device is nonflammable and durable, so that it can be used in heavy industry and on horizontally constrained and uneven surfaces, and is comfortable to use while kneeling, thereby improving worker productivity.

# data[].attributes.body.processed
This CDC-developed technology describes a novel ergonomic device that supports a portion of the worker's weight while kneeling, relieving the knee pressure and pain common to many manual labor occupations. Unfortunately, many of the devices that have been used in the past to relieve pressure on the knees are bulky, heavy, and of questionable durability.

This device relieves pressure from the knees while kneeling, is easily portable, is attachable to the body, and can be moved automatically by the user without the user having to pick up the device and manually move it to a new position. The device is nonflammable and durable, so that it can be used in heavy industry and on horizontally constrained and uneven surfaces, and is comfortable to use while kneeling, thereby improving worker productivity.

# data[].attributes.field_commercial_applications.value
Knee pain, low-back pain alleviation and prevention

Improved workplace ergonomics

Osteoarthrosis concerns, geriatric medicine applications and for aging populations in the workforce

Occupations such as shipbuilding, welding, mining, plumbing, carpet and floor installation, construction, repair services, and auto body repair in which people must spend a considerable amount of time kneeling or squatting

# data[].attributes.field_commercial_applications.processed
Knee pain, low-back pain alleviation and prevention

Improved workplace ergonomics

Osteoarthrosis concerns, geriatric medicine applications and for aging populations in the workforce

Occupations such as shipbuilding, welding, mining, plumbing, carpet and floor installation, construction, repair services, and auto body repair in which people must spend a considerable amount of time kneeling or squatting

# data[].attributes.field_competitive_advantages.value
Comfortable; relieves pressure from the knees while kneeling, increasing on-the-job comfort and worker productivity

Device is extremely portable

Easily attaches to a user's lower leg; allows for unhindered movement and ambulation

Device automatically moves with the user; no manual readjustments or manipulations are required

Durable and nonflammable

Ideal for heavy industry applications; can be used on horizontally constrained and uneven surfaces

# data[].attributes.field_competitive_advantages.processed
Comfortable; relieves pressure from the knees while kneeling, increasing on-the-job comfort and worker productivity

Device is extremely portable

Easily attaches to a user's lower leg; allows for unhindered movement and ambulation

Device automatically moves with the user; no manual readjustments or manipulations are required

Durable and nonflammable

Ideal for heavy industry applications; can be used on horizontally constrained and uneven surfaces

# data[].attributes.field_development_status.value
In situ data available (on-site)

Prototype

# data[].attributes.field_development_status.processed
In situ data available (on-site)

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications.

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2002/016790
Filed on 2002-05-28
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2002/016790
Filed on 2002-05-28
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 60/300,315
Filed on 2001-06-22
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 60/300,315
Filed on 2001-06-22
Status: Abandoned

# data[].attributes.field_patents[].value
US Patent 7,152,919
Filed on 2003-12-19
Status: Abandoned

# data[].attributes.field_patents[].processed
US Patent 7,152,919
Filed on 2003-12-19
Status: Abandoned

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2002/016790
Filed on 2002-05-28
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 60/300,315
Filed on 2001-06-22
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 7,152,919
Filed on 2003-12-19
Status: Abandoned

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)

# data[].attributes.title
Mobile Instrumentation for the Detection and Sampling of Aerosol Particles

# data[].attributes.body.value
Hazardous airborne particles pose a risk for health and safety in a variety of environments and thus detection of these small particles is essential. Current particle magnification systems are bulky and require a lot of power for operation, making them unsuitable to easily detect and analyze small particles in mobile and personal settings.

CDC/NIOSH scientists have developed a space-saving miniature instrumentation and methods for the direct sampling and analysis of small particles (diameter < 300-400nm). The systems can effectively sample air at a rate of a few liters per minute and concentrate the particulate matter into microliter or milliliter liquid samples. The novel system uses proton exchange membranes to grow small particles for optical detection using standard methods. Further, these methods allow the system to separate condensation and aerosol flow to enhance user mobility. Moreover, the described methods use inexpensive materials and require low power for operation.

# data[].attributes.body.processed
Hazardous airborne particles pose a risk for health and safety in a variety of environments and thus detection of these small particles is essential. Current particle magnification systems are bulky and require a lot of power for operation, making them unsuitable to easily detect and analyze small particles in mobile and personal settings.

CDC/NIOSH scientists have developed a space-saving miniature instrumentation and methods for the direct sampling and analysis of small particles (diameter 300-400nm). The systems can effectively sample air at a rate of a few liters per minute and concentrate the particulate matter into microliter or milliliter liquid samples. The novel system uses proton exchange membranes to grow small particles for optical detection using standard methods. Further, these methods allow the system to separate condensation and aerosol flow to enhance user mobility. Moreover, the described methods use inexpensive materials and require low power for operation.

# data[].attributes.field_commercial_applications.value
Condensation particle detectors

Particle size magnification systems

Microfluidic devices for sampling, detection, and growth of hazardous particles

# data[].attributes.field_commercial_applications.processed
Condensation particle detectors

Particle size magnification systems

Microfluidic devices for sampling, detection, and growth of hazardous particles

# data[].attributes.field_competitive_advantages.value
Cost-effective

Offers overall reduction of measurement time

Requires minimal power to operate

Mobile, wearable

Space-saving miniature systems as small as 1" x 1" x 3"

# data[].attributes.field_competitive_advantages.processed
Cost-effective

Offers overall reduction of measurement time

Requires minimal power to operate

Mobile, wearable

Space-saving miniature systems as small as 1" x 1" x 3"

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles.

# data[].attributes.field_patents[].value
US Patent 10,583,410
Filed on 2015-07-20
Status: Issued

# data[].attributes.field_patents[].processed
US Patent 10,583,410
Filed on 2015-07-20
Status: Issued

# data[].attributes.field_patents[].value
Patent Cooperation Treaty
(PCT) PCT/US2015/041142
Filed on 2015-07-20
Status: Expired

# data[].attributes.field_patents[].processed
Patent Cooperation Treaty
(PCT) PCT/US2015/041142
Filed on 2015-07-20
Status: Expired

# data[].attributes.field_patents[].value
US
Provisional (PRV) 62/026,559
Filed on 2014-07-18
Status: Abandoned

# data[].attributes.field_patents[].processed
US
Provisional (PRV) 62/026,559
Filed on 2014-07-18
Status: Abandoned

# data[].attributes.field_patent_htmls[]
US Patent 10,583,410
Filed on 2015-07-20
Status: Issued

# data[].attributes.field_patent_htmls[]
Patent Cooperation Treaty
(PCT) PCT/US2015/041142
Filed on 2015-07-20
Status: Expired

# data[].attributes.field_patent_htmls[]
US
Provisional (PRV) 62/026,559
Filed on 2014-07-18
Status: Abandoned

# data[].attributes.field_patent_titles[]
Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes

# data[].attributes.field_patent_titles[]
Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes

# data[].attributes.field_patent_titles[]
AEROSOL PARTICLE GROWTH SYSTEMS FOR PERSONAL SAMPLING APPLICATIONS USING POLYMER ELECTROLYTE MEMBRANES

# data[].attributes.field_related_inventions[].processed
E-146-2013-0

# data[].attributes.field_technology_names[]
Aerosol Particle Growth Systems For Personal Sampling Applications Using Proton Exchange Membranes

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC), Regents of the University of Minnesota

# data[].attributes.body.value
Boats and other watercrafts have emergency lifesaving equipment like strobe lamps to help rescuers locate individuals overboard in the event of a disaster. The battery life of the equipment is limited, so the amount of time rescuers have to find the victims is also limited. An emergency battery charger that can power emergency equipment is needed to remove this limitation.

Investigators at NIOSH have developed a battery that is powered by wave action in the water. Using a derivation of Faraday's Law, the principles of Lentz's Law were used to induce a current in a wire coil and manipulated to charge emergency batteries. This technology offers a back-up charger for equipment on boats and watercrafts.

# data[].attributes.body.processed
Boats and other watercrafts have emergency lifesaving equipment like strobe lamps to help rescuers locate individuals overboard in the event of a disaster. The battery life of the equipment is limited, so the amount of time rescuers have to find the victims is also limited. An emergency battery charger that can power emergency equipment is needed to remove this limitation.

Investigators at NIOSH have developed a battery that is powered by wave action in the water. Using a derivation of Faraday's Law, the principles of Lentz's Law were used to induce a current in a wire coil and manipulated to charge emergency batteries. This technology offers a back-up charger for equipment on boats and watercrafts.

# data[].attributes.field_commercial_applications.value
Battery charger that can be used on personal or commercial boats.

Maritime battery charger that can be used for specialized rescue vessels.

# data[].attributes.field_commercial_applications.processed
Battery charger that can be used on personal or commercial boats.

Maritime battery charger that can be used for specialized rescue vessels.

# data[].attributes.field_competitive_advantages.value
Charging system is configured to be powered by wave action.

Powering mechanism allows the maritime battery charger to be used in boats, life rafts, and personal flotation devices.

Maritime charger can be used to charge radios, lamps, and back up batteries for emergency systems.

# data[].attributes.field_competitive_advantages.processed
Charging system is configured to be powered by wave action.

Powering mechanism allows the maritime battery charger to be used in boats, life rafts, and personal flotation devices.

Maritime charger can be used to charge radios, lamps, and back up batteries for emergency systems.

# data[].attributes.field_development_status.value
Early-stage

Prototype

# data[].attributes.field_development_status.processed
Early-stage

Prototype

# data[].attributes.field_licensingcontact_hrefs[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger.

# data[].attributes.field_licensingcontact_htmls[]
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].value
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts[].processed
Prabhu, Yogikala
yogikala.prabhu@nih.gov

# data[].attributes.field_licensing_contacts_uris[]
yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger.

# data[].attributes.field_technology_owners[]
Centers for Disease Control and Prevention (CDC)